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Chronic transplant rejection remains a persistent barrier to transplant survival. 
One approach to tackle this is to target the indirect pathway of allorecognition, 
the major contributor to chronic mediated rejection. Modifying the recipient’s 
antigen- presenting cells which have a major role of presenting graft-derived 
donor alloantigens to recipient T cells, which proliferate and differentiate into 
effector cells thereby leading to an immune attack against the transplanted 
organ, has been undertaken. Previous studies found that targeting alloantigens 
derived from BALB/c MHC Class I H-2Kd via specific cell surface receptors to 
immature dendritic cells (DCs), impaired indirect allorecognition leading to 
murine skin grafts survival. Siglec receptors have previously been targeted on 
murine DCs to induce tolerance in an autoimmune mouse model. These 
receptors specifically bind to sialylated ligands and have a role in down-
regulating immune responses due to their immunoreceptor tyrosine-based 
inhibitory motif. To date, it has not been established whether targeting these 
receptors can induce transplantation tolerance; therefore our aim was to target 
Siglecs on a heterogeneous population of recipient DCs with sialylated H-2Kd 
alloantigen to modify the indirect pathway of allorecognition and to promote 
organ transplant survival.  
In this study it was established Siglecs were expressed on DCs, B cells and 
macrophages. Targeting sialylated alloantigen to DCs impaired indirect 
alloreactive CD4+ T cell proliferation and cytokine production; and were able to 
induce/expand CD4+ Foxp3+ Tregs in vitro following targeting.  
Additionally, we have demonstrated in vivo that sialylated alloantigen treatment 
prior to MHC-mismatch donor skin transplantation to wild-type B6 recipient mice 
resulted in graft prolongation and also a significant increase of CD4+ CD62L+ 
Foxp3+ Tregs in recipient blood, a possible contributor to the observed graft 
survival. In addition, there was a marked decrease of alloantibodies, signifying 
that alloreactive B cells activated via indirect pathway of allorecognition are 
being inhibited. This was attributed to Siglec expression on DCs requiring Batf3 
transcription factor for their development (CD103+ and CD8α+ DCs). It was also 
observed that mice treated with sialylated alloantigen deleted indirect CD4+ T 
iii 
 
cells in vivo, suggesting that this could be one of the mechanisms contributing 
to allograft survival.  
In conclusion, targeting recipient DCs with sialylated alloantigen may represent 



































List of figures ix 




Awards and grants xviii 
Publications xix 
Chapter 1: Introduction 1 
1.1. Historical outline of transplantation 2 
1.2 Transplant rejection and allorecognition 3 
1.2.1 Major histocompatibility complex and alloantigens 4 
1.2.2 Allorecognition and contribution to transplant rejection 6 
1.2.2.1 Direct allorecognition  6 
1.2.2.2 Indirect allorecognition  8 
1.2.2.2.1   Role of B cells in indirect allorecognition 10 
1.2.2.3 Semi-direct allorecognition  11 
1.2.3. Immune responses that constitute allograft rejection  14 
1.2.4 The role of macrophages in rejection 15 
1.3  Mechanisms of peripheral tolerance and contribution to transplant tolerance   16 
1.3.1 Immune  tolerance mechanisms to contain allorecognition 16 
1.3.1.1 Deletion 16 
1.3.1.2 Anergy 17 
1.3.1.3 Regulatory T cells 18 
1.3.1.3.1 How do Regulatory T cells mediate immunosuppressive functions? 19 
1.3.1.3.2 Regulatory T cells in murine transplant models [Table.1] 21 
1.4. Using DCs, B cells and Macrophages for transplant tolerance 24 
1.4.1 Dendritic cells 24 
1.4.1.1 Mechanisms used by TolDCs to mediate tolerance 25 
1.4.1.2 Use of tolerogenic DCs in human clinical trials 27 
1.4.1.3 Modifying and targeting alloantigens to DCs to promote transplant tolerance 27 
1.4.1.3.1 Modifying donor-derived DCs and recipient-derived DCs to promote graft 
prolongation 
27 
1.4.1.3.2 Pulsing recipient DCs with alloantigens 29 
1.4.1.3.3  Targeting alloantigens to cell surface receptors expressed on DC to induce 
tolerance   
32 
1.4.2. B cells and their role in transplant tolerance 36 
1.4.3. Macrophages and their role in transplant tolerance 37 
v 
 
1.5 Sialic acid-binding immunoglobulin-like lectins 38 
1.5.1. Targeting ITIM-bearing Siglecs to impair aberrant immune responses  39 
1.5.2  Examples of murine Siglecs and their inhibitory roles  41 
1.6 Aims of the investigation 46 
Chapter 2: Materials and Methods 47 
2.1 Mice [Table.5] 48 
2.2 Cell culture media 49 
2.3 Cell isolation 50 
2.3.1 Preparation of DCs from mouse bone marrow (BM) and spleen (SPLN) 50 
2.3.1.1 Bone marrow derived DCs (BM-DCs) 50 
2.3.1.2 Spleen 52 
2.3.2 Isolation and expansion of macrophages from mouse BM (BM- DMs) 53 
2.3.3 Preparation of B cells from mouse spleen 54 
2.3.4 Preparation of T cells from mouse spleen 55 
2.3.4.1 CD4+ T cell isolation for in vivo adoptive transfer  56 
2.4 Antibodies 56 
2.5 Flow cytometry  56 
2.5.1 Extracellular staining: phenotypic analysis of mouse cells  56 
2.5.2 Intracellular staining for Foxp3 expression 57 
2.5.3 CFSE labelling 57 
2.6 H-2Kd 54-68 peptide: sialylated and non-sialylated conjugates 59 
2.6.1. Kd peptide derived from BALB/c MHC I H-2Kd molecule is an established 
alloantigen peptide  
59 
2.6.2 Purity of peptides 62 
2.7 Binding of FAM5/6 labelled alloantigen constructs to APCs  66 
2.7.1 In vitro 66 
2.7.2 In vivo 67 
2.8 DC microscopic imaging 68 
2.9 LPS stimulation of BM-DCs and BM-DMs 68 
2.10 T cell activation assays 69 
2.11 In vitro Treg induction assay 71 
2.12 Enzyme-Linked Immunosorbent Assay 71 
2.13 Skin transplants  71 
2.13.1 Alloantigen peptide administration intravenously  72 
2.13.2 CD8+ cell depletion 72 
2.14 Treg analysis in transplant recipients 73 
2.15 Alloantibody detection in skin transplant recipients  73 
2.16 Antigen specific T cell deletion and Treg expansion in vivo 74 





Chapter 3: Targeting recipient APCs with α2,3 Sia-Kd and α2,3L Sia-Kd 
alloantigen peptides dampens indirect alloreactive immune responses in vitro 
75 
3.1 Introduction 76 
3.1.1 Dendritic cells 76 
3.1.2 B cells 78 
3.1.3 Macrophages 78 
3.2 Aims 80 
3.3 Results  81 
3.3.1 BM-DCs express well characterised DCs surface markers following GM-CSF 
expansion 
81 
3.3.2. Siglec- expressing BM-DCs and SPLN-DCs bind α2,3 Sia-Kd alloantigen 
peptide in vitro  
83 
3.3.3 Engaging Siglecs with α2,3 Sia-Kd peptide down-regulated MHC expression on 
BM-DCs  
87 
3.3.4 Siglec engagement with a2,3 Sia-Kd does not lead to maturation resistant  BM-
DCs 
91 
3.3.5 In vitro targeting of α2,3 Sia-Kd to B6 BM-DC reduces proliferation as well as  
IL-2 and IFN-γ production of Kd alloantigen- specific CD4+ T cells 
94 
3.3.6 Long construct of α2,3 sialylated alloantigens (α2,3L Sia-Kd) impairs 
proliferation and IL-2 production of indirect alloreactive CD4+ T cells  
97 
3.3.7 Targeting α2,3 or α2,3L Sia-Kd to Siglecs leads to DCs with a greater ability to 
expand/induce Tregs 
100 
3.3.8 Immunomodulatory molecules ICOS-L and PDL-1 are not induced following 
Siglec ligation 
104 
3.4 Targeting B6 B cells with α2,3 and α2,3L sialylated alloantigen  106 
3.4.1 Siglecs expressed on B cells bind to α2,3 Sia-Kd alloantigen 106 
3.4.2 In vitro targeting of Kd peptide, α2,3 Sia-Kd or α2,3L Sia-Kd to B6 B cells does 
not stimulate proliferation of antigen specific CD4+ T cells 
110 
3.5 Targeting B6 macrophages cells with α2,3 and α2,3L sialylated alloantigen  115 
3.5.1 Targeting alloantigen to Siglec-expressing macrophages reduces IL-12 
production in presence of LPS  
115 
3.6 Discussion 119 
Chapter 4: Targeting DCs with α2,6 Sia-Kd alloantigen peptides leads to 
reduced allogeneic responses in vitro 
127 
4.1 Introduction 128 
4.2 Aims 129 
4.3 Results 130 
4.3.1. α2,6 Sia-Kd binds to Siglec-expressing BM-DCs 130 
4.3.2 α2,6 Sia-Kd targeted DCs impair indirect allorecognition and induce Tregs 131 





4.4  Targeting B6 B cells with α2,6 sialylated alloantigen  138 
4.4.1 α2,6 Sia-Kd binds to B cells  138 
4.4.2 Targeting Siglec on B6 B cells with α2,6 Sia-Kd peptides in vitro does not 
stimulate T cells proliferation or induce/expand Tregs 
141 
4.5 Targeting B6 macrophages cells with α2,6 sialylated alloantigen  146 
4.5.1 α2,6 Sia-Kd peptides bind Siglec-expressing macrophages 146 
4.6 Discussion 149 
Chapter 5: Targeting Siglecs on Batf3-dependent DCs prolongs skin transplant 
survival and leads to reduced alloantibody responses 
154 
5.1 Introduction 155 
5.2 Aims 156 
5.3 Results 157 
5.3.1 Sialylated alloantigen peptides bind to endogenous DCs and B cells in the 
SLOs when administered intravenously 
158 
5.3.2. Treating recipient B6 mice with Sia-alloantigens 10 days before a B6.Kd skin 
transplant did not prolong allograft survival  
161 
5.3.3. Targeting Siglecs in vivo with α2,3 Sia-Kd one day prior to a transplant 
prolonged allograft survival  
167 
5.3.4 Targeting recipient DCs with α2,3 Sia-Kd prolonged skin allograft survival in 
B6.Rag2-/- recipients  
170 
5.3.5. Targeting α2,3 Sia-Kd to recipient mice devoid of CD8+ DCs and CD103+ DCs 
did not prolong transplant survival 
173 
5.4 Discussion 179 
Chapter 6: T cell deletion and increase of CD4+ CD62L+ Foxp3+ regulatory T 
cells contribute to graft prolongation following α2,3 Sia-Kd alloantigen 
treatment 
186 
6.1 Introduction 187 
6.2. Aim 188 
6.3. Results  190 
6.3.1 Indirect alloantigen-specific CD4+ T cells are deleted following peptide targeting 
in vivo  
190 
6.3.2. α2,3 Sia-Kd administration increased proportions of CD4+ CD62L+ Foxp3+ 
Tregs 
193 
6.3.3. Targeting α2,3 Sia-Kd to Siglecs expressed on Batf3-/- DCs did not induce CD4+ 
CD62L+ Foxp3+ Tregs  
197 
6.4 Discussion 203 
Chapter 7: Final discussion & future work 207 
7.1. Final discussion on findings 208 
7.1.1 Can sialylated alloantigen targeting to APCs inhibit indirect allorecognition?  208 
7.1.2 Not all sialylated alloantigens mediate allograft survival  223 
7.1.3 Targeting with Kd monomer instead of Kd peptide 225 
viii 
 
7.1.4 Can sialylated alloantigen targeting to DCs be applicable to humans transplant 
survival therapy?  
225 
7.2 Final conclusion 229 
Chapter 8: References 231 

































List of Figures 
 
Figure 1.1. 3D CT scan of patient before and after receiving a full face transplant 3 
Figure 1.2. 3D structures of MHC I and II 5 
Figure 1.3. MHC genetic disparity can contribute to transplant rejection.  6 
Figure 1.4. Three pathways of allorecognition. 13 
Figure 1.5. Inhibitory function of regulatory T cells 24 
Figure 1.6. Phenotypic profile of mature DCs versus immature tolerogenic DCs 34 
Figure 1.7. Structure and function of ITAM and ITIM 39 
Figure 1.8. Structures of Siglecs conserved in mammals and present in human 
or mouse 
44 
Figure 2.1  Schematic for the generation of BM-DCs 51 
Figure 2.2. Gating strategy for assessing CD11c+ BM-DCs via flow cytometry 51 
Figure 2.3.  Gating strategy for the analysis of CD11c+ SPLN-DCs by flow 
cytometry.   
53 
Figure 2.4.  Gating strategy for the analysis of  F4/80 BM-DMs by flow 
cytometry.   
54 
Figure 2.5.  Gating strategy for the analysis of B220+ B cells by flow cytometry.   55 
Figure. 2.6.  Kd 54-68 is most stimulatory peptide out of the entire MHC I H-2Kd 
molecule 
60 
Figure 2.7. H-2Kd alloantigen peptide.  61 
Figure: 2.8. Purity of sialylated and non-sialylated alloantigen Kd peptides 63-66 
Fig. 2.9. Gating strategy for T cell proliferation assays. 70 
Figure 3.1.  BM-DC express CD11c and are MHC IIhigh, MHC Ilow/int, CD80low/int 
and CD86low/int. 
82 
Figure. 3.2. Siglecs are expressed on B6 BM-DCs and SPLN-DCs 85 
Figure 3.3. α2,3 Sia-Kd- FITC binds to BM- and SPLN-DC in vitro. 86 
Figure 3.4. α2,3 Sia-Kd treatment down-regulates MHC I and MHC II on BM-
DCs. 
88 
Figure 3.5. Kd or Sia-Kd treatment does not increase significant IL-10 or IL-12 
production from BM-DCs.   
90 
Figure 3.6. MHC, co-stimulatory molecules, IL-10 and IL-12 remain unchanged 
between peptide and unpulsed BM-DCs 
93 
Figure 3.7. Targeting BM-DC Siglecs with Sia-Kd lead to impaired TCR75 CD4+ 
T cell proliferation as well as IL-2 and IFN-γ production in vitro. 
96 
Figure 3.8. Targeting B6 BM-DCs with α2,3 Sia-Kd and α2,3L Sia-Kd suppressed 
proliferation of TCR75 CD4+ T cells   
99 





Figure 3.10.  Sialylated Kd peptide and Siglec interaction on BM-DCs does not 
affect ICOS-L or PD-L1 expression.   
105 
Figure 3.11. Siglec G and CD22 are expressed on B6 B cells. 107 
Figure 3.12. α2,3 Sia-Kd binds to Siglec expressing B cells in vitro. 108 
Figure. 3.13 Sialylated and non-sialylated alloantigens bind to transitional, MZ 
and FO B cell subsets 
109 
Figure 3.14 Targeting alloantigens to B6 B cells do did not stimulate alloantigen-
specific CD4+ T cells proliferation nor IL-2 and IFN- gamma production. 
112 
Figure 3.15. a2,3 Sia-Kd targeted B cells do not induce CD4+ Foxp3+ Tregs in 
vitro. 
114 
Figure 3.16. Sia-Kd binds to Siglec expressing macrophages in vitro. 117 
Figure. 4.1. α2,6 Sia-Kd binds to Siglec-expressing DCs in vitro. 131 
Figure 4.2. Targeting B6 BM-DCs with α2,6 Sia-Kd suppressed proliferation of 
TCR75 CD4+ T cells   
133 
Figure 4.3.  Siglec targeting with α2,6 Sia-Kd induces CD4+ Foxp3+ Tregs in vitro. 135 
Figure 4.4. α2,6 Sia-Kd peptide treated BM-DCs do not affect ICOS-L or PD-L1 
expression.   
137 
Figure 4.5. α2,6 Sia-Kd binds to Siglec expressing B cells in vitro. 138 
Figure. 4.6 Sialylated and non-sialylated alloantigens bind to T1, T2, MZ and FO 
B cell subsets 
140 
Figure. 4.7. Targeting Siglecs on B6 B cells does not stimulate alloantigen-
specific CD4+ T cells proliferation. 
143 
Figure. 4.8. Kd targeted B cells induces produce more IL-10 in vitro 145 
Figure. 4.9.  α2,6 Sia-Kd binds to Siglec expressing macrophages in vitro and 
produces less IL-12 when treated with alloantigens.   
147 
Figure. 5.1. Sialylated and unsialylated allopeptides bind to DCs in the lymph 
node following intravenous administration 
158 
Figure 5.2. Sialylated alloantigen preferentially binds to Siglecs expressed on 
lymph node B cells following intravenous administration 
160 
Figure 5.3. Graft survival was not prolonged when B6 mice were treated with 
α2,3 Sia-Kd 10 days before transplant, however alloantibodies were reduced. 
164 
Figure 5.4. Graft survival was not prolonged when B6 mice were treated with 
α2,3 Sia-Kd 10 days before transplant, despite prolonged anti-CD8 treatment. 
166 
Figure 5.5. Graft survival was prolonged when B6 mice were treated with α2,3 
Sia-Kd one day before transplant. 
168 
Figure 5.6. Allogeneic graft survival was prolonged in B6.Rag 2 -/- mice following 
α2,3 Sia-Kd treatment. 
172 
Figure 5.7. Alloantigen peptides bind to B6.Batf3-/- SPLN-DCs 174 




does not prolong allograft survival. 
Figure 5.9. Targeting Siglecs expressed on Batf3-/- DCs with α2,3 Sia-Kd does 
not prolong allograft survival. 
177 
Figure 6.1. CD4+ T cells are deleted following peptide targeting, however, CD4+ 
Foxp3+ Tregs numbers remain unchanged.   
192 
Figure 6.2. Gating strategy for peripheral CD4+ CD62L+ Foxp3+ Tregs. 195 
Figure 6.3. Targeting Siglecs on DCs in vivo with α2,3 Sia-Kd one day before 
transplant treatment leads to significant increase of peripheral CD4+ CD62L+ 
Foxp3+ Tregs 
197 
Figure 6.4. Gating strategy for peripheral CD4+ CD62L+ Foxp3+ Tregs in 
B6.Batf3-/- mice 
199 
Figure 6.5. CD8α+ and CD103 DCs may be required for the development of 
peripheral CD4+ CD62L+ Foxp3+ Tregs following α2,3 Sia-Kd targeting and B6.Kd 
skin transplant 
201 
Figure. 7.1. Graphical representation for the outcome from targeting DCs, B cells 
and macrophages with Sia-Kd in vitro. 
210 
Figure. 7.2. Graphical representation for the transplant outcome following α2,3 
Sia-Kd targeting in vivo. 
212 
Appendix figure. 1.  Siglecs are expressed on B6 BM-DCs 265 
Appendix figure 2. Targeting BM-DC Siglecs with Sia-Kd leads to suppressed 
proliferation of TCR75 CD4+ T cells and IL-2 in vitro. 
266 
Appendix figure 3. Gating strategy for T cell proliferation assays. 268 
Appendix Figure 4. Gating strategy and titration experiments for in vitro Treg 
induction.   
269 
Appendix Figure 5. Gating strategy for ICOS-L and PD-L1 expression on BM-
DCs. 
271 
Appendix figure 6. Trial transplant experiment on B6.Rag2-/- mice to compare 
graft survival following B6 CD4+ T cell or CD4+ TCR75 T cell reconstitution. 
273 
Appendix Figure 7. Indirect alloantigen-specific CD4+ T cells are deleted 
following peptide targeting, however the without deleting CD4+ Foxp3+ Tregs in 



























Table. 1: Murine Regulatory T cell subsets and examples for their contribution to 
transplant tolerance 
23 
Table 2: Examples of murine DC subsets (modified from Eisenbarth, 2019. 32 
Table 3: Targeting murine recipient DC in situ to promote transplant tolerance.  35 
Table 4. Examples of Human Siglecs and some of their roles in 
immunoregulation 
45 
Table 5: Wild-type and genetic strains used in this study 49 
Table 6: Summary of Monoclonal antibodies used for flow cytometry  58 









AICD Activation-induced cell death 
APC Antigen presenting cell 
APC Allophycocyanin 
ANOVA Analysis of variance 
Anti Antibody 
ATCC American Type Culture Collection 
B B lymphocyte 
B6 C57BL/6J 
Batf3 Basic leucine zipper transcription factor 
BCR B cell receptor 
BD Becton Dickinson 
BDCA2 Blood dendritic cell antigen 2 
BM Bone marrow 
Bcl-xL B-cell lymphoma-extra large 
BM-DC Bone marrow-derived dendritic cell 
BM-Macs Bone marrow-derived macrophages 
Breg Regulatory B cell 
BV421 Brilliant violet 421 
CD Cluster differentiation 
cDC Conventional dendritic cell 
CFA Complete Freund's adjuvant   
CFSE Carboxyfluorescein succinimidyl ester 
CO2 Carbon dioxide 
CTLA-4 Cytotoxic T-lymphocyte-associated protein 4 
DAMP Damage-associated molecular patterns 
DAPI 4′,6-diamidino-2-phenylindole 
Dex-D3 Dexamethasone- Vitamin D3 
DHRS9 Dehydrogenase/reductase 9  
DNA Deoxyribonucleic acid 
DR5 Death receptor 5 
DST Donor-specific transfusion 
EAE Experimental autoimmune encephalomyelitis 
E.coli Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
FACS Fluorescence-activated cell sorting 
xiv 
 
FAM5/6 5(6)-FAM (5(6)-Carboxyfluorescein 
FasL Fas ligand 
FCS Fetal calf serum 
FITC Fluorescein isothiocyanate 
FLT3-L FMS-like tyrosine kinase 3 ligand 
FO Follicular 
Foxp3 Forkhead box P3 
FSC Forward scatter 
 g Times gravity 
GM-CSF Granulocyte-macrophage colony-stimulating factor 
GVHD Graft-versus-host disease 
HEL Hen egg white lysozyme 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
KHCO3 Potassium bicarbonate 
HLA Human leukocyte antigen 
hNC16A Human type XVII collagen  
HPLC High Performance Liquid Chromatography 
ICOS-L Inducible T cell costimulator ligand 
IFN‐α Interferon alpha 




ITAM Immunoreceptor tyrosine-based activation motif 
ITIM Immunoreceptor tyrosine-based inhibition motif 
ISD Immunosuppressive drugs 
I.V. Intravenous 
Kd H-2Kd 54-68 peptide 
KO Knock-out 
LN-DC Lymph node-derived dendritic cell 
LN Lymph node 
LPS Lipopolysaccharide 
M-CSF Macrophage colony-stimulating factor 
ME 2- Mercaptoethanol 
MFI Mean fluorescence cell sorting 
MHC Major histocompatibility complex 
miRNA MicroRNA 
ml Millilitre 
MOG Myelin oligodendrocyte glycoprotein 
MST Mean survival time 
xv 
 
Mreg Regulatory macrophage 
MR1 CD40 ligand antibody 
mTOR Mammalian target of rapamycin  
MZ Marginal zone 
Neu5Ac N-acetyl neuraminic acid  
NFAT-5 Nuclear factor of activated T-cells 5 
NF-kB Nuclear factor kappa-light-chain-enhancer of activated B cells 
NH4Cl Ammonium chloride 
NK Natural killer cell 
NZW New Zealand White 
OVA Ovalbumin 
PBMC Peripheral blood mononuclear cells 
PBS Phosphate buffered saline 
pDC Plasmacytoid dendritic cell 
PD-L1 Programmed death-ligand 1 
PE R-phycoerythrin 
PMA Para-Methoxyamphetamine 
PVDF Polyvinylidene fluoride 
RAG Recombination-activating gene 
RBC Red blood cells 
RPMI Roswell Park Memorial Institute 
s.c. Subcutaneous 
SD Standard deviation 
SEB Staphylococcal entertotoxin B 
SEM Standard error of the mean 
Sia Sialic acid 
Siglec Sialic acid-binding immunoglobulin-type lectin 
SHP Src homology region 2 domain-containing phosphatase 
SPF Specific pathogen free 
SPLN Spleen 
SPLN-DC Splenic-derived dendritic cell 
SLO Secondary lymphoid organs 
SSC Side scatter 
T T lymphocyte 
TCR T cell receptor 
TGFβ Transforming growth factor β 
Th T Helper cell 
TLR Toll like receptor 
TNF-α Tumor necrosis factor alpha 
TolDC Tolerogenic dendritic cell 
xvi 
 
TRAIL TNF-related apoptosis-inducing ligand 
Treg Regulatory T cell 
Tr1 Type 1 regulatory cells 
TSDR Treg-specific demethylated region 
Tx Transplant 
T1 Transitional 1 
T2 Transitional 2 
U Units 
UK United Kingdom 
































Firstly, I would like to thank the School of Health, Sport and Bioscience, 
University of East London for funding this PhD project and to the British Heart 
foundation grant from King’s College London, for providing some funding 
towards the in vivo aspects of this study.  
 
Secondly, my gratitude goes towards my Director of Studies, Dr Lesley Smyth, 
UEL, for being an exceptional supervisor and for giving me the confidence to 
tackle any obstacles met throughout my PhD. With Dr Smyth’s help and 
expertise, I achieved the milestones of this project and have gained numerous 
skills that I will apply throughout my future career. 
 
In addition, I would like to thank my external supervisor, Professor Giovanna 
Lombardi from King’s College London, for her outstanding contribution to the 
development of this study and for her support and advice throughout this 
project. 
 
I am very grateful to Professor Yvette van Kooyk and Dr Martino Ambrosini from 
VU University Medical Centre (VUmc), Amsterdam, NL, for the manufacturing of 
the peptide conjugates that were imperative to this study.  
 
I would like to thank my second supervisor, Dr David Guilliano (UEL) for his 
support, Dr Qi Peng (KCL) for assisting with the imaging aspects of this study 
and Mrs Kulachelvy Ratnasothy (KCL) for helping with the genotyping of mice. I 
would especially like to thank all the people that assisted this study, Mr Azizillo 
Karimov, Ms Baiba Nimane, Ms Danesse Nebiar and Mr Imad Mourafik.  
 
Last but certainly not least, I would like to express my profound gratitude to my 
family, particularly my parents Mita Sen and Sushanta Lal Sen, my sister 
Tanushree Sen and my grandmother, Jharna Choudhury. Their understanding, 







Oral Presentations  
❖ School of Health, Sport and Biosciences Post-graduate research 
conference – March 2017  
❖ Post 92 Bioscience Research Conference, London, England- May 2017. 
❖ SIICA, EFIS, International retreat for PhD students in Immunology, 
Verona, Italy – October 2017 
❖ School of Health, Sport and Biosciences Post-graduate research 
conference – March 2018  
❖ Division of Transplantation Immunology and Mucosal Biology, King’s 
College London, UK – April 2018 
❖ AHC College Research Day (Three-minute Thesis competition) – June 
2018 
❖ Research Update Conference (RUC) for the School of Immunology & 
Microbial Sciences, King’s College London, UK- September 2018. 
❖ 5th European Congress of Immunology, Amsterdam, Netherlands- 
September 2018.  
❖ School of Health, Sport and Biosciences Post-graduate research 
conference – February 2019  
Poster presentations  
 
❖ British Society for Immunology Annual Congress, Brighton, England- 
December 2017 
 
Awards and grants 
 
❖ UEL HSB funded PhD Studentship- February 2016  
❖ Travel grant: SIICA International retreat of PhD students in Immunology- 
October 2017  
❖ Travel grant: BSI Annual Congress-  December 2017  
❖ Three Minute Thesis (3MT) competitions: United Kingdom semi-finalist-  
June 2018  
❖ Travel grant: European Congress of Immunology- September 2018  
❖ UEL Health, Sports and Bioscience postgraduate conference: First prize 
presentation- October  2018. 
❖ UEL Health, Sports and Bioscience postgraduate conference: First prize 





Sen, M., Ratnasothy, K., Peng, Q., Nebiar, D., Mourafik, I., Ambrosini, M.,  
Guiliano, D., van Kooyk, Y., Lombardi, G. and Smyth, L.A. (2020). Targeting 
recipient dendritic cells with sialic acid modified donor alloantigen induces 
antigen-specific tolerance and promotes skin transplantation survival in vivo - 























































1.1 Historical outline of transplantation 
 
Transplantation has been one of the most ground breaking medical 
interventions for organ failure for centuries, with procedures dated back to 
600B.C (Barker & Markmann, 2013). The process of transferring a functional 
organ from one individual to another has been a sought after medical 
phenomenon for centuries and due to on-going research in the following years, 
successes have included heart, liver, intestinal and the most recent triumph, the 
full face transplant [Fig. 1.1] (Barret et al., 2011).  However, successful organ 
transplantation has always been challenging.  
 
A study by Voronoy (1937) highlighted this problem and demonstrated that 
human kidney transplants between individuals with major mismatched blood 
groups were quickly rejected (Barker & Markmann, 2013).  Amongst the 
pioneers of transplantation, Peter Medawar paved the way in understanding the 
link between transplantation success and the graft recipient's immune 
response.  He investigated skin allograft (donor organ from a genetically non-
identical individual, derived from the same species) outcomes in rabbits and 
observed complete or partial degeneration of the architecture of rejected skin 
grafts (Medawer, 1944; Barker & Markmann, 2013). His study highlighted organ 
tissue destruction to be a possible outcome of acute inflammation induced by a 
large repopulation of recipient leucocytes within the genetically non-identical 
skin graft, an assessment made using histological analysis (Medawer, 1944; 
Barker & Markmann, 2013). Later, Medawar and Billingham performed skin 
transplants on larger animals, cows, in order to ascertain that genetically 
identical donor and recipients (such as twins) as opposed to genetically non-
identical individuals, have a greater chance of transplant acceptance (Barker & 
Markmann, 2013).  
 
This led to further research on the exchange of blood and stem cells between 
twins in utero. In 1954 Dr Murray and Dr Hume at Brigham Hospital in Boston, 
were able to successfully engraft kidneys between identical twins, marking this 
as the world’s first successful kidney transplant (Delmonico, 2002). Medawer’s 
pioneering research led to studies which determined whether modifying the 
transplant recipient prolonged skin graft survival. To assess this, recipient mice 
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foetuses were inoculated with donor spleen cells which led to skin graft 












Figure 1.1. 3D CT scan of patient before and after receiving a full-face 
transplant. A. Image taken before full-face transplant. B. Image taken 4 months 
post full-face transplant. Figure adapted from: Barret et al., (2011).  
 
1.2 Transplant rejection and allorecognition 
 
Despite these successes, transplant rejection remains a persistent problem, 
particularly in non-identical individuals. This is due to the recipient's immune 
system. The immune system has developed the ability to distinguish ‘self’ (own 
proteins) and ‘non-self’ (foreign pathogens/ proteins) molecules. In the context 
of transplantation, a donor’s organ is recognised as non-self foreign 'invader', 
resulting in activation of the recipient's immune cells and the eventual 
destruction of the transplanted organ. The process whereby the recipient 
immune cells recognise antigens on donor tissue is known as allorecognition. 
Allorecognition is driven by recipient T cells, which recognise donor antigens 
presented via major histocompatibility complexes (MHC) on antigen presenting 









1.2.1 Major histocompatibility complex and alloantigens 
 
MHC molecules expressed on immune cells are the driving force for 
allorecognition and initiation of an immune response, following a transplant 
(Benichou et al., 2011).  There are two types of MHC, MHC Class I (MHC I) 
which is present on all nucleated cells and its role is to present endogenous 
peptide antigen to CD8+ T cells (cytotoxic T cells), whereas MHC Class II (MHC 
II) is mainly present on APCs and presents exogenous antigens to CD4+ T cells 
(helper T cells) [Fig. 1.2] (Benichou et al., 2011).  
 
MHC molecules are highly polymorphic and each individual possess multiple 
variants of genes that encode for their MHC. The genes that encode MHC is 
located on murine chromosome 17 (Stuart, 2015) and on human chromosome 6 
(Francke & Pellegrino, 1977). The human MHC molecules are referred to as 
Human Leukocyte Antigen (HLA) (MHC I subclasses: HLA- A, B, and C and 
MHC II subclasses:  HLA- DP,DM, DQ and DR) and in mouse as H-2 genes 
(MHC I subclasses: H-2D, K, L and MHC II subclasses: H-2A(I-A) or H-2E(I-E). 
In a transplant setting, the donor graft consists of cells expressing donor MHC 
molecules which the recipient immune cells will recognise as foreign leading to 
rejection- in this case the donor MHC (whether it be intact or processed into 
peptides) is then referred to as an alloantigen [Fig. 1.3]. To assess the 
likelihood of rejection, laboratory tests such as mixed lymphocyte reactions 
(MLRs) involving co-culture of recipient and donor lymphocytes and assessing 
their proliferative capacity will help decipher whether an immune response 
occurs, additionally, HLA-tissue typing is another method that determines the 
level of genetic similarity between the donor and the recipient thus providing an 
effective predictor for graft rejection. However, the presence of minor 
histocompatibility antigens (non-MHC derived such as placenta-derived Ags, H-
Y Ags) (Linscheid & Petroff, 2013), which also contribute to rejection, make 
finding a complete match extremely challenging. The minor histocompatibility 
antigens are effective at mediating the indirect pathway of allorecognition, which 
is described in section 1.2.2.2 (pg.8), and provides an explanation as to why 
MHC-matched skin grafts can be rejected (Warrens et al., 1994; Roopenian et 
















Figure 1.2. 3D structures of MHC I and II. A. 3D structure of MHC I molecule 
present on all nucleated cells containing α1, α2, α3 and β2-microglubulin 
subunits and a peptide binding groove with the capacity to bind to peptides 
approx. 8-11 amino acids in length. B. 3D structure of MHC II molecule present 
on APCs containing α1, β1, β2 and α2 subunits and a peptide binding groove 
with the capacity to bind to peptides approx. 13-25 amino acids in length. Image 




























Figure 1.3. MHC genetic disparity can contribute to transplant rejection.  
MHC mismatched skin graft between two genetically non-identical individuals 
can contribute to rejected allograft. Skin transplant between genetically identical 
individuals with matched MHC does not amount to transplant rejection. 
Transplant between unmatched MHC individuals (eg: H2-Kd donor and H2-Kb 
recipients) contributes to transplant rejection.  
 
1.2.2 Allorecognition and contribution to transplant rejection 
 
Allorecognition consists of three pathways which include; direct, indirect and 
semi-direct pathways of allorecognition. All of which contribute towards 
rejection, however each pathway is characteristically different (Siu et al., 2018).  
 
1.2.2.1 Direct allorecognition  
 
Direct allorecognition is defined by pre-existing alloreactive recipient T cells 
recognising donor MHC molecules on donor-derived DCs or ‘passenger cells’, 
(Boardman et al., 2016). The aforementioned T cells make up approximately 
10% of the T cells present within the recipient (Veerapathran et al., 2011; 
Boardman et al., 2016).  In order to understand how these alloreactive T cells 
respond to donor MHC, one model proposed that the amino acid polymorphic 
regions of allogeneic MHC on the surface of donor DCs are recognised by 
recipient TCRs and elicit T cell activation- this is known as high determinant 
density model (Bevan, 1984). The second model, known as the multiple binary 
complex model, describes that the allopeptide bound to the donor MHC forms 
an allogeneic MHC-peptide complex which mimics self-MHC molecules so that 
MHC I (H2-Kb) 
MHC I (H2-Kd) 
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they can be recognised by a vast range of recipient TCRs (Matzinger & Bevan, 
1977).  
 
Earlier studies have demonstrated the importance of this pathway, for example 
Lechler and Batchelor (1982), demonstrated the role of donor-derived DCs in T 
cell activation which was confirmed in a rat kidney transplant model where graft 
survival was prolonged in recipients depleted of passenger leukocytes. Another 
study demonstrated that kidney allograft rejection was imminent in the presence 
of donor-derived DCs in irradiated recipient mice administered with direct-
allospecific CD4+ T cells (Braun et al., 1993). In fact, it was recently shown that 
a particular subset of donor-derived skin CD103+ DCs are able to present 
allogeneic MHC II to prime T cells with direct allorecognition and induce acute 
rejection (Borges et al., 2018). The donor CD103+ DCs were able migrate to 
host lymph nodes from the donor skin allograft and drive the direct pathway 
(Borges et al., 2018). Additionally, when donor skin grafts were incubated with 
M. tuberculosis DnaK (DnaK) solution which is a bacterial ortholog of heat 
shock protein 70 which can decrease MHC II expression on skin donor CD103+ 
DCs, followed by applying skin grafts onto mice, direct alloreactivity was 
reduced and thus improved murine skin graft survival (Borges et al., 2018).  
 
Effector CD4+ and CD8+ T cells are crucial for the establishment of direct 
allorecognition. One study using SCID and Rag1-/- mice demonstrated that 
cardiac allografts containing MHC II- expressing donor cells were acutely 
rejected in the presence of adoptively transferred CD4+ T cells (Pierta et al., 
2000).  On the contrary, the aforementioned recipient mice transplanted with 
donor heart grafts with MHC II-deficient cells and adoptively transferred CD4+ T 
cells, also rejected the cardiac graft, but at a distinctly slower pace (Pierta et al., 
2000) demonstrating the requirement of both donor MHC II cells and CD4+ T 
cells to initiate rejection (Pierta et al., 2000). To further stress the importance of 
CD4+ T cells in acute rejection, help from CD4+ T cells that have been activated 
via the direct pathway, stimulate CD8+ T cell cytotoxic immunity in response to 





Direct allorecognition gives rise to acute transplant rejection which is 
characterised by fast-paced onset of transplanted organ failure which develops 
days to a few weeks post transplant. This was attributed to MHC gene disparity 
between the donor and the recipient contributing to antibody-mediated rejection 
and cellular rejection (Benzimra et al., 2017). Acute cellular rejection is 
mediated by the recognition of donor MHC on APCs which present antigens to 
recruited effector T lymphocytes (Benzimra et al., 2017). This type of rejection 
can be identified quickly and alleviated through the use on immunosuppressive 
drugs (ISD) such as corticosteroids, however recurrent episodes of rejection 
would inevitably lead to chronic rejection.   
 
1.2.2.2 Indirect allorecognition  
 
In 1982, Lechler and Batchelor proposed the pathway of indirect allorecognition. 
The aforementioned study noticed that despite depletion of donor DCs that led 
to prolonged allograft survival, rat kidney grafts were still rejected (Lechler and 
Batchelor, 1982). It was then discovered that recipient APCs were able to 
present peptides derived from donor MHC from graft tissue to recipient T cells 
to stimulate allograft rejection- indirect allorecognition (Fangmann et al., 1992; 
Benichou et al., 1992; Auchincloss et al., 1993; Pierta et al., 2000; Benichou et 
al., 1997). Benichou et al., (1992) demonstrated recipient APCs that presented 
peptide derived from polymorphic regions from the donor MHC where able to 
instigate proliferation of T cells derived from murine skin grafted recipients. It 
was published one year later in 1993 that skin grafts derived from donor MHC II 
knock-out mice and transplanted onto recipient mice with CD4+ T cells 
(depleted of CD8+ T cells), had rejecting skin grafts suggesting that donor Ags 
were presented via self-MHC II molecules, thus confirming the role of recipient 
APCs and CD4+ T cells in indirect allorecognition (Auchincloss et al., 1993).  
 
The CD4+ T cell mediated direct allorecognition has been shown to be 
aggressive. Post transplantation, NK cells (Garrod et al. 2010) and CD4+ T cells 
assist in the removal of donor cells, thereby limiting number of donor DCs to 
instigate direct allorecognition (Ali et al., 2016).  The direct pathway only 
remained persistent for an extended period of time when immune cells such as 
NK cells and CD4+ T cells were depleted (Ali et al., 2016). Within the recipient, 
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donor DCs are depleted by prolonged interactions with recipient NK cells, 
however it was shown that depleting donor DCs did not prevent allograft 
rejection (Garrod et al., 2010). One study demonstrated using CD11c-DTR 
mice, (B6 mice expressing the diphtheria receptor under the CD11c promoter 
where injection of diphtheria toxin (DT) into these mice leads to the transient 
loss of all CD11c+ DCs and/or macrophages (van Blijswijk et al., 2013)), that 
heart allografts were prolonged when recipient DCs were depleted as opposed 
to just depleting donor DCs (Garrod et al., 2010).   
 
Indirect allorecognition is known to be long-lived and can remain for many years 
post-transplant, thereby leading to chronic graft rejection that cannot be 
alleviated using ISD (Baker et al., 2001). Brennan et al., (2009), confirmed the 
contribution of indirect allorecognition to chronic transplant rejection, when 
comparisons were made with direct allorecognition in a murine skin graft model. 
Their study found that recipient T cells that were activated by donor APCs via 
direct allorecognition were not able to continue the allorecognition response 
when donor passenger cells were depleted (Brennan et al., 2009). However, in 
the absence of donor APCs, T cells that were activated via indirect 
allorecognition were still able to reject murine skin grafts, demonstrating the 
persistence of this response (Brennan et al., 2009). 
  
Unlike direct allorecognition, indirect allospecific T cells are restricted to specific 
TCRs recognising specific alloantigens. The indirect alloresponse occurs in 
reaction to a few determinants which are the highly polymorphic regions on the 
donor MHC (Benichou et al., 1994; Benichou et al., 1997). In fact, Ali et al., 
2016 published that murine MHC I alloantigen peptides presented via self-MHC 
II restricted DCs could increase proliferation of indirect CD4+ T cells within the 
host, as opposed to MHC II- derived alloantigen peptide.  They reasoned that 
this was due to the limited and short-lived presence of donor hematopoietic 
cells within the recipient which was the source of donor MHC II alloantigens (Ali 
et al., 2016). Whereas MHC I alloantigens were derived from the donor’s organ 
parenchyma cells which are more persistent within the recipient (Ali et al., 
2016). Therefore, the origin of alloantigens can contribute towards the 




Ali et al., (2016) study compared the duration of allorecognition pathways and 
determined that indirect allorecognition remained persistent in establishing 
rejection. Unlike acute rejection, chronic rejection is much more difficult to treat 
due to its persistence and can occur months-years post transplant. This disease 
results in complete tissue injury and loss of graft function, caused by the 
activation of alloreactive T and B cells and narrowing of graft blood vessels, 
thereby restricting blood-flow to the graft and scarring of graft tissue (Kloc & 
Ghobrial, 2014). This kind of rejection is particularly prominent in MHC- 
mismatched individuals. 
 
1.2.2.2.1   Role of B cells in indirect allorecognition 
 
B cells and APCs are known to express MHC molecules and are thus able to 
contribute to transplant rejection via their ability to activate T cells and 
production of donor-specific antibodies (alloantibodies) (Constant et al., 1995; 
Brandle et al., 1998). Antigen presenting B cells recognise Ags via their BCR, 
followed by processing and presenting of Ag via MHC II (Adler et al., 2017). 
Following this interaction, B cells present Ag via MHC II to the corresponding 
TCR resulting in T cell activation which is also supported by the engagement of 
B cells CD40 and CD40L on the T cell (Adler et al., 2017).  They also have the 
ability to support the proliferation of memory T cells which in turn has shown to 
accelerate murine skin graft rejection as a consequence of B cell help (Ng et al., 
2010).  
 
The antigen presenting potential of B cells has been demonstrated by Rossetti 
et al., (2018), where B cells treated with anti-CD40 upregulated MHC II and 
stimulated T cell anti-tumour responses, whereas DCs were resistant to anti-
CD40 stimulation. To support the role of B cells in rejection, a murine cardiac 
transplant model demonstrated that mice deficient of MHC II expressing B cells 
had prolonged allograft survival in comparison to wild type mice (Noorchashm 
et al., 2006). Previous transplant regimens have adopted B cell depletion using 
anti-CD20 monoclonal antibodies for the purpose of suppressing the 
development of alloantibodies which contribute to organ rejection (Clark & 
Ledbetter, 2005). Production of donor-specific IgG antibodies or alloantibodies 
against donor MHC, has been shown to enhance heart and skin transplant 
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rejection in murine models. One study in particular demonstrated that anti-Kd 
alloantibodies act as opsonins that are acquired by APCs to enhance the 
indirect pathway of allorecognition by supporting proliferation of adoptively 
transferred CFSE- labelled Kd-specific T cells in B6 mice (Burns and Chong, 
2011).  They also observed that administering anti-Kd alloantibodies to BALB/c 
skin transplant recipients who also received anti-CD154 (or CD40L) and DST of 
splenocytes, acutely rejected transplants in comparison to mice that were not 
treated with anti-Kd (Burns and Chong, 2011). Overall, this demonstrates a role 
of B cells for stimulating transplant rejection and targeting these cells may help 
to promote tolerance.   
 
1.2.2.3 Semi-direct allorecognition  
 
It has been established that the indirect pathway is a CD4+ T cell response; 
however, it was introduced by Matzinger (1977) that alloreactive CD8+ cells 
could also be indirectly activated, therefore making indirect allorecognition less 
restricted to CD4+ T cell activation (Benichou et al., 2011).  Theoretically, 
exogenous alloantigens are presented via MHC II to CD4+ T cells to mediate 
indirect allorecognition. CD8+ T cells require assistance from CD4+ T cells in 
order for them to become activated. For this interaction to occur, two APCs are 
required; one recipient APC presenting alloantigen via MHC II to indirect 
allospecific CD4+ T cells and one MHC I expressing donor APC to present Ag to 
direct alloreactive CD8+ T cells, thus a total of four cells. This is also known as 
the ‘four-cell’ conundrum which led to a perplexing question regarding the 
logistics of this interaction. This conundrum was resolved during the discovery 
of the semi-direct pathway of allorecognition or ‘cross-dressing’, where one 
APC is required rather than two (Herrera et al., 2004) [Fig 1.4C].  
 
Transplant rejection is not only mediated via antigen presenting DCs, but also 
by antigen transporting DCs, where allogeneic intact MHC molecules are 
acquired by recipient DCs that then prime alloreactive T cells. This process is 
able to initiate both direct CD8+ T cell and indirect CD4+ T cell allorecognition 
pathways simultaneously on the same recipient DC: one by the transfer of intact 
MHC class I molecules by donor DCs/parenchyma to recipient DCs (direct 
pathway) and the other mechanism in which donor MHC class I molecules are 
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processed and presented as peptides via recipient DCs MHC class II (indirect 
pathway). Therefore, leading to the three-cell model and solving the ‘four-cell 
conundrum’. The semi-direct pathway was first described by Herrera et al., 
(2004) as acquisition and presentation of the entire donor MHC molecules 
present on endothelial cells by recipient DCs and extended to acquisition of 
MHC on donor DCs  (Smyth et al., 2017; Brown et al., 2008). They discovered 
in vitro that recipient DCs acquired donor MHC from allogeneic endothelial cells 
or DCs isolated from mice, this was also observed in vivo under 
proinflammatory conditions where mice where administered with IFN-γ to 
induce local inflammation followed by CFSE- labelled DCs (Herrera et al.,  
2004). Furthermore, Smyth et al., (2017), demonstrated that recipient DCs were 
able to acquire MHC I from allogeneic skin graft which can be sustained for 
more than one month following murine skin transplantation, thereby 
demonstrating the persistence of CD8+ T cell effector immune response and the 
semi-direct pathway (Smyth et al., 2017).  
 
Recently, it has been shown that recipient DCs can acquire donor MHC through 
the uptake of extracellular vesicles (EVs). EVs are small vesicles that can be 
50-100nm in size that may contribute to activation of graft specific T cells 
throughout the lifespan of the graft and to chronic rejection (Liu et al., 2001; Liu 
et al., 2016; Morelli et al., 2017). It is not only DCs that can acquire EVs, we 
have unpublished data demonstrating that murine B cells are able to acquire 
donor- DC-derived  EVs, which can in turn stimulate proliferation of antigen-
specific T cells in vitro. This would suggest that both DCs and B cells may play 
a role in semi-direct allorecognition, however, further studies would need to 






































Figure 1.4. Three pathways of allorecognition. A. Direct allorecognition- donor 
APCs present intact donor MHC to recipient CD4+ or CD8+ T cells. B. Indirect 
allorecognition- recipient APCs acquire donor alloantigens and are presented via 
self-MHC to recipient CD4+ T cells. C. Semi-direct allorecognition- Recipient 
APCs are able to acquire (i) donor MHC- expressing cells or (ii) uptake intact 
donor MHC molecules via vesicles, which are presented to CD4+ or CD8+ T cells 
(direct), (iii) Recipient APCs can also acquire alloantigens (donor MHC-derived) 
which have been shed by donor cells and are then presented via self-MHC to 
recipient CD4+ T cells (indirect).  
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1.2.3. Immune responses that constitute allograft rejection  
 
Effector immune responses occur almost immediately post transplantation. 
Donor DCs or passenger leukocytes migrate to the recipient’s secondary 
lymphoid organs where they then activate naïve recipient T cells into 
alloreactive effector T cells. These effector T cells then go on to migrate 
towards the donor’s transplanted organ where they initiate damage. Th1 cells 
contribute to acute rejection by the secretion of cytokines such as IFN-γ,TNF-α 
and IL-2 which helps for the recruitment of NK cells, macrophages and 
stimulate cytotoxic CD8+ T cells (CTL). These CTLs release cytolytic 
component such as granzyme B and perforin which can induce cell apoptosis 
(Benichou et al., 2011). 
 
Memory T cells in particular are robust at maintaining rejection due to their 
ability to become activated by low antigen stimulation and resistance to 
immunosuppression which constitutes a major barrier to transplant tolerance 
(Benichou et al., 2011). Memory CD4+ T cells have various roles such as 
providing help to CTLs and/or assisting in the generation of pathogenic IgG 
alloantibodies despite costimulatory blockade using donor-specific cell 
transfusion and anti-CD40 ligand antibody (Chen et al., 2004). In addition, B 
cells that generate IgG alloantibodies can be influenced by the release of IFN-γ 
by memory CD4+ T cells (Gorbacheva et al., 2015).  
 
DCs can increase in numbers, recognise alloantigens and migrate to secondary 
lymphoid organs where they make contact and activate T cells, resulting in their 
differentiation to cytotoxic, T helper or memory effector T cells (Liu & 
Nussenzweig., 2010). Recipient DCs also have the capability to migrate and 
infiltrate the donor’s organ to elicit rejection. One study tested whether recipient 
DCs simply circulate through the donor’s organ and uptake alloantigens derived 
from the graft, which are then presented to recipient T cells in the secondary 
lymphoid organs, or the possibility that these DCs mediate effector function on 
T cells within the graft (Zhuang et al., 2016). They discovered that within the 
donor organs, donor DCs were eventually replaced with recipient DCs, these 
recipient DCs were able to support proliferation and effector function of T cells 
15 
 
within the graft thereby supporting rejection of transplanted cardiac and kidney 
tissues in mice (Zhuang et al., 2016).  
 
1.2.4 The role of macrophages in rejection 
 
The role of macrophages in transplant rejection is yet to be fully elucidated, 
however several studies have demonstrated the contribution by these cells to 
transplant rejection. It is established that macrophages are phagocytic cells with 
APC ability that can form as first-line defence to foreign pathogens as well as 
foreign allografts. The role of macrophages was confirmed when one study 
found that ablation of macrophages in CD11b-DTR mice (diphtheria toxin 
receptor gene under CD11b reporter so that administration of DT can ablate 
CD11b+ macrophages)  led to reduced infiltration of macrophages towards the 
donor kidney and less incidences of acute allograft rejection (Qi et al., 2008). 
Extensive macrophage proliferation at transplant sites can release a variety of 
proinflammatory mediators resulting in local inflammation that gives rise to 
donor organ damage (Grau et al., 1997). Once macrophages have infiltrated 
the organ, they can produce large amounts of proinflammatory cytokines such 
as TNF-α, IFN-γ, IL-1, IL-6 and IL-12 which can lead to tissue damage to the 
organ (Li et al., 2019). With regard to IL-12, Yang et al., (2003) demonstrated 
the importance of this cytokine in chronic rejection and observed that blocking 
the action of IL-12 which is a cytokine required for Th1 development, reduced 
allograft injury. In fact IL-12 KO mice were more resistant to renal ischemia and 
reperfusion injury, thus demonstrating the importance of this cytokine in 
rejection (de Paiva et al., 2009). The specific subset of macrophages which are 
known to produce these cytokines upon stimulation such as LPS are known as 
M1 macrophages, that are thought to support Th1 responses as opposed to M2 
which are regarded as anti-inflammatory characterised by the release of IL-10 
and TGF-β (Martinez and Gordon, 2014).  
 
Macrophages extend their role in transplant rejection by acting as APCs. IFN-γ 
released by activated T cells upregulate expression of MHC II on their surface 
and present antigens which have been phagocytosed by the macrophage to 
CD4+ T cells. In fact macrophages have the ability to phacogytose materials of 
the graft and present these to CD4+ T cells, leading to anti-donor T cell 
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responses (Wyburn et al., 2004). In 2018, one study demonstrated the 
importance of Nuclear factor of activated T-cells 5 (NFAT5) for the expression 
of MHC II on the surface of macrophages (Buxadé et al., 2018). OVA peptide 
loaded- NFAT5 deficient macrophages reduced their capability to stimulate OT-
II CD4+ T cell proliferation, in addition skin derived from NFAT5−/− donor mice 
delayed allograft rejection when transplanted onto recipient WT mice (Buxadé 
et al., 2018). Therefore, this would suggest that macrophages with antigen 
presenting ability can instigate rejection. Nonetheless, macrophages can also 
be considered as tolerance inducers given their ability to present commensal 
bacteria and host antigens to CD4+ T cells and their tolerogenic capacity will be 
discussed in later sections (Shouval et al., 2014).  
 
1.3 Mechanisms of peripheral tolerance and contribution to transplant 
tolerance   
 
1.3.1 Immune tolerance mechanisms to contain allorecognition 
 
Peripheral tolerance occurs outside of the thymus and can be described as the 
unresponsiveness to self-antigens presented via self-MHC restricted APCs. The 
outcome is the prevention of the development of self-reactive T cells, which 
were not negatively selected in the thymus. Deletion, anergy and the induction/ 
expansion of regulatory T cells (Tregs) are all mechanisms identified to maintain 
peripheral tolerance (Sakaguchi et al., 1995; Shaban et al., 2018) and all of 
which have been utilised for promotion of transplant tolerance. The definition of 
transplant tolerance was introduced by Medawer as unresponsiveness to 
antigens (Billingham et al., 1953) or has been described as tolerance when 
recipients are able to maintain stable allografts once weaned from ISD for more 
than a year (Feng et al., 2012).  Several mechanisms that induce peripheral 




T cell clonal deletion occurs in the thymus when TCRs expressed on 
thymocytes bind strongly to self-Ag MHC complex, leading to apoptosis. This 
plays a key role in central tolerance. It is not only in the periphery where 
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alloreactive T cell deletion supports allograft survival, intrathymic deletion can 
also prolong transplant survival (Manilay et al., 1998) such as one study that 
injected antigen-pulsed APCs that promote tolerance, or also known as, 
‘tolerogenic APCs’, via intrathymic injection and noticed donor type allografts 
were indefinitely accepted (Garrovillo et al., 1999).  
 
This mechanism is also employed in inducing peripheral transplantation 
tolerance by T cell apoptosis, such as activation induced cell death (AICD), 
which can occur after repetitive antigen exposure. Deletion is crucial for the 
control of clonal expansion alloreactive T cells so that the population size of 
these T cells are small and can in turn be easily controlled via other peripheral 
tolerance mechanisms.  
 
Wells et al., (1999), demonstrated the importance of passive cell death for 
transplant tolerance by utilising B-cell lymphoma-extra large (Bcl-xL) transgenic 
mice which over-express Bcl-xL gene on T cells, which prevents apoptosis of 
alloreactive T cells by cytokine deprivation. Chronic rejection and 
arteriosclerosis of MHC-mismatched cardiac transplant was observed in mice 
over-expressing Bcl-xL and could not be abrogated in the presence of tolerance 
induction protocols such as (Cytotoxic T-lymphocyte-associated protein 4) 
CTLA-4 – immunoglobulin (Ig) or anti-CD154 blockade (Wells et al., 1999). 
Therefore, this demonstrates the importance of alloreactive T cell deletion for 




The term anergy can be described as long-term hyporesponsiveness caused by 
partial activation, leading to the failure of T cells to proliferate or produce cues 
to support T cell proliferation- this can be utilised to support allograft survival 
(Lechler et al., 2001; Chen et al., 2017). One study discovered that pancreatic 
islet transplant recipient mice were rendered tolerant to the allograft following 
treatment with an anti-CD3 antibody which contained alloantigen-specific CD4+ 
T cells (Besançon et al., 2017). These CD4+ T cells were anergic and displayed 
high expression of PD-1 inhibitory receptor and CD73hiFR4hi, two markers 
known to be expressed on anergic T cells (Besançon et al., 2017). The former 
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study also found that along with anergy, Tregs assisted in murine pancreatic 
islet allograft survival, thereby demonstrating that multiple peripheral tolerance 
mechanisms could contribute to allograft survival (Besançon et al., 2017).  
CTLA-4 is known to interact with CD80/86 which has been shown to promote T 
cell anergy (Greenwald et al., 2008). CTLA-4 Ig in particular has the ability to 
prevent CD28 interaction with CD80/86, thus impairing T cell activation and has 
demonstrated its use in transplant tolerance induction of murine cardiac 
allograft survival (Pearson et al., 1994; Schwarz et al., 2016).  
 
 
1.3.1.3 Regulatory T cells 
 
Tregs maintain self-tolerance, protecting the body from disorders such as 
autoimmune disease by suppressing self-reactivity through the recognition of 
self-antigen (Ag) (Corthay, 2009). Tregs are a heterogeneous population of 
CD4+ and CD8+ T cells, the former subdivided into thymic derived Tregs 
(tTregs) which constitute 5-10% of CD4+ T cells and peripheral Tregs (pTregs) 
which develop in the periphery upon Ag-recognition and cytokine stimulation 
such as transforming growth factor β (TGFβ) and are the main drivers of 
peripheral tolerance (Issa and Wood, 2012). Tregs are known to constitutively 
express high levels IL-2 receptor α-chain (CD25) and require absorption of 
proinflammatory IL-2 for their survival and development and limiting the 
availability of IL-2 for effector T cells to utilise (Sakaguchi et al., 1995; Fan et al., 
2018). They also express transcription factor Forkhead box P3 (Foxp3) and the 
loss in function of this transcription factor has been known to break tolerance 
and cause autoimmune diseases (Brunkow et al., 2001; Wildin et al., 2001). 
This transcription factor has also shown to be crucial for the suppression of 
proinflammatory cytokines such as IL-2 and IFN-γ (Khan, 2016). As mentioned 
previously, Tregs constitute of naturally occurring Tregs derived from the 
thymus (tTregs) or peripherally derived Tregs (pTregs) and markers such as 
Neuropillin-1 (Yadav et al., 2012; Weiss et al., 2012) and Helios (Thornton et 
al., 2010) help to establish differences between the two. In addition, Tregs 
generated ex vivo are known as induced Tregs (iTreg). Subsets of murine Tregs 
include Treg type 1 cells (Tr1) which lack Foxp3 expression, inducible 
costimulator (ICOS+) Tregs, and double negative Tregs- all types secrete 
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immunosuppressive cytokines, IL-10 and TGFβ (Zhang et al., 2014) (Juvet & 
Zhang, 2012; Zhang et al., 2015). A subset of CD8+ T cells also has 
suppressive properties; the CD8+ Tregs (Guillonneau et al., 2010).  
 
Human Tregs are also considered a highly heterogeneous population. They 
express markers such as CD4, CD25 and express low levels of CD127 (an IL-7 
receptor α chain) and Foxp3. Level of Foxp3 expression in human Tregs can 
vary; such as Tregs which are naïve or resting are CD45RA+ Foxp3low, Tregs 
that are effector or activated Tregs are CD45RA-Foxp3high. However, it becomes 
further complicated in humans as conventional and activated CD4+CD25- T 
cells can also develop Foxp3 expression, therefore in order to characterise 
Foxp3+ Treg cells, the methylation state on Treg specific demethylation regions 
(TSDR) on the Foxp3 gene can be assessed, where suppressive Foxp3+ Tregs 
have demethylated TSDR (Toker et al., 2013). Other subsets of Tregs exist 
including Th3 which can be induced from CD4+ CD25- cells by TGF-β and IL-4 
cytokines (Weiner et al., 2001) and similarly to mouse, humans comprise of Tr1 
Tregs in the presence of IL‐10 and IFN‐α (Levings et al., 2001).  
 
1.3.1.3.1 How do Regulatory T cells mediate immunosuppressive functions?  
 
Tregs have the ability to suppress immune cells in various ways. They have the 
ability to suppress T effector cells via cytokines IL-10, IL-35 and TGF-β release 
(Burrell et al. 2012). Tregs also have role in suppressing costimulatory 
molecules, CD80 and CD86 on APCs, which in turn makes them poor 
stimulators of effector T cells. One study reported bone marrow (BM) and 
spleen (SPLN)- derived  DCs that were co-cultured with Tregs resulted in down-
regulation of CD80/86, mediated via CTLA-4 expressed on Tregs, resulting in 
inhibited T cell proliferation (Oderup et al., 2006). A mechanism of how CTLA-4 
down-regulates CD80/86 expression was described by Qureshi et al., (2011) 
where CTLA-4 interacted with CD80/86 on opposing APCs by mediating trans-
endocytosis, resulting degradation of these costimulatory molecules.  
 
As well as CTLA-4, Tregs also express lymphocyte activation gene-3 (LAG-3) 
which has ability to bind to MHC II on murine BM-DCs, and as a result can 
inhibit DC activation (Liang et al., 2008). The aforementioned study assessed in 
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vitro that LAG-3 deficient OT-II Tregs were not as suppressive as WT OT-II-
specific Tregs when co-cultured with OT-II peptide- pulsed BM-DCs. In addition 
maturation of MHC II-/- BM-DCs, as measured by CD86 expression, was 
increased when co-cultured with Tregs (WT or LAG-3-/- Treg), as opposed to 
Treg co-culture with WT BM-DCs (Liang et al., 2008). Therefore, LAG-3 on 
Tregs and MHC II on BM-DCs interactions are required to prevent maturation of 
BM-DCs (Liang et al., 2008).  
 
Another function of Tregs is cytolysis, described as the killing of target cells. 
Granzyme B is a serine protease present is cytolytic NK cells, CD8+ T cells and 
CD4+ Tregs where the latter can promote apoptosis of effector T cells (Cao et 
al., 2007). One study found that Tregs that had a loss of Granzyme B function 
were not able to induce indefinite murine skin allograft survival as opposed to 
normal Tregs (Gondek et al., 2008). Another apoptosis inducing mechanism is 
Fas/FasL interaction, where one study demonstrated that interaction between 
FasL expressing Tregs with Fas expressing DCs, mediated DC apoptosis and 
limited their antigen-presenting capacity to initiate effector CD8+ T cell immune 
responses (Gorbachev and Fairchild, 2010).  In addition to the aforementioned 
mechanisms, Galectin-9 interaction with  Tim-3 has been found to enhance the 
induction of Foxp3+ Tregs from conventional CD4+ CD25- T cells in humans, 
and reduced expression of both Galectin-9 and Tim-3, as seen in intracranial 
aneurysm patients, significantly impaired Treg induction (Zhao et al., 2018; 
Madireddi et al., 2017).  
 
Tregs have a role of depriving effector T cells of cytokines. As mentioned 
previously, Tregs express high levels of CD25, IL-2 receptor, which has shown 
to utilise IL-2 for their survival and in turn deprive this cytokine from proliferating 
effector T cells and/or lead to apoptosis of effector T cells (Sakaguchi et al., 
1995; Padiyan et al., 2007; Bull et al., 1990).  Another mechanism for how 
Tregs mediate apoptosis of target cells is via tumour necrosis factor-related 
apoptosis inducing ligand (TRAIL)/ death receptor 5 (DR5) pathway (Ren et al., 
2007). In fact, blocking of this receptor using DR5 blocking antibodies led to 
decrease of CD4+ effector T cell apoptosis in vitro and reduced murine skin 
allograft survival when this antibody was mixed with adoptively transferred 
Tregs (Ren et al., 2007).  
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Human and murine Tregs have the ability to make extracellular vesicles (EVs) 
that are able to suppress T cells activation and cytokine production. For 
example, EVs known as exosomes derived from Tregs have been shown to 
contain MicroRNA (miRNA), particularly miR-150-5p and miR-142-3p, which 
were shown to be taken up by DCs, rendering them tolerogenic indicated by an 
increase of  immunosuppressive IL-10 cytokine secretion (Tung et al., 2018). 
Furthermore, Tregs have the ability to disrupt metabolic pathways by 
expressing ectoenzymes CD73 and CD39, their expression generates anti-
inflammatory adenosine known to suppress effector T cells proliferation 
(Deaglio et al., 2007).  In fact exosomes derived from murine Tregs were shown 
to secrete secreting CD73 to mediate immune suppression (Smyth et al., 2013).  
  
Given that Tregs have the ability to modify immune responses, there has been 
a growing interest in their role in transplantation with respect to immune 
tolerance. As Tregs were present in accepted grafts [Table 1], many 
researchers have focused on increasing the number of Tregs in the transplant 
by either administering Tregs (exogenous) or by manipulating DCs to expand or 
induce (endogenous) Tregs. The next section focuses on the role of Tregs in 
murine transplant models.  
 
1.3.1.3.2 Regulatory T cells in murine transplant models [Table. 1] 
 
During allorecognition in murine models, Tregs elicit their suppressive function 
by initially migrating to the donor organ and then to the draining lymph nodes 
(dLN) to continually dampen effector alloreactivity and promote tolerance, 
(Zhang et al., 2009).  In the study by Zhang et al., (2009), adoptively transferred 
PKH26 (red fluorescent dye that labels the cell membrane) labelled Tregs were 
administered locally to the islet allograft and were monitored in recipient mice, 
the authors noticed that in mice with surviving allografts, Tregs were able to 
migrate towards the afferent lymphatics and to the dLN to mediate suppression 
of effector T cells (Zhang et al., 2009).  
 
Alloantigen-specific Tregs can also be generated in vitro and adoptively 
transferred in vivo to prolong allograft survival (Yu et al., 2011; Nikolouli et al., 
2017). Alloantigen-specific Tregs generated by co-culture of Foxp3+ Tregs with 
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donor SPLN-DCs treated with vitamin C were able to demonstrate stable Foxp3 
expression, as well as increased murine skin graft survival when administered 
to recipient mice (Nikolouli et al., 2017). In another murine study, Tregs with 
indirect specificity which have been ex vivo expanded by donor MHC- specific 
DCs, when administered to murine recipients in combination with anti-CD8 
depletion (to deplete CD8+ direct alloreactive cells) and Rapamycin, induced 
indefinite cardiac allograft survival (Tsang et al., 2009).  
 
In addition to administering ex vivo generated Tregs, endogenous Tregs may 
be increased to improve transplant survival (Ochando et al., 2006; Battaglia et 
al., 2006). As an example, Magee et al., (2019), recently showed that blocking 
Notch-1 signalling using an anti-Notch-1 antibody, significantly prolonged MHC-
mismatched allograft survival. These authors showed that this was due to 
reduced graft-infiltrating conventional T cells and an increase of Foxp3+ Tregs.  
 
It is established that Tregs are important in prolonging transplant survival and 
there are protocols to increase the amount of Tregs using APCs such as DCs 



















Table. 1: Murine Regulatory T cell subsets and examples for their 








Sorted naïve CD4+CD25+ T cells and CD4+CD25- 
from CBA mice were administered to recipient CP1-
CBA mice, followed by B10.BR skin (Graca et al., 
2002). Mice co-transferred with naïve CD4+ CD25+ 
T cells had skin graft prolongation, suggesting that 
naturally-derived Tregs also have the potential to 




pDCs presenting donor alloantigens induced 
alloantigen CD4+, CD25+, Foxp3+ Tregs  via TGF-β 
which mediated cardiac allograft survival (Ochando 
et al., 2006). 
Tregs with indirect allospecificity were generated 
and expanded ex vivo using autologous DCs pulsed 
with donor alloantigen. When these Tregs were 
introduced into recipient mice along with IST, 
indefinite fully MHC- mismatched heart allograft 
survival as induced (Tsang et al., 2009). 
Another study demonstrated the potential of 
expanding adoptively transferred Tregs in vivo by 
administering low dose IL-2; this was shown to 
prolong murine skin allograft survival (Kulachelvy et 
al., 2019). 
Tr1 CD4, CD25 
These Tregs are also induced in the periphery. In an 
murine islet allograft model, mice treated with IL-10 
and rapamycin were able to promote tolerance as a 




Studies have found that CD8+ Tregs, along with low 
dose of immunosuppressant, were able to prevent 
allograft rejection (Lin et al., 2009). CD8+Tregs have 
shown to be cross-immunosuppressive towards 
CD4+ effector T cells and can be induced from CD4+ 














Figure 1.5. Inhibitory function of regulatory T cells: production of anti-
inflammatory cytokines, cell-death as a consequence of cytolysis, competition 
for interaction with DCs with effector T cells, metabolic disruption, modifying 
DCs and miRNA released from Treg exosomes. Image adapted from: Martin- 
Moreno et al., (2018). 
 
1.4 Using DCs, B cells and Macrophages for transplant tolerance 
 
Given the immunoregulatory role of Tregs in transplantation, strategies have 
been developed to increase the number of these cells by targeting specific cells 
such as APCs. APCs (such as DCs, B cells and macrophages) are some of the 
key players in allorecognition and rejection. DCs in particular have been 
modified and administered to recipients, or have been targeted in situ in order 
to modify the recipient’s immune system to favour transplant survival.  
  
1.4.1 Dendritic cells 
 
DCs have a crucial role in stimulating immune responses as well as promoting 
tolerance. In vivo, steady-state DCs promote tolerance to self-antigens - these 
are known as tolerogenic DCs (TolDCs) (Morelli & Thomson 2011). These 
TolDCs have an inability to initiate effector T cell responses, due to their low 
expression of MHC I and II as well as costimulatory molecules (CD80/86), 
however, they have the ability to induce/ expand Tregs  (Lutz, et al., 2004; 




1.4.1.1 Mechanisms used by TolDCs to mediate tolerance 
 
As previously mentioned, peripheral tolerance can be induced via deletion, 
anergy or Treg induction/ expansion. DCs express many surface markers, 
including some that directly interact with cognate receptors on T cells to 
promote tolerance. For example, DCs promote T cell deletion following 
interaction of Fas-L on DCs and Fas on T cells. Murine BM-DCs transfected to 
express Fas-L induced apoptosis of Fas+ T cells in vitro and when 
administered into fully MHC-mismatched cardiac transplanted recipients, grafts 
prolongation was observed (Min et al., 2000). Another surface marker 
expressed on DCs, Programmed death-ligand 1 (PD-L1), also impairs effector 
T cell responses. Administering kidney MHC-mismatched allograft rat 
recipients with BM-DCs transfected with adenovirus expressing PD-L1, 
resulted in transplant survival as a result of impaired CD8+ T cell proliferation, 
as well as IL-2 and IFN-γ production (Peng et al., 2011). PD-L1 expressing 
murine BM-DCs are also able to promote expansion of Tregs, which induced 
islet allograft tolerance (Wu et al., 2013).  
 
Cell surface markers expressed on DCs such as ICOS-L and Ig-like transcript 
(ILT) 2, 3 and 4 can promote T cell anergy. Following interaction of ICOS-L on 
human monocyte-derived DCs and ICOS expressing T cells, CD4+ T cell anergy 
was observed which was blocked when ICOS expression on T cells was 
removed (Tuttenberg et al., 2009). In addition to ICOS-L, Ig-like transcript 
(ILT)2, 3, and ILT4, two of which are expressed on tolerogenic DCs, have been 
shown to promote T cell anergy (Chang et al., 2002). DCs that express these 
markers were shown to promote anergic T cells, preventing their ability to 
proliferate (Chang et al., 2002). To support the aforementioned author’s 
findings, one study reported that DCs isolated from human PBMCs were 
rendered tolerogenic under the influence of IL-10 and 1α, 25-dihydroxyvitamin 
D3 (D3) and identified increased expression of ILT3 and ILT4 as a 
consequence of IL-10 treatment (Manavalan et al., 2003).  
 
DCs have been reported to release immunomodulatory cytokines such as IL-
10 and TGF-β to promote tolerance (Comi et al., 2018; Laouar et al., 2008). IL-
10 is a cytokine known to down-regulate proinflammatory responses and 
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impair antigen presentation. A subset of DCs known to produce IL-10 present 
in humans, known as DC10, are able to induce hyporesponsive T cells as well 
as induce Tr1 Tregs, therefore establishing themselves as a regulatory DC 
(Comi et al., 2018). TGF-β is a cytokine produced by DCs with a role in 
tolerance induction by impairing T cell proliferation and inducing Tregs from 
CD4+ T cells. Transgenic mice expressing an inactivated TGF-β receptor on 
DCs have exacerbated autoimmunity in an EAE model with strong 
inflammation and T cell proliferation in the central nervous system (Laouar et 
al., 2008). 
 
DCs also impair effector immune responses by modulating metabolic activity via  
vitamin D3 (Gregori et al., 2001), Indoleamine 2,3- dioxygenase (IDO) (Xie et 
al., 2015), inducible nitric oxide synthase (iNOS) and arginase (Arg) (Simioni et 
al., 2017). Vitamin D3 is known to be involved in calcium and bone metabolism 
as well as impairing effector immune responses (Casteels et al., 1995), along 
with mycophenolate mofetil (MMF) which inhibits B and T cell activation, were 
able to modify DCs in favour of a tolerogenic phenotype (Gregori et al., 2001). 
Administration of vitamin D3 and MMF to islet allograft murine recipients 
displayed allograft survival and increase in Tregs in tolerant mice (Gregori et al., 
2001). DCs from mice treated with vitamin D3 and MMF were tolerogenic, 
demonstrated by down-regulation of costimulatory CD80/86 molecules and 
dampened production of IL-12 (Gregori et al., 2001). Another nutrient 
deprivation mechanism is though IDO, which is an enzyme that assist with 
tryptophan catabolism and deprives T cells of tryptophan resulting in their 
suppression. IDO expressing DCs were shown to suppress T cell proliferation in 
vitro and mice receiving IDO treated DCs in a murine small bowel 
transplantation model, had surviving allografts (Xie et al., 2015). 
 
Overall, given that steady state/immature DCs have the ability to perform 
peripheral tolerance by some of the mechanisms named above, these APCs 
have become a prime target to prevent unwanted aberrant immune responses, 
and have therefore established themselves as cellular immunotherapy to battle 





1.4.1.2 Use of tolerogenic DCs in human clinical trials 
 
Extensive preclinical research using animal models have paved the way to the 
use of TolDCs in human clinical trials. The ONE study was a collaborative effort 
by laboratories based in the UK, US, Germany, France and Italy, to develop 
immunotherapeutic approaches to tackle kidney allograft rejection without the 
reliance of ISD (Geissler, 2012). Amongst the regulatory cell types studied, DCs 
were one of cells tested, particularly monocyte-derived DCs (Geissler, 2012). 
Research has suggested that certain IL-10 producing monocyte-derived human 
DCs have the ability to induce Tregs and suppress effector T cell proliferation 
(Boks et al., 2012; Naranjo-Gomez et al., 2011).  
 
TolDC immunotherapeutic approach can not only be used to overcome 
transplant rejection, but also other autoimmune disorders such as rheumatoid 
arthritis (RA), Chron’s disease, etc. (Joo et al., 2014; Jauregui-Amezaga et al., 
2015). A study by Harry et al., (2010), assessed the stability of TolDCs in RA 
patients and established TLR 2 expression as a marker for TolDCs due to its 
high expression in these DCs and low expression in mature DCs. In addition, a 
Phase 1 clinical trial in 2014 demonstrated a good outcome of RA patients that 
were administered with autologous DCs pulsed with recombinant 
peptidylarginine deiminase 4 (PAD4), heterogeneous nuclear ribonucleoprotein 
A2/B1(RA33), citrullinated-filaggrin (cit-FLG) and vimentin antigens, 
demonstrating an increase in Tregs in peripheral blood (Joo et al., 2014).  
 
1.4.1.3 Modifying and targeting alloantigens to DCs to promote transplant 
tolerance 
 
1.4.1.3.1 Modifying donor-derived DCs and recipient-derived DCs to promote 
graft prolongation 
 
Given the promising data obtained by the aforementioned clinical trials 
(Benham et al., 2015; Joo et al., 2014; Jaregui-Amezaga et al., 2015), TolDCs, 
either of donor or recipient origin, may prove to be an effective 
immunotherapeutic approach to battle unwanted immune responses such as 
transplant rejection as discussed in a review by Moreau et al., (2012).   
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Various studies have determined the potential of treating transplant recipients 
with donor-derived DCs as a means of promoting allograft survival (Lutz et al., 
2000; Lu et al., 1997; DePaz et al., 2003; O’Flynn et al., 2013). Particularly, 
Lutz et al., (2000) demonstrated that donor-derived murine BM-DCs could be 
rendered tolerogenic ex vivo by growing DCs in the presence of low dose 
granulocyte-macrophage colony-stimulating factor (GM-CSF). These DCs were 
phenotypically immature and were insufficient at activating an effector T cell 
response in vitro as opposed to BM-DCs treated with higher concentration of 
GM-CSF. When these low-dose GM-CSF-treated donor BM-DCs (derived from 
C57BL/10J mice) were introduced into CBA recipient mice, 7 days prior to 
C57BL/10J cardiac transplantation, allograft prolongation or indefinite skin graft 
was induced (Lutz et al., 2010). This response was identified to be antigen-
specific as third-party NZW/LacJ cardiac allografts were rejected (Lutz et al., 
2010).   
 
Smyth et al., (2013) investigated whether donor-derived DCs can modulate 
indirect allorecognition in favour of allograft survival in a murine MHC-
mismatched transplant model. Dexamethasone (Dex)-D3  treated donor-derived 
BM-DCs, which in vitro were resistant to activation via proinflammatory stimuli 
(LPS, anti-CD40, TNF-α), promoted antigen specific T cell hyporesponsiveness 
to alloantigen rechallenge and expanded Tregs in vitro. However, these DCs 
failed to prolong MHC I-mismatched skin transplant survival in vivo even in the 
absence of CD8+ T cells (Smyth et al., 2013). In fact these authors observed 
that administration of donor TolDCs prior to transplant led to accelerated graft 
rejection. To explain the rejection observed, it was established that MHC 
alloantigens, derived from the drug-treated donor DCs, were presented to 
alloreactive T cells by recipient DCs and primed CD4+ T cell responses via the 
indirect pathway (Smyth et al., 2013). These authors observed transplant 
survival using Dex and D3 treated donor DCs, but only when recipient mice 
were devoid of cross-presenting recipient CD8α+ DCs, suggesting a role of 
CD8α+ DCs in priming alloantigen specific T cells (Smyth et al., 2013).  
 
In addition to the aforementioned, there are several other disadvantages of 
administering donor-derived DCs, one being the risk of donor DCs depleted by 
host NK cells after administration, which has been shown by Yu et al., (2006) 
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and may enhance the risk of sensitization. In addition, in vitro generated 
tolerogenic donor DCs therapy is only applicable to live donors, whereas 
tolerogenic DCs derived from the live recipient can be generated at any time 
point (Morrelli and Thomson, 2007). Therefore, an alternative to administering 
‘tolerogenic’ donor DCs, would be the administration of ‘tolerogenic’ recipient-
derived DCs (Peche et al., 2005; Bériou et al., 2005). One study aimed to 
address the efficacy of recipient DCs, in comparison to donor DCs, in a rat 
cardiac transplant model (Peche et al., 2005). They identified that an adherent 
population of recipient derived rat BM-DCs, generated in vitro with low dose of 
GM-CSF and IL-4, were tolerogenic. These BM-DCs which were administered 
one day before a mismatched heart transplant, led to improved allograft survival 
(Median survival: 22.5 days) far better than recipient rats receiving donor-
derived BM-DCs (Median survival: 16.5 days). Thus, this adherent population of 
recipient derived BM-DCs have proven to be successful in allograft survival 
(Peche et al., 2005; Hill et al., 2011), and multiple studies have opted for the 
use of injecting recipient DCs for transplant immunotherapy (Bass et al., 2014; 
Segovia et al., 2014; Garrovillo et al., 1999).  
 
1.4.1.3.2 Pulsing recipient DCs with alloantigens 
 
Treating transplant recipients with donor Ag-pulsed recipient DCs in order to 
induce tolerance via inhibiting the indirect allorecognition pathway has also 
been studied. Garrovillo et al., intrathymically injected recipient Lewis rats with 
allogeneic MHC class I (RT1.Au) peptide only or RT1.Au peptide- pulsed 
recipient DCs, followed by a Wistar Furth  (WF, RT1u) rat heart graft 7 days 
post infusion (Garrovillo et al., 1999). They showed that targeting recipient rats 
with donor Ag-pulsed recipient DCs intrathymically or administering native 
donor-Ag, with complementary transient antilymphocyte serum 
immunosuppressant, led to long-term allograft survival (Garrovillo et al., 1999). 
Interestingly, in comparison to Smyth et al., (2013) study, the aforementioned 
found that Ag-pulsed recipient-derived DCs significantly prolonged heart 
allograft survival, therefore suggesting that thymus targeting may be useful for 
targeting indirect allorecognition (Garrovillo et al., 1999). However, it should be 
taken into account that both studies are different in terms of transplant models 




In a murine heart transplant model, rapamycin (RAPA) treated recipient-derived 
BM-DCs help to prolong allograft survival (Taner et al., 2004) due to their poor 
capacity to stimulate T cells, and their resistance to maturation stimuli such 
CD40 stimulation (Turnquist et al., 2007). These RAPA-DCs when pulsed with 
donor alloantigen and infused into murine recipients, with a short course of 
RAPA post-transplant, led to indefinite allograft survival accompanied by an 
increase in Treg numbers (Turnquist et al., 2007). The loading of recipient DCs 
with donor alloantigen  was extended to non-human primate models. Ezzelarab 
et al., (2017) investigated renal transplant tolerance in Indian rhesus macaques 
following administration of donor alloAg-pulsed recipient monocyte-derived 
DCs. In this study recipient macaques received untreated or donor Ag-pulsed 
monocyte-derived DCs, which were pulsed via cell-membrane vesicles derived 
from donor peripheral blood mononuclear cells (PBMCs), one day before an 
MHC-mismatched kidney graft (Ezzelarab et al., 2017). Recipient-derived, 
donor alloAg-pulsed DCs, in addition to low-dose immunosuppressant 
rapamycin treatment, improved transplant survival by an increase in mean 
survival time of 27 days in comparison to transplant recipients treated with 
unpulsed DCs. In addition this treatment decreased donor-reactive IL-17+ T 
cells, which were associated with human renal allograft rejection (Ezzelarab et 
al., 2017; Krummey et al., 2014).  
 
Another issue to administering 'tolerogenic' DCs is that they appear to be short-
lived within the host and rather than performing their role of presenting 
antigens, administered DCs are in fact re-processed by recipient APCs (Divito 
et al., 2010; Smyth et al., 2013). Therefore, targeting endogenous DCs at 
quiescent state in situ may be more advantageous. The obvious disadvantage 
to in vitro-generated DCs for clinical use is the time it takes to generate 
'tolerogenic' DCs which can take several days, this is not an issue when DCs 
are targeted in situ.  
 
One way to promote alloantigen specific tolerance is by targeting alloantigen to 
specific cell surface receptors expressed by different DC subsets [Table 2]. An 
example; includes targeting recipient CD11chigh CD8α+ and CD8α- DC in situ 
using donor-derived apoptotic cells given intravenously, promoted aortic 
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allograft survival (Wang et al., 2009). Along with allograft survival, T cell 
deletion and Foxp3+ cells were induced as well as a decrease of 






Table 2: Examples of murine DC subsets (modified from Eisenbarth, 2019. 
DC subset 
Example of cell 
surface markers 








Require Batf3, IRF8 for their 
development. 
 
CD8α and C103 DCs have the 
ability to cross- present Ags to 
CD8+ T cells and are also known to 
express Langerin.  
 
Hildner et al., 
2008; Sichien 
et al., 2016 ; 
den Haan et al., 
2000; Haniffa et 
al., 2012; 
Sanchez- 
Paulete et al., 
2017; Bigley et 
al., 2014. 
cDC2 
CD4, DCIR2, signal 




This is subset may be involved in 
CD4+ T cell priming  
Suzuki et al., 
2004; 
Gao et al., 
2014; Williams 
et al., 2013. 
Plasmacytoid 
DC 




Requires IRF8 for their 
development. 
Release Type 1 Interferons and is 
associated with fighting viral 
infections. 
Sichien et al., 
2016; 
Asselin- Paturel 
et al., 2001; 






Constitute a population of tissue-
resident macrophages that serve 
as APCs within skin by priming 
naïve T cells against foreign Ags. 
Indoyaga et al. 




1.4.1.3.3 Targeting alloantigens to cell surface receptors expressed on DCs to 
induce tolerance  
 
Antigens can be targeted to specific receptors in vivo when coupled to a 
monoclonal antibody directed towards a specific cell surface marker [Table. 3]. 
Targeting cell surface receptors present on DCs with antigens, to induce 
peripheral tolerance was extensively reviewed by Steinman et al., (2003). For 
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example, CD205 (DEC-205), abundantly found on CD8α+ CD4-DCs within 
lymphoid tissues, is a well-studied receptor to assess tolerance induction.  It 
has been shown that targeted CD8α+ DCs in vitro and in vivo with ovalbumin 
protein antigen (OVA) coupled to a monoclonal antibody recognising DEC-205, 
rendered OVA-specific CD8+ T cells unresponsive to OVA (Bonifaz et al., 2000). 
A study by Hawiger et al., (2001) also found that targeting DEC-205 expressing 
DCs in vivo, with a DEC-205 specific monoclonal antibody fused with hen egg 
white lysozyme (HEL) protein antigen, resulted in reduced T cell activation 7 
days post infusion (Hawiger et al., 2001).  They also found that T cells from 
these mice could not be reactivated when re-challenged with HEL peptide in 
Complete Freund's adjuvant (CFA) 7 or 20 days later (Hawiger et al., 2001). 
Whereas mice that were treated with saline and rechallenged with HEL peptide/ 
CFA, showed strong HEL-specific T cell proliferation ex vivo (Hawiger et al., 
2001).  Therefore highlighting that this targeting regimen induced antigen-
specific tolerance. 
 
In addition, alloantigen coupled to DC receptor specific antibodies, have proven 
to be an effective immunotherapeutic approach to combat transplant rejection. 
A mouse donor MHC Class I alloantigen (Kd) conjugated to a monoclonal 
antibody directed towards DCIR2 (33D1), a receptor present on murine CD4+ 
CD8- DCs, was shown to induce indirect pathway-mediated antigen-specific 
tolerance in a mouse skin transplant model (Tanriver, et al., 2010). These 
authors demonstrated indefinite transplant survival in mice treated with this 
construct, however only when mice were depleted on CD8+ T cells (Tanriver, et 
al., 2010). They also observed that unlike alloreactive CD4+ T cells, which were 
deleted following targeting, Tregs numbers remained intact.  In addition to 
targeting DCIR2 subset of DCs, targeting the immunodominant domain of 
human type XVII collagen (hNC16A) to DEC-205 receptors expressed on CD8α 
DCs using a DEC-205 Ab (DEC-hNC16A) significantly prolonged hNC16A 






Figure 1.6. Phenotypic profile of mature DCs versus immature tolerogenic 












Method Outcome Ref.  






DEC-205 murine DCs were 
targeted by administering 
immunodominant domain 
of human type XVII 
collagen, hNC16A, which 
was conjugated to DEC-
205 Ab (DEC-hNC16A) to 
naive B6 mice 14 days 
prior to skin transplant. 
Skin transplants from 
human type XVII 
collagen transgenic 
mice, were either 
indefinitely prolonged 






cDC2 DCIR2 33D1- MHC I (H2-Kd) 
monomer was 
intravenously administered 
to target DCIR2 DCs in B6 
mice,14 days prior to MHC 
I mismatched skin 
transplant.  
B6.Kd skin transplant 
was only indefinitely 
prolonged with 
administration of anti-
CD8 to abrogate CD8+ 
T cell responses and 
was accompanied by a 
reduction in 



















1.4.2. B cells and their role in transplant tolerance 
 
Transitional B cells are a specific subset of B cells present at the intermediate 
stages of B cell development between the bone marrow and the spleen. After 
development in the bone marrow, immature B cells are developed in the 
periphery through various stages and can be divided into transitional phases 
and cell populations: transitional 1 (T1) (IgMhighIgD−CD21−CD23−), transitional 2 
(T2) (IgMhighIgD+CD21+CD23+) (Chung et al., 2003; Allman and Pillai, 2008) and 
mature B cells constituting of marginal zone (MZ) B cells (IgMhighCD21hiCD23-) 
(Zouali and Richard, 2011) which make up 5% of the B cell population in the 
spleen and are known to be efficient antigen presenters to CD4+ T cells 
(Attanavanich and Kearney, 2004) and follicular (FO) B cells 
(IgMlowCD21+CD23+) (Petro et al., 2002; Allman and Pillai, 2008), which can 
interact with CD4+ helper T cells via CD40/CD40L and differentiate into plasma 
cells or memory B cells (Steele et al., 1996). The stages of development begin 
from the bone marrow to then migration to the spleen which are characterised 
by T1 B cells, followed T2 and finally mature B cells (Petro et al., 2002). T1 are 
thought to undergo apoptosis following BCR engagement (Petro et al., 2002) 
whereas T2 B cells are more responsive to antigen stimulation (Chung et al., 
2002).  
 
A particular subset of B cells described T2, are believed to be regulatory and 
promote allograft survival (Moreau et al., 2014). When T2 B cells isolated from 
mice that were rendered tolerant to MHC I mismatched skin graft were 
adoptively transferred to murine skin transplant recipients, prolonged allograft 
survival was observed (Moreau et al., 2014). These as well as T1 B cells were 
also found to contribute to allograft survival in mice that were housed under 
non-SPF conditions (Alhabbaba et al., 2015).  In humans, IL-10 producing 
Transitional B cells were found in recipients that were tolerant to kidney 
allografts as opposed to recipients experiencing chronic rejection (Lamperti et 
al., 2016).  Another subtype of murine regulatory B cells (Bregs) known as 
CD5+CD1dhi B10 cells, has been shown to produce IL-10 even in the presence 
of  LPS, PMA/ Ionomycin stimulation, thus demonstrating their anti-inflammatory 
potential (Yanaba et al., 2008; Mauri and Bosma, 2012).  
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Volchenkov et al., (2013) showed that Dex-D3 treated IL-10 producing human 
TolDCs, were capable of inducing Tr1 Tregs and surprisingly, Bregs 
(Volchenkov et al., 2013). Interestingly, it was recently discovered that IL-10 
producing Bregs were able to form strong interactions with antigen-specific 
effector CD8+ and CD4+ T cells impairing their function. As a consequence, this 
Breg: T interaction inhibited subsequent DC: T interactions, thereby limiting T 
cell responses (Mohib et al., 2020). Using microscopic imaging studies, they 
demonstrated that in the presence of conventional B cells, OVA pulsed BM-DCs 
were able to make contact with OVA-specific CD8+ T cells (OT-I), whereas in 
the presence of Bregs, contact between OT-I T cells and DCs were impaired 
(Mohib et al., 2020). Whether this interaction between Breg: T cells interferes 
with TolDCs interaction with T cells has yet to be determined.   
 
1.4.3. Macrophages and their role in transplant tolerance 
 
Macrophages also have a regulatory role and have been shown to promote 
transplant tolerance in human and murine recipients (Hutchinson et al., 2011; 
Riquelme et al., 2013). Like DCs, macrophages display various functions 
depending on their activation status (M1, M2), from killing invading 
microbes/antigens to regulating the immune responses (Mregs). This plasticity 
in function is dependent on the immune microenvironment. Mregs are known to 
produce IL-10 and low levels of IL-12 and can also be induced by co-culturing 
human macrophages with Tregs (Tiemessen et al., 2007). There have been 
several studies that have targeted/modified macrophages to promote 
transplantation tolerance (Zhao et al., 2018; Conde et al., 2015). Recently Zhao 
et al., (2018) showed that inhibiting the mammalian target of rapamycin (mTOR) 
in M2 anti-inflammatory macrophages induced expression of PD-L1 and 
prevented chronic cardiac allograft rejection. In addition macrophages express 
specific receptors that promote tolerance, one being DC-SIGN, and it has been 
demonstrated that these particular macrophages were able to support the 
accumulation of Tregs and promoted heart allograft survival (Conde et al., 
2015). Overall, macrophages make an interesting target to improve graft 
survival with experiments and trials being undergone (Hutchinson et al., 2011; 
Riquelme et al., 2017) and markers such as dehydrogenase/reductase 9 
(DHRS9) expressed on human regulatory macrophages make it feasible to 
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identify and target these cells to promote tolerance (Riquelme et al., 2017). 
 
1.5  Sialic acid-binding immunoglobulin-like lectins 
 
Siglecs are type 1 transmembrane proteins found on human and mouse cells 
which consist of an extracellular N-terminal V-set immunoglobulin domain, 
designated for sialic acid binding, and an immunoreceptor tyrosine-based 
inhibitiory motif (ITIM) receptor in its cytoplasmic portion [Fig.1.7-1.8] (Jandus et 
al., 2011). Siglecs E, F, G, and CD169 (Siglec H does not bind to sialic acids) 
are able to bind to sialic acid containing glycans or sialylated ligands and are 
present on the surface of leucocytes such as DCs, macrophages, B cells, 
eosinophils and T cells (Jandus et al., 2011).  
 
There are two types of immunoreceptor tyrosine motifs, one is an 
immunoreceptor tyrosine-based activation motif (ITAM) and the inhibitory 
counterpart is known as an ITIM [Fig. 1.7] (Barrow & Trowsdale, 2006). Siglec 
receptors inhibit certain immune response, due to their ITIM in the cytosolic 
region which down-regulates cell signalling [Fig.1.7-1.8] (Avril et al., 2004; 
Paulson et al., 2012). ITIMs upon phosphorylation by Src tyrosine kinases act 
as docking sites for SHP or Src homology 2 (SH2)-domain cytoplasmic 
phosphatases such as SHP-1 or SHP-2 [Fig. 1.7] (Barrow & Trowsdale, 2006). 
This interaction leads to dampening of intracellular signalling pathways and 
immune responses as outlined in Table 4.  
 
Sialic acids are a group of sugars composed of 9 carbon residues derived from 
neuraminic acids and within this group, N-acetyl neuraminic acid (Neu5Ac) is 
primarily found in humans. Sialic acids are known to be distributed at the end of 
glycoproteins present on the cells surface, making them available for 
interactions with cognate cells (Cohen and Varki, 2010). Sialic acids have an 
importance role in immunoregulation, with deficiencies in sialic acids causing 
autoimmunity, immunological abnormalities such as deficiencies in T and B cell 
proliferation in animals (Jenner et al., 2006). In addition, sialic acids binding to 
Siglecs lead to the concept of sialic acids acting as self-associated molecular 
patterns (SAMPs), making Siglecs receptors for ‘self’ recognition (Varki, 2011).  
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Siglecs have specificity for different configurations of sialic acids such as α2,3, 
α2,6 and α2,8 linked sialic acids, where the α2,8- linked sialic acids are a 
combination of α2,3 and α2,6 linked, configurations (Pillai et al., 2012). Siglecs 
present on DCs and macrophages have been shown to have specificity for α2,3 
and/or α2,6 sialic acids, whereas α2,6 linked sialic acids are mostly recognised 
by Siglecs CD22 and Siglec G expressing B cells, however some Siglec G 













Figure 1.7. Structure and function of ITAM and ITIM. A. Activatory ITAM. B. 
Inhibitory ITIM can counteract activatory ITAM upon tyrosine phosphorylation 
and inhibit cellular processes. Image adapted from Munitz & Levi-Schaffer 
(2007).  
 
1.5.1. Targeting ITIM-bearing Siglecs to impair aberrant immune responses  
 
Several pathogens as well as certain tumours, have exploited Siglec receptors; 
sialic acid interactions to evade host immune defences (Laϋbli et al., 2014). In a 
mouse metastasis model, blocking Siglecs on neutrophils enhanced anti-tumour 
responses (Laϋbli et al., 2014). In fact Siglec E knockout mice, which is a 
homologue of human Siglec 9, showed enhanced killing of tumour cells, 
demonstrating that hypersialylated tumours and interactions with Siglecs can 
dampen the immune system, thus allowing the tumour to survive (Laϋbli et al., 
2014). In addition to hypersialylated tumours, pathogens expressing sialic acid 




structures on the flagellum of Campylobacter jejuni, are able to engage with 
Siglecs on host human monocyte-derived DCs leading to a profound increase 
of IL-10 supporting an anti-inflammatory environment favouring the survival of 
C.jejuni within the host (Stephenson et al., 2014).  
 
Due to the modulatory characteristic of these Siglecs, Siglec-sialic acid 
interaction has been utilised to inhibit the immune system. Recently, Perdicchio 
et al., (2016) targeted Siglecs on BM-DCs, SPLN-DCs and endogenous DCs in 
mice to induce tolerance (Perdicchio et al., 2016). These authors adopted two 
different mouse models to address their investigation: OVA protein and an 
encephalitogenic peptide derived from myelin oligodendrocyte glycoprotein 
(MOG). In the OVA model, these authors observed that murine SPLN-DCs were 
able to induce tolerance in vitro and in vivo following α2,3 or α2,6-linked 
sialylated OVA (Sia-OVA) treatment (Perdicchio et al., 2016). This was 
demonstrated in mixed lymphocyte reactions whereby OVA specific CD4+ and 
CD8+ effector T cells (isolated from OT-II and OT-I mice, which express a 
transgenic receptor specific for OVA, respectively) stimulated with ex vivo 
isolated mouse SPLN-DCs pulsed with either α2,3 or α2,6 Sia-OVA, had 
reduced production of pro-inflammatory cytokines (IFN-γ and TNF-α) and 
increased proportions of Foxp3+ Tregs as compared to untreated and non-
sialylated OVA pulsed DCs (Perdicchio et al., 2016). In order to assess whether 
targeting endogenous DCs using sialylated antigen can promote tolerance in 
vivo, the authors of the aforementioned study administered 50μg of α2,6 Sia-
OVA, followed by priming of mice with a subcutaneous injection of 
OVA/polyinosinic–polycytidylic acid [poly(I:C)]/anti-CD40 antibody (Perdicchio et 
al., 2016). In mice treated with sialylated OVA as opposed to OVA alone, the 
authors observed a significant reduction of IFN-γ producing CD8+ and CD4+ T 
cells, which were also accompanied by an increased frequency of Foxp3+ 
Tregs. This observation suggests that sialylated antigen treatment promoted an 
immunosuppressive environment, indicated by a reduction of effector T cells 
and an increase in Tregs, in vivo (Perdicchio et al., 2016). These authors 
suggested that their findings were mediated via Siglec E. When they targeted 
Sia-OVA to Siglec E knock out BM-DCs, the efficiency of Tregs induction was 
reduced in vitro as opposed to Sia-OVA targeted WT BM-DCs (Perdicchio et al., 
2016). Lastly and importantly, these authors also described that targeting 
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sialylated-peptide antigen rather than native antigen also induced antigen-
specific tolerance in vitro (Perdicchio et al., 2016). DCs pulsed with Sia-MOG 
peptide and co-cultured with MOG-specific CD4+ T cells (2D2 T cells), induced 
these cells to express Foxp3 and reduced differentiation of 2D2 T cells into IFN-
γ producing effector cells (Perdicchio et al., 2016). However the author did not 
present data on the effects of sialylated peptide antigens in vivo, which is what 
the current thesis will address.  Overall their study highlighted that targeting 
Siglecs on recipient DCs with a sialylated protein or peptide, can induce 
antigen-specific tolerance in vivo (Perdicchio et al., 2016). 
 
Below we highlight murine Siglecs and give examples of their expression and 
known inhibitory immune responses.  
 
1.5.2  Examples of murine Siglecs and their inhibitory roles  
 
❖ Siglec F 
Examples of Siglec F- expressing cells: Eosinophils, DCs, Macrophages 
Siglec F -/- mice challenged with an allergen had enhanced lung eosinophillic 
inflammation in a lung allergy model, suggesting that ITIM containing Siglec F 
has a role in modulating allergic responses in vivo (Tateno et al., 2007). Siglec 
F is also present on macrophages in murine alveoli and expression can be 
induced following GM-CSF treatment (Guilliams et al., 2013) (Tateyama et al., 
2019). The exact role of Siglec F on murine macrophages remains to be 
determined, however by Liu et al (2019), identified that Siglec F engagement in 
murine alveolar macrophages does not affect their phagocytic ability. It has 
been reported that Siglec F is expressed on both BM-DCs and BM-DMs, 
however the authors did not present this data (Tetano et al., 2007). 
 
❖ Siglec E 
Examples of Siglec E- expressing cells: DCs and macrophages 
Sialylated Trypansoma cruzi are able to evade the host immune system through 
interaction with Siglec E expressing DCs, resulting in decreased production of 
the proinflammatory cytokine IL-12 and reduced Th1 responses (Erdmann et 
al., 2009). Siglec E- expressing murine macrophages targeted with α2,8 sialic 
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acid decorated nanoparticles reduced production of proinflammatory cytokines 
in response to LPS stimulation and were found to be beneficial in treating a 
pulmonary injury model in mice (Spence et al., 2015). 
 
❖ Siglec G 
Examples of Siglec G- expressing cells: DCs and B cells 
Siglec G-/- B cells display enhanced BCR signalling and increased accumulation 
of B1a cells, which resulted in increased humoral immunity (Pillai et al., 2013).  
Siglec G has also been studied as an inhibitor of DAMPs; CD24 is a 
sialoglycoprotein which associates with Siglec ligands as side chains, 
particularly Siglec G (Pillai et al., 2013). CD24 forms a complex with HMGB1 
(high mobility group protein box 1), which is a DAMP released in response to 
tissue damage, and in turn associates with Siglec G/ 10 to produce reduced NF-
kB activation and suppressed immune response towards HMGB1, thus 
preventing uncontrolled inflammation (Chen et al., 2009). In fact, Siglec G-/- 
mice displayed an aberrant increase of proinflammatory cytokines and acute 
organ failure in response to HMGB1 in an acetaminophen (AAP)-induced liver 
necrosis model (Chen et al., 2009). In relation to transplantation, this CD24- 
Siglec G interaction has been shown to be a negative regulator of DAMP 
release and adaptive T cell allorecognition in a graft-versus-host disease mouse 
model (Toubai et al., 2014). CD24+ donor T cells are able to interact with Siglec 
G recipient DCs to mitigate the severity of GVHD in comparison to donor CD24-
/- T cells and recipient Siglec G-/- DCs in vivo (Toubai et al., 2014). Furthermore, 
Siglec G expression is not only limited to the surface of immune cells but can 
additionally be found within murine CD8α+ DC phagosome (Ding et al., 2016). 
Siglec G can inhibit CD8+ T cell adaptive immune response by impairing DC 
cross presentation in response to pathogenic antigens (Ding et al., 2016). Ding 
et al., (2016) demonstrated how Siglec G interaction with Listeria monoyctes 
inhibited MHC I- peptide complex formation by impairing NADPH oxidase 2 
(NOX 2) activation thus acidifying the DC phagosome, which in turn causes 
excessive antigen degradation within the DC phagosome and inhibited antigen 





❖ Siglec H 
Examples of Siglec H- expressing cells: Plasmacytoid dendritic cells (pDCs), 
Siglec H in comparison to other Siglecs, has two major differences. Firstly, it 
does not need to recognise sialic acid to function and secondly it contains an 
ITAM instead of an ITIM (Zhang et al., 2006). Although, these differences 
suggest that a sialylated ligands might not interact with Siglec H, this Siglec has 
been shown to inhibit immune responses. For example, Loshko et al., (2007) 
inhibited Ag-specific Th responses in an autoimmune mouse model by targeting 




Examples of Siglec CD22- expressing cells: B cells 
CD22 has a high affinity for α2,6-linked sialic acids. It is highly expressed on 
mature B cells and is one of the most studied amongst all the Siglecs (Mahajan 
et al., 2016). CD22 and Siglec G are known to inhibit immune responses by 
downregulating B cell receptor (BCR) signalling, either by BCR crosslinking 
interaction of α2,6 sialic acids present on the same surface (cis interaction) or 
via α2,6 sialylated ligands present on target cells (trans interaction) (Jellusova 
et al., 2011). 
 
❖ CD169 (Sialoadhesin) 
Examples of Siglec CD169- expressing cells: Macrophages  
CD169 is an endocytic receptor expressed on macrophages. Its main role is 
internalising and transporting cargo as it lacks an ITIM or ITAM (Jandus et al., 
2011). In fact several studies have suggested a proinflammatory role for this 
receptor. These include impairing the proliferation of Tregs and interacting with 
cross-presenting DCs to support CD8+ effector T cell immunity  (Wu et al., 
2009; van Dinther et al., 2018). The role of Siglecs and macrophages varies 
however; some studies have found that CD169+ macrophages are involved in 
preventing viral dissemination by capturing the virus, transferring them to 
conventional DCs which then present these to CTLs for anti-viral immunity 
(Uchil et al., 2019).  
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Additionally, CD169+ macrophages have a role in self-tolerance by removing 
apoptotic cell material and presenting them to cDC1s. Depletion of these 
macrophages resulted in a break in self-tolerance (Miyake et al., 2007). TIM-4hi 
(T-cell immunoglobulin mucin protein-4) CD169+ cells which are a subset of M2 
macrophages have been found to promote induction of Tregs and cardiac 
allograft survival (Thornley et al., 2014). 
 
Unlike mouse, human Siglecs are denoted numerically. Some of these 





Figure 1.8. Structures of Siglecs conserved in mammals and present in 
human or mouse. Adapted from Jandus et al., (2011). 
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Table 4. Examples of Human Siglecs and some of their roles in 
immunoregulation 
 
Human Siglec Examples of their inhibitory roles Ref. 
Siglec 8 (mouse 
homologue, 
Siglec F) 
The human homologue of Siglec F is Siglec 8, both of which 
are known to be expressed on eosinophils and impair 
effector functions of eosinophils allergic inflammation. 
Gao et al., 
2010; 
Kiwamoto et 





Siglec 10 expressed on human DCs has been shown to 
interact with DAMP receptor, CD24, to negatively regulate 
DC inflammatory immune responses towards molecules 
released by damaged cells in response to tissue injury 
(DAMPs). 
Chen et al., 
2009.  
Siglec 9 (mouse 
homologue, 
Siglec E) 
Siglec 9 activation on human neutrophils can trigger 
apoptosis of neutrophils.  
This receptor is also expressed on human macrophages, 
and has demonstrated potential to down-regulate CCR7 and 
regulate genes associated with inflammation in the presence 
of proinflammatory stimuli.  
Siglec 9 is expressed on human immature DCs. Ligation of 
tumour-produced mucins with Siglec-9 expressed on DCs, in 
the presence of LPS, resulted in down-regulation of IL-12, 
but no decrease of IL-10. Therefore, suggesting that under 
proinflammatory stimulus, immune responses are down-
regulated which suggest a role of this Siglec in evading anti -
tumour attacks.  




Higuchi et al., 
2016;  
Ohta et al., 
2010. 
Siglec 2 (mouse 
homologue, 
CD22) 
Similarly to murine CD22 Siglecs on B cells, Siglec 2 has 
been shown negatively regulate BCR activation and 
reducing Ca2+ signalling which is associated with BCR 
activation.  








1.6 Aims of the investigation 
 
Targeting alloantigens to DCs using monoclonal antibodies, specific for 
molecules present on DC subsets has led to improved transplant outcomes. 
However, these studies are restricted to looking at one subset of DCs and 
indefinite survival was not observed. What may be required to improve this 
strategy is to target many subsets of DCs, given that targeting multiple DC 
subsets have proven to promote tolerance. Targeting Siglec receptors, which 
are expressed on many DC subsets, with sialylated antigens, including peptide, 
has been shown to render DCs ‘tolerogenic’ leading to the expansion/ induction 
of Tregs. The aim of the work presented in this thesis was to address whether 
targeting sialylated donor alloantigen peptides to Siglecs expressed on DCs 
leads to prolongation of graft survival.  
 
The specific objectives of this investigation are; 
1. To test the possibility of improving skin transplant survival by targeting 
Siglec-expressing cells using Sia-alloantigen (Kd) peptide as model 
alloantigens.  
2. To identify whether specific DC subsets, B cells or macrophages are 
targeted by sialylated alloantigen and whether this contributes to 
transplantation outcome.  
3. If improved transplant outcome occurs, to assess what are the 
mechanisms of ‘tolerance’ following targeting recipient APCs with 
sialylated alloantigen.  
 
 
Importance of the research: The information that we obtained from this thesis 
will directly inform the design of the protocols for the induction of tolerance in 
the context of transplantation. In the future, if successful, this strategy may be 
applied to patients receiving a transplant organ from deceased or live donors.  
 
Overall, this study could contribute to the Phase 1 trials of tolerogenic 
APC therapy aimed at reducing the development and incidences of 













CHAPTER 2:  















2.1 Mice [Table. 5] 
Wild type (WT) mice used in this study included C57BL/6J (B6, H-2b) and 
BALB/c (H-2d). Both of which were purchased from Charles River Laboratories 
(Margate, UK). 
B6.Rag-2-/- (H-2b) mice which contains a disruption in the Rag 2 gene, resulting 
in impaired V(D)J recombination and therefore no generation of B and T 
lymphocytes, and B6.Batf3-/- mice, which lack exons 1 and 2 of the basic 
leucine zipper transcription factor, ATF-like 3 gene (Batf3), which is a gene 
required for development of CD11c+CD8α+ and CD11c+CD103+ DCs (Hildner et 
al., 2008) were used.  
Transgenic lines used in this study included; (i) TCR75 Rag-/- mice: B6 mice 
express a TCR that recognises processed BALB/c MHC I peptide (Kd 54-68) 
presented by B6 MHC II I-Ab (Honjo et al., 2000) and (ii) B6.Kd mice: B6 
expressing a transgene encoding BALB/c MHC I (H-2Kd) (Honjo et al., 2000). 
Both lines were kind gifts from Pat Bucy (Honjo et al., 2000).  
All transgenic, knockout and WT mice were sex and age matched. Wild-type 
mice, TCR75 Rag-/-, B6.Rag-2-/-, B6.Kd, and B6.Batf3-/- mice were bred and 
housed at the Biological Services Unit, King’s College London under specific 
pathogen free (SPF) conditions and were kind gifts from Professor Giovanna 
Lombardi, King’s College London, UK. All procedures involving mice were 
carried out in accordance with the institutional and Home Office Animals 
Scientific Procedures Act (1986) under the Home Office Project Licence: 
709066. Mice were sacrificed under Schedule 1 protocol by exposure to CO2 at 








Table 5: Wild-type and genetic strains used in this study 
 
 
2.2 Cell culture media 
 
Cells were maintained in complete media consisting of Roswell Park Memorial 
Institute (RPMI) 1640 medium (Thermo Fisher Scientific, Paisley, UK) without L-
glutamine supplemented with 100 IU/ml penicillin, 100 mg/ml streptomycin, 2 
mM L-glutamine, 10mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES) (ThermoFisher, Paisley, UK), 50 mM 2- Mercaptoethanol (ME) 
(ThermoFisher) and 10% heat-inactivated FCS (PAA, Biopath stores, 
Cambridge, UK) or 10% FCS (ThermoFisher). Cell cultures were maintained at 










C57BL/6J Wild- type 
MHC I: Kb Db Lnull  
MHC II: I-Ab I-Enull  
BALB/c Wild-type 
MHC I: Kd Dd Ld 
MHC II: I-Ad I-Ed 
B6. Rag 2-/- 
(Brennan et al., 
2009) 
B and T cell deficient  
MHC I: Kb Db Lnull  
MHC II: I-Ab I-Enull 
B6.TCR75 Rag 1-/- 
 (Honjo et al., 
2000) 
TCR transgenic strain (Vα1.1, Vβ8.3). Consist 
of CD4+ T cells with TCR that specifically 
recognises Kd peptide 54-68 
(QEGPEYWEEQTQRAK) derived from MHC I 
H-2Kd in the context of MHC II I-Ab  
MHC I: Kb Db Lnull  
MHC II: I-Ab I-Enull 
B6. Kd  
(Honjo et al., 2000) 
B6 mice expressing Kd transgene  
MHC I: Kbd Db Lnull 
 MHC II: I-Ab I-Enull 
B6. Batf3-/- (Hildner 
et al., 2008) 
B6 mice lacking batf3 transcription factor. 
Devoid of CD103+ and CD8α+ DCs. 
MHC I: Kb Db Lnull  
MHC II: I-Ab I-Enull 
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2.3 Cell isolation 
 
2.3.1 Preparation of DCs from mouse bone marrow (BM) and spleen (SPLN) 
 
2.3.1.1 Bone marrow derived DCs (BM-DCs) 
 
BM-DCs were prepared according to a protocol published by Smyth et al., 
(2013) [Fig 2.1]. Briefly, B6 mice were sacrificed and the hip, femur and tibia 
bones were harvested by dissection. Sides of the bones were cut on each side 
so that the BM can be harvested by flushing bones with fresh RPMI media 
using a 27 ½ G needle (Appleton Woods, Birmingham, UK) and a 20ml syringe 
(Appleton Woods). BM cells were then passed through a 70µm cell strainer 
(Appleton Woods) to obtain a single-cell suspension, before being washed with 
20ml of RPMI and spun (Eppendorf, Stevenage, UK) for 5 mins at 4°C at 562g. 
The cell pellet was then treated for 30 seconds at room temperature with 500µl 
of Ammonium-Chloride-Potassium (ACK) buffer (0.15 M NH4Cl, 1 mM KHCO3, 
0.1 mM Na2- EDTA, pH 7.2-7.4) to lyse red blood cells (RBCs) and washed with 
RPMI. Next, RBC-depleted cells were incubated, with constant shaking for 30 
mins at 4°C, with 300µl of each the following hydridoma culture supernatants: 
YTS 191 (rat anti-CD4; American Type Culture Collection (ATCC), Manassas, 
Virginia, USA), YTS 169 (rat anti-CD8, ATCC), M5/114 (rat anti-Class II. 
ATCC), RA3-3A1 (rat anti-B220, ATCC) all of which were kind gifts from Prof. 
Giovanna Lombardi, for the depletion of CD4+, CD8+, MHC II expressing cells 
and B cells, respectively. After incubation, cells were washed with RPMI to 
remove unbound antibodies and incubated with pre-washed polyclonal sheep 
anti-rat IgG coated magnetic Dynabeads® (Invitrogen, ThermoFisher) for 30 
min at 4°C, followed by magnetic separation using DynaMag™-15 Magnet 
(ThermoFisher). BM-DC progenitor cells were collected via negative selection, 
and cultured in complete media supplemented with 4ng/ml GM-CSF (kind gifts 
from Prof. Giovanna Lombardi) in 24 well plates (Appleton Woods) for 7 days. 
Cell media was replaced with 1ml of fresh media on day 2 and 4 of culture. 
Purity of BM-DCs was assessed by CD11c+ antibody staining and flow 








Figure 2.1 Schematic for the generation of BM-DCs. Bone marrow was 
isolated from mouse tibia, femur and hip bones and DC progenitors cultured 
with GM-CSF for the expansion of BM-DCs. After 7 days BM-DCs appear in 


















Figure 2.2. Gating strategy for assessing CD11c+ BM-DCs via flow 
cytometry.  BM-DCs were stained with anti-CD11c specific antibodies, followed 
by flow cytometry analysis. Cells were gated on live cells (FSC vs. SSC) and 








For splenic DC isolation, B6 and B6.Batf3-/- mice were sacrificed, and spleens 
harvested and diced into small sections using Swann-Morton® sterile blades 
(Appleton Woods) in non-treated Petri-dishes (Appleton Woods). A single cell 
suspension was made by digesting the spleen pieces with 0.5 mg/ml 
collagenase (Sigma, Dorset, UK) in the presence of 10µM/ml DNase (Sigma, 
Dorset, UK) for 30 mins at 37°C. Disaggregated splenic cell suspension was 
collected from the Petri-dishes and passed through a 70 µm cell strainer to 
obtain a single-cell suspension before RBCs were lysed with 1ml of ACK buffer 
followed by washing with RPMI. DCs were isolated from splenocytes using 
CD11c microbeads, MS/LS columns and MACS (Miltenyi Biotech, Cologne, 
Germany) according to manufacturer’s protocol. Briefly, splenocytes were 
counted, using Trypan Blue (Sigma, Dorset, UK) and 108 splenocytes were 
resuspended in 400µl in isolation buffer (2% FCS, 2mM EDTA/PBS) incubated 
with 100µl of CD11c Microbeads (volumes of beads were adjusted according to 
number of cells). After 10-minute incubation at 4°C, cells were placed into 
prewashed LS column and placed on an OctoMACS magnet (Miltenyi Biotech). 
Splenic DCs were isolated by positive selection, with the column being washed 
twice to remove contaminant cells. After all the unlabelled cells were removed 
(non-DCs), bead-bound DCs were flushed and isolated from the column using 
isolation media and a plunger.  
 
Purity of splenic DCs was assessed by CD11c+ antibody staining and flow 

















Figure 2.3. Gating strategy for the analysis of CD11c+ SPLN-DCs by flow 
cytometry.  SPLN-DCs were stained with CD11c, followed by flow cytometry 
analysis. Cells were gated on live cells (FSC vs. SSC) and doublets were 
excluded. FACS plot is a representative for one experiment out of three 
experiments.  
 
2.3.2 Isolation and expansion of macrophages from mouse BM (BM- DMs) 
 
Mice were sacrificed, bones dissected, and RBCs depleted BM cells were 
prepared as previously described in section 2.3.1.1. (pg. 50). BM-DMs were 
isolated using a protocol described by Trouplin et al., (2013). Briefly, 1x107 
RBC-depleted BM cells were re-suspended in 10ml of complete media 
supplemented with 10% FCS (Gibco, ThermoFisher), RPMI without L-glutamine 
supplemented with 100 IU/ml penicillin, 100 mg/ml streptomycin 
(ThermoFisher), 2 mM L-glutamine, 10mM HEPES, (ThermoFisher) 50 mM 2- 
ME (ThermoFisher) and 50ng/ml M-CSF (Biolegend, California, US) and placed 
in 10cm non-TC treated Petri-dishes. BM-DMs were grown for 7 days at 37°C in 











added on day 3 of culture. Purity of cells was determined by assessing F4/80 





Figure 2.4. Gating strategy for the analysis of F4/80 BM-DMs by flow 
cytometry.  BM-DMs were stained with F4/80, followed by flow cytometry 
analysis. Cells were gated on live cells (FSC vs. SSC) and doublets were 
excluded. FACS plot is a representative for one experiment out of three 
experiments.  
 
2.3.3 Preparation of B cells from mouse spleen 
 
Spleens were harvested from B6 mice, and a splenocyte single cell suspension 
was obtained by disaggregating organ through a 70µm cell strainer. Next, a 
RBCs free splenocyte suspension was obtained, as previously described, and B 
cells isolated through negative selection using a Dynabeads™ Mouse CD43 
Untouched™ B Cells kit (Invitrogen, Thermofisher) according to manufacturer’s 
instructions. Briefly, 5 x 107 splenocytes were resuspended in 1ml isolation 
buffer (2% FCS, 2mM EDTA/PBS) were incubated with 125µl of prewashed 
anti-CD43 coated magnetic beads for 20 minutes at 18-25°C, constant rotation. 
After incubation, the cells and bead mixture was placed onto a DynaMag™-15 
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Magnet (ThermoFisher) and ‘untouched’ B cells were isolated by negative 
selection. Dynabeads containing the non-B cells were removed using the 
magnet. B cell purity was measured by assessing B220+ expression by flow 
cytometry [Fig. 2.5].  
B cell subsets were assessed by IgM, CD21 and CD23 expression by flow 


















Figure 2.5. Gating strategy for the analysis of B220+ B cells by flow 
cytometry.  B cells were stained with B220-APC, followed by flow cytometry 
analysis. Cells were gated on live cells (FSC vs. SSC) and doublets were 
excluded. FACS plot is a representative for one experiment out of three 
experiments.  
 
2.3.4 Preparation of T cells from mouse spleen 
 
CD4+ T cells were isolated from the spleen of TCR75 Rag-/- mice. A single-cell 
RBC- free cell suspension was prepared as described in section 2.3.1.2 (pg. 
52). Following counting, cells were resuspended in complete medium at a 











2.3.4.1 CD4+ T cell isolation for in vivo adoptive transfer  
 
In some experiments T cells were administered. For adoptive transfer to 
B6.Rag2-/- transplant recipients, CD4+ T cells were isolated from B6 spleens 
using CD4 Dynabeads Untouched isolation kit (Thermo Fisher Scientific) 
following manufactures instructions. Recipient mice received 0.5x 106 B6 CD4+ 





Fluorescent and non-fluorescent monoclonal antibodies were used for flow 
cytometry [Table. 6] and were purchased from a number of suppliers.  
 
2.5 Flow cytometry  
 
Cells were analysed using either a LSR FortessaTM, BD FACSCelestaTM or BD 
Accuri C6TM flow cytometer. Acquired data was analysed using FlowJo 
(TreeStar, Ashland, Oregon, USA) or BD Accuri C6 software. 
 
2.5.1 Extracellular staining: phenotypic analysis of mouse cells 
 
All immunostaining was performed using the following buffer; phosphate 
buffered saline (PBS) supplemented with 2% FCS and 2mM EDTA (all Thermo 
Fisher, known as FACS buffer). Cells were washed with FACS buffer and 
pelleted at 562g for 5 minutes before staining.  Staining was performed using 
between 0.5x106-1x106 cells in a volume of 100µl of FACS buffer. Firstly, to 
block Fc receptors and reduce non-specific antibody binding, cells were 
incubated with anti-CD16/CD32 antibody (clone 93), 1/100 dilution) for 20 
minutes at 4°C. The cells were then stained with fluorescently-conjugated 
antibodies specific to the antigens of interest for 30 minutes at 4°C. Appropriate 
dilutions of fluorochrome-conjugated antibodies used was according to 
manufactures protocols, see Table 6. After immunostaining cells were washed 
twice with FACS buffer and resuspended in 200µl of FACS buffer before being 
acquired. In some experiments, cells were fixed using BD CellFIX™ 
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(ThermoFisher). Briefly, following the final wash, cells were resuspended in 
100ul of 1x BD CellFix and incubated for 10 minutes in the dark at room 
temperature before being washed, twice, with FACS buffer and resuspend as 
above.  
 
2.5.2 Intracellular staining for Foxp3 expression 
 
Intracellular staining for Foxp3 expression was performed following 
manufactures instructions (eBioscience, Thermofisher). After cell surface 
staining, cells were fixed and permeabilised using 200µl of eBioscience Fixation 
and Permeabilisation buffer (ThermoFisher) for 30 minutes at room 
temperature. Cells were then washed twice with permeabilisation buffer and 
resuspended in 100μl of anti-Foxp3-APC conjugated antibody for 60 minutes at 
room temperature. After staining, cells were washed twice with permeabilisation 
buffer, before being resuspended in 200μl FACS buffer for flow cytometry 
analysis.  
 
2.5.3 CFSE labelling 
 
To assess T cell proliferation, we used Carboxyfluorescein succinimidyl ester 
(CFDA SE or CFSE) labelling of responder T cells. CD4+ T cells were isolated 
from mice, washed and resuspended in PBS before being labelled, in the dark, 
with 0.5µM Vybrant™ CFDA SE (ThermoFisher) for 15 minutes at 37°C water 
bath. Labelling was stopped by the addition of 10X excess of FCS containing 























CD3ε PE 145-2C11 1/50 eBioscience 
CD4 FITC RM4-5 1/100 eBioscience 
CD4 PE RM4-5 1/100 eBioscience 
33D1 PE 33D1 1/100 Biolegend 
XCR1 PE REA707 1/50 MACS Miltenyi 
CD62L PE MEL-14 1/100 eBioscience 
CD11c APC N418 1/200 eBioscience 
CD11c APC N418 1/200 Biolegend 
CD11c  PE N418 1/100 eBioscience 
F4/80 PE BM8 1/100 Biolegend 
B220 APC RA3-6B2 1/100 Bioscience 
B220 FITC RA3-6B2 1/100 eBioscience 
CD23 PerCP Cy5.5 B3B4 1/100 Biolegend 
CD21/35 PE CR2/CR1 1/100 Biolegend 
IgM BV421 RMM-1 1/100 Biolegend 
IgG FITC - 1/200 Sigma- Aldrich 
Siglec E FITC 8D2 1/100 MBL 
Siglec F PE ES22-10D8 1/50 MACS Miltenyi 
Siglec G APC SH2.1  1/100 eBioscience 
Siglec H PE 551.3D3 1/50 MACS Miltenyi 
CD169 
(Sialoadhesin-1) 
PE REA197 1/100 MACS Miltenyi 
CD22 PE Cy34.1 1/50 MACS Miltenyi 
Foxp3 APC FJK-16s 1/100 eBioscience 
CD90.1 (Thy 1.1) PE HIS51 1/100 eBioscience 
CD275 (ICOS-L) PE HK5.3 1/100 eBioscience 
CD274 (PD-L1) PE MIH5 1/100 eBioscience 
H-2Kb FITC 28-14-8 1/200 eBioscience 
I-A/Eb FITC AF6-120.1 1/200 eBioscience 
CD80 FITC 16-10A1 1/100 eBioscience 
CD86 FITC GL1 1/100 eBioscience 
CD16/32 Fc 
Block™ 
- 93 1/200 eBioscience 
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2.6 H-2Kd 54-68 peptide: sialylated and non-sialylated conjugates 
 
2.6.1. Kd peptide derived from BALB/c MHC I H-2Kd molecule is an established 
alloantigen peptide  
 
As mentioned in Chapter 1, the intact MHC molecule or the peptides derived 
from the MHC can act as highly immunogenic alloantigens that can stimulate 
allorecognition and transplant rejection. The importance of the MHC to graft 
rejection was investigated when transplants were carried out on genetically 
identical or congenic mice, and it was found that the MHC region on 
chromosome 17 was responsible for rejection (Gorer et al., 1938; Gorer et al., 
1948). It has been said that the highly polymorphic transplantation genes of 
MHC I, which are known to mediate transplant rejection, are denoted by letters, 
K, D and L which are located in the H-2 region of MHC I (Hood et al., 1983). In 
a review by Hood et al., (1983), they explain that each mouse has a 
combination of alleles (haplotype) associated with transplant genes K or D.  For 
example, in BALB/c MHC I, one haplotype is denoted as d (lower-case and 
superscript) and its gene that it is associated with would be denoted in a capital 
letter, e.g. K, so the overall gene combination to describe MHC I would be 
called H-2Kd (Kd) [Fig. 2.7] (Hood et al., 1983). Kd 54-68 peptide, derived from 
H-2Kd has been established as a highly stimulatory allopeptide in comparison to 
other peptide sequence derived from the α1 hypervariable region of BALB/c 
MHC I and has been used as an alloantigen in transplant models since the 
early 2000s [Fig. 2.6] (Honjo et al., 2000). Given that the aforementioned Kd 
peptide derived from BALB/c MHC I H-2Kd molecule is an established 

























Figure. 2.6.  Kd 54-68 is most stimulatory peptide out of the entire MHC I H-2Kd 
molecule by increasing proliferation of alloreactive cells and increased 
production of IFN-γ - image acquired from Honjo et al., (2000). 
 
 
All Kd peptides were manufactured by Professor Yvette van Kooyk lab (VU 
University Medical Centre, Netherlands), sialylated peptides were produced 
using a patented procedure mentioned by Perdicchio et al., (2016) [Fig. 2.8]. 
Briefly, malemide-activated Neu5Acα2,3Galβ1,4Glc or Neu5Acα2,6Galβ1,4Glc 
was conjugated to thio-activated Kd peptide to form α2,3 Sia-Kd or α2,6 Sia-Kd, 
respectively (Perdicchio et al., 2016).  Some peptides were also supplied with 
FAM5/6 (FITC) conjugation for the assessment of peptide binding [Fig. 2.8]. The 
structures show that the initial Cysteine residue (C) was used for coupling of the 
sialic acid glycan on the N terminus. The FAM 5/6 fluorochromes was attached 
































Figure 2.7. H-2Kd alloantigen peptide. A. Kd peptide is derived from H-2Kd 
molecule derived from donor BALB/c strains. B. Indirect allorecognition of Sia-
Kd by TCR75 T cells. This model proposes that sialylated Kd will bind to Siglec-
expressing recipient B6 DC (or B cell/ macrophage), followed by antigen 
presentation via MHC II to TCR75 T cells. The T cells are isolated from TCR 
transgenic mice (TCR75 Rag-/-) that have a high specificity for a particular Kd 
alloantigen and are an excellent tool for measuring rates of transplant rejection 










The following Kd peptides 54-68 [Fig. 2.8] plus their 16 amino acid sequences 
were used:  
 
 
1. Unlabeled  
Kd: CQEGPEYWEEQTQRAK.  
α2,3 Sia-Kd: Sia-α2,3- CQEGPEYWEEQTQRAK.  
2,6 Sia-Kd : Sia-2,6- CQEGPEYWEEQTQRAK.  
2,3L Sia-Kd : LSTd-2,3- CQEGPEYWEEQTQRAK.  
 
2.  FAM5/6 labeled 
Kd- FITC: CQEGPEYWEEQTQRAK-FAM5/6 (FITC).  
α2,3 Sia-Kd- FITC: Sia-α2,3- CQEGPEYWEEQTQRAK-FAM5/6 (FITC).  




2.6.2 Purity of peptides 
 
The purity of the peptides was assessed and analysed by Prof Yvette van 
Kooyk’s lab at VUmc using HPLC, where each peak represents a component 
within the peptide sample and purity was deemed as >90%. Mass spectrometry 

































































Figure: 2.8. Purity of sialylated and non-sialylated alloantigen Kd peptides: 
HPLC (upper plot) and mass spectrometry (lower plot) analysis of sialylated and 
non-sialylated Kd alloantigen peptides. A. Kd peptide, B. α2,3 Sia-Kd, C. 2,6 
Sia-Kd ,  D. 2,3L Sia-Kd, E. Kd-FITC, F. α2,3 Sia-Kd-FITC, G. α2,6 Sia-Kd- 
FITC. This data was generated by Dr Martino Ambrosini from VUmc, 
Amsterdam, NL.  
 
 
2.7 Binding of FAM5/6 labelled Kd alloantigen constructs to APCs  
 
2.7.1 In vitro 
 
Bone marrow-derived cells, BM-DCs and BM-DMs, were gently harvested from 
the tissue culture plastic, using a rubber plunger from a 1ml syringe, after 7 
days of culture. For splenic-derived B cells and DCs, cells were isolated as 
previously mentioned in section 2.3. (pg. 50) and used immediately. Binding of 
labelled Kd peptide conjugates to APCs (BM-DCs, SPLN-DCs, BM-DMs and B 




x 106- 1 x 106 cells in 100μl of complete media with either 10µg/ml Kd-FAM5/6, 
or sialylated Kd-FAM5/6 fluorescent peptides for 4 hours at 37°C 5% CO2 in a 
24-well flat bottom TC-treated plate. APCs left untreated were the negative 
controls. At the end of the incubation step excess peptide was removed by 
harvesting and washing cells twice with FACS buffer. Cells were counted and 
0.2 x 106 cells were incubated firstly with anti-CD16/32 antibody, as described 
above, followed by either anti-CD11c-APC conjugated antibody (for DCs), anti-
F4/80-APC (for macrophages) and anti-B220-APC conjugated antibodies (for B 
cells). For B cell subset stain, cells were stained with anti-B220-APC, IgM-
BV421, CD21-PE or CD23- PerCP Cy5.5. Cells were assessed by flow 
cytometry. Expression was compared to an unstained control and single stained 
controls (no peptide).  
 
2.7.2 In vivo 
 
B6 and B6.Batf3-/- mice were placed into a 38°C heated incubator for 10 
minutes to allow their tail veins to dilate and become visible. Once warm, mice 
were transferred into a mouse restrainer and their tail cleaned with a 70% 
ethanol sterile cotton swab. Intravenous administration (i.v.) of 10μg of peptides 
in 200μl of saline/mice was achieved using a 0.3 ml BD MicroFine™ syringe 
and 30G needle (Medisave UK Ltd, Dorset, UK). After 2 hours, mice were 
sacrificed and both spleens and lymph nodes (axillary, brachial, inguinal, 
mesenteric) were harvested and digested with 0.5 mg/ml collagenase in the 
presence of 10µM/ml DNase for 30 mins at 37°C, as previously mentioned, in 
section 2.3.1.2 (pg. 52). Cell suspensions were then passed through a 70 µm 
cell strainer to obtain a single-cell suspension before the RBCs were lysed. 
RBC-free cells were washed in FACS buffer, counted and 2 x 106 cells were 
stained with in 100µl of the aforementioned, following a blocking step, with 
conjugated antibodies specific to CD11c, F4/80 or B220. Cells were assessed 
by flow cytometry. Expression was compared against an unstained control and 







2.8 DC microscopic imaging 
 
BM-DCs (2x 106/ml) were grown (similarly to the protocol mentioned in section 
2.3.1.1, pg. 50) onto circular cover slips (Appleton Woods) placed into wells of a 
24 well plate for 7 days and pulsed with 10µg/ml with Kd- FITC or sialylated-Kd- 
FITC for 2 hours at 37°C 5% CO2. The wells containing DCs were washed for 5 
minutes with 1ml of PBS under gentle agitation; this was repeated 3 times to 
remove complete media. Cells were then treated with 4% paraformaldehyde 
(Sigma, Dorset, UK) for 5 minutes at room temperature. Cover slips containing 
cells were carefully transferred to a 24-well plate, followed by adding 300µl of 
300 nM DAPI (ThermoFisher) /PBS solution onto the coverslip ensuring that 
slide is fully covered and after 5 minutes the slides were washed 3 times with 6 
ml PBS. Coverslips were mounted onto slides using 1 drop of prolong gold 
antifade (ThermoFisher). Slides were visualised at 200x magnification using 
Nikon microscopic imaging (Olympus BX51 Fluorescence Microscope). 
 
2.9 LPS stimulation of BM-DCs and BM-DMs 
 
On day 6 of culture, BM-DCs and BM-DMs were harvested and counted. 0.5 x 
106 BM-DCs and BM-DMs were pulsed with 10µg/ml unsialylated or sialylated 
Kd peptide in 1ml of complete media for 4 hours at 37°C/ 5% CO2, or left 
untreated. Some cells were treated for 24 hours/37°C with either 100ng/ml or 
200ng/ml LPS derived from E.coli (serotype: O111:B4) (Sigma, Dorset, UK). 
Negative controls were cells that were not treated with peptide or LPS.  Before 
the cells were harvested for flow cytometry analysis, 50µl of culture 
supernatants from each conditioned well was collected and stored at -20°C for 
subsequent cytokine analysis. 0.2 - 0.5 x 106 cells were stained with 
fluorescently conjugated antibodies to MHC class I-FITC and II-FITC, CD80-
FITC, CD86-FITC and CD11c- PE/ APC or F4/80- PE/ APC. To assess surface 
marker expression, cells were gated on CD11c or F4/80 to identify the DC and 
macrophage population respectively, followed by measuring the MFI of FITC to 






2.10 T cell activation assays 
 
Splenic-derived B6 B cells and BM-DCs were pulsed with various 
concentrations of Kd or sialylated-Kd peptide (1µg/ml, 5µg/ml or 10µg/ml) for 4 
hours/ 37oC, before being washed twice, counted and resuspended at 1 x 106 
cells/ml in complete medium. DCs and T cells were co-cultured at different 
ratios in triplicate in a 96-well round bottom plate (Appleton Woods) (a total 
volume of 250µl complete media) for 3 days at either 1:1, 1:5 and 1:10 DC:T 
cell ratios. In these experiments TCR75 Rag-/- CD4+ T cells were used. 
Unpulsed APCs and TCR75 Rag-/- CD4+ T cells, as well as T cells alone were 
used as negative controls. Fifty microlitres of supernatants were collected on 
day 2 of co-culture for cytokine analysis. Proliferation of TCR75 Rag-/- CD4+ T 
cells was assessed using two methods. The first was via a thymidine 
incorporation assay. On day 2 of cultures, cells were pulsed with 1µCi per well 
of 3H-thymidine (Perkin Elmer UK, Beaconsfield) and on day 3, thymidine 
incorporation was measured by liquid scintillation (Perkin Elmer UK) counting 
using a β-plate counter (Perkin Elmer UK). Samples were carried out in 
triplicates and proliferation was assessed as counts per minute (CPM).  
 
The second method used to assess CD4+ T cell proliferation was by CFSE 
labelling the responder T cells. CD4+ T cells were isolated from TCR75 Rag-/- 
mice as previously mentioned in section 2.3.4 (pg. 55) and were CFSE labelled. 
CFSE labelled CD4+ T cells were co-cultured with either alloantigen-pulsed DCs 
(10µg/ml) or alloantigen-pulsed B cells (10µg/ml) for 3 days or 5 days at 37°C 
5% CO2. Unpulsed APCs and CFSE labelled TCR75 Rag-/- CD4+ T cells, as well 
as unlabelled T cells alone were used as negative controls. Following 
incubation, cells were harvested and counted and 0.2- 0.5 x 106 cells were 
stained with anti-CD4 antibody conjugated to PE and analysed via flow 
cytometry. To assess proliferation of TCR75 Rag-/- CD4+ T cells, cells were 
gated on CD4 PE and proliferation was observed on a histogram plot against 


























Fig. 2.9. Gating strategy for T cell proliferation assays. B6 BM-DCs or B 
cells were cocultured with CFSE labelled TCR75 CD4+ T cells at 1:10 ratio. 
After 3 days, cells were surface stained with CD4 antibody, followed by analysis 
of CFSE proliferation. Cells were gated on live cells (FSC vs. SSC); doublets 
were excluded followed by gating on CD4+ T cells that were CFSE+. A. Gating 
strategy for DC/T co-cultures and. B. Gating strategy for B/T co-cultures in the 















2.11 In vitro Treg induction assay 
 
B6 BM-DCs and B cells were treated with 10µg/ml of peptides as previously 
mentioned and co-cultured with CFSE labelled TCR75 Rag-/- CD4+ T cells at a 
ratio of 1:10 (APC: T cell) for either 3 or 5 days in 96 U-bottom plates at 37°C (a 
total volume of 250µl complete media). IL-2 (5 U/ml) was added to cells at the 
beginning of the culture on day 0. Supernatants were harvested for IL-10 
cytokine analysis and cells were stained with anti-CD4-FITC or PE conjugated 
antibody. Intracellular Foxp3 expression was assessed using intracellular 
staining with anti-Foxp3-APC conjugated antibody (ThermoFisher), as 
mentioned in section 2.5.2 (pg. 57). Expression was assessed using flow 
cytometry and gating on live cells, followed by CD4 vs. Foxp3 gating.  
 
2.12 Enzyme-Linked Immunosorbent Assay 
 
After the incubation period on the co-cultures, 50 -100 μl of supernatants were 
harvested for ELISA. IL-10 and IL-12 production by BM-DCs and BM-DMs were 
assessed using a Mouse IL-10 sandwich ELISA (ThermoFisher) and IL-12 
sandwich ELISA (Biolegend, California, US) respectively following 
manufactures instructions. To measure IL-2 and IFN-γ cytokine production from 
T cells, IL-2 and IFN-γ sandwich ELISAs were used following manufactures 
instructions (ThermoFisher). All supernatants were diluted 1:10 and each 
sample was measured in duplicates or triplicates. Absorbance was read using 
Multi-Mode Reader (Synergy HTX) (BioTek, US).  
 
2.13 Skin transplants  
 
Skin transplant were performed as previously described by Golshayan et al., 
(2007). All surgery was done using sterile suture packs and autoclaved surgical 
scissors and forceps to ensure minimal infection. In brief, B6.Kd or BALB/c 
donor mice were sacrificed on the day of transplant and tail skin was 
immediately harvested using sterile forceps and stored in a sterile Petri-dish 
containing saline. Skin was cut using sterile forceps (Sigma) into 1-1.5cm2 
sections and stored at 4oC until used. Before skin transplantation recipient B6, 
B6.Batf3-/- and B6.Rag2-/- mice were administered with 2µg/mouse Vetergesic® 
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analgesia (Ceva, Amersham, UK) diluted in saline (i.p.) and the back of the 
animal shaved prior to surgery under anaesthesia using IsoFlo® isoflurane 
(Zoetis, Kalamazoo, Michigan) and oxygen (3.5 L/min). Once shaved, recipient 
mice were placed on a heat mat and kept under anaesthesia using a face cone. 
Mice were prepared for surgery by washing the shaved skin with Vetasept 
povidone-iodine antiseptic solution (Animalcare Ltd, York, UK) and draped with 
sterile robes leaving a small section on the dorsal thorax of recipient mice 
exposed for surgery. A small section, similar to the size of donor skin, was 
excised and donor skin was sutured onto the recipient using 45mm polyamide 
Ethilon sutures (Ethicon Inc, Edinburgh, Scotland). All 4 corners of the donor 
skin were sutured onto the recipient skin, to ensure vascularisation, before the 
transplant area was secured with a waterproof Elastoplast plaster (Hamburg, 
Germany) wrapped around the mid section of the mouse. This was then 
secured in place with autoclave masking tape. After surgery, mice were kept in 
a 29°C heated incubator for recovery until mice were fully awake and mobile. 
Mice were checked daily to ensure that the plaster remained in place and were 
recast if the plaster fell off. 
 
On day 7 the plaster and tape were removed and grafts were observed daily 
thereafter to measure rejection. Rejection was considered when there was 
>90% necrosis of donor tissue. Skin grafts that had not engrafted after 7 days 
were treated as a failed experiment and were excluded from analysis.  
 
2.13.1 Alloantigen peptide administration intravenously  
In some experiments, mice received 10μg of either Kd, α2,3 Sia-Kd, α2,3L Sia-
Kd or α2,6 Sia-Kd peptides administered intravenously in 200µl of saline either 1 
or 10 days prior to skin transplant. This peptide concentration was chosen 
based on experiments published by Tanriver et al., (2010). Untreated mice were 
injected with 200µl of saline only. All injections were into the tail vein of recipient 
mice. 
 
2.13.2 CD8+ cell depletion 
To deplete CD8+ cells in B6 recipient mice, 250μg of anti-CD8 antibody 
(YTS169) in 100µl of saline was given via i.p on various days mentioned in 
Chapter 5-6 (Smyth et al., 2013).  
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2.14 Treg analysis in transplant recipients 
 
To analysis Treg populations in transplant recipients, mice were bled 14 days 
post transplant. To collect blood, mice were placed in a 38°C heated incubator 
for 10 minutes and blood extracted from the tail vein using a 26½ G needle into 
a Microvette® CB 300 tube (Sarstedt, Numbrecht, Germany), lined with EDTA 
to prevent clotting. To isolate cells, blood was diluted into 15ml of PBS and 
spun at 562g for 5 minutes to obtain a cell pellet. Following RBCs lysis, 
leucocytes were stained with anti-CD4 FITC and anti-CD62L PE antibodies 
followed by intracellular staining for Foxp3, as previously described. 
Percentages of CD4+CD62L- Foxp3+ cells and CD4+CD62L+ Foxp3+ cells were 
measured using BD Fortessa Flow Cytometer and analysed by FlowJo.  
 
2.15 Alloantibody detection in skin transplant recipients  
 
To measure anti-Kd alloantibody production by transplant recipients, blood 
samples were collected from the tail vein 4 weeks post-transplant (i.v). Blood 
was stored overnight at 4oC before being spun for 3 minutes at  2419g to pellet 
lymphocytes and RBCs. Serum was collected and stored at -20°C until further 
analysis. To detect Kd-specific IgG alloantibodies. RBC lysed splenocytes were 
isolated from B6.Kd (positive control) and B6 (negative control) mice as 
previously described. Fc receptors were blocked with anti-CD16/32 antibodies/ 
5% goat serum/ PBS for 20 mins at 4°C, before staining with anti-CD3ε 
antibodies PE for a further 20 mins at 4°C. After incubation, cells were washed 
with FACS buffer; splenocytes were then resuspended in FACS buffer 
supplemented with transplant recipient’s serum at a 1:20 dilution for 20 minutes 
at 4°C. Serum Ab-bound splenocytes were washed in FACS buffer, followed by 
addition of goat anti-mouse IgG FITC (Sigma-Aldrich) at a 1:100 dilution in 
FACS buffer for a further 20 mins at 4°C. Cells were washed twice in FACS 
buffer and assessed by flow cytometry. To quantify IgG alloantigens within the 
sample, B6 or B6.Kd CD3-PE+ cells were gated, followed by histogram plots to 






2.16 Antigen specific T cell deletion and Treg expansion in vivo 
 
For in vivo deletion experiments, CD4+ T cells were isolated from spleens of 
TCR75 Rag-/- mice (Thy1.1) as previously described in section 2.3.4 (pg. 55). 
Purity of CD4+ T cell was assessed as >90% CD4+ total cell population. 
Approximately, 2 x 106 cells/ 200µl saline were intravenously injected into B6 or 
B6.Batf3-/- mice and 10 days later LNs and spleens were harvested. A RBC-free 
single-cell suspension was made and counted as previously mentioned. After 
washing cells twice with FACS buffer, approximately 0.5 x106- 1 x106 cells were 
stained with anti-mouse Thy1.1- PE antibody (ThermoFisher) to assess the 
recovery of TCR75 CD4+ T cells. Cells were also stained with anti-mouse CD4 
FITC (ThermoFisher) and anti-mouse Foxp3 APC (ThermoFisher) to observe 
Treg induction/ expansion. After staining, cells were gated on live cells (FSC vs. 
SSC), doublets were excluded, cells were gated on CD4 followed by Thy1.1 to 
assess recovery of TCR75 T cells, or gated on CD4 and Foxp3 to assess 
induction/ expansion of Tregs.  
 
2.17 Statistical analysis  
 
In vitro experiment: Statistical analysis was performed using unpaired Student’s 
t tests and One-way ANOVA with Tukey’s multiple comparisons test using 
GraphPad Prism (GraphPad Software, California, US). 
 
In vivo experiments: The mean survival time (MST) of skin grafts was calculated 
using Mantel Cox and log rank test using GraphPad Prism. Data shown is mean 
± standard error of the mean (SEM). Statistical significance was expressed as 






















CHAPTER 3:  
TARGETING RECIPIENT APCs WITH α2,3 
SIA-Kd AND α2,3L SIA-Kd ALLOANTIGEN 
PEPTIDES DAMPENS INDIRECT 



















3.1.1 Dendritic cells 
 
Immature/ semi-mature DCs and those maintained at a steady-state are 
capable of promoting tolerance as opposed to matured/ activated DCs. 
Immature/ semi-mature DCs display a 'tolerogenic' phenotype, demonstrated by 
their inability to initiate an effector immune response due to their low expression 
of MHC molecules and co-stimulatory molecules such as CD80/86, which gives 
rise to insufficient co-stimulation, and their ability to induce/ expand Tregs (Lutz, 
et al., 2004; Marin et al., 2018).  
 
As outlined in section 1.4.1 (pg. 24); ex vivo generated tolerogenic DCs can 
exhibit an immunoregulatory role. In one report by Lee et al., (2017), antibiotic 
Minocycline and steroid Dexamethasone treated BM-DCs displayed reduced 
levels of MHC II and CD80/86 molecules in comparison to DCs that were 
matured with proinflammatory stimuli IFN-γ and TNF-α (Lee et al., 2017). These 
tolerogenic DCs also had the ability to induce CD4+ Foxp3+ Tregs in vitro and 
additionally, when these Minocycline/Dexamethasone treated DCs were pulsed 
with MOG antigens and introduced into mice, there was reduced clinical signs 
of induced EAE in a mouse model, therefore supporting the use of tolerogenic 
DCs to promote tolerance in vivo (Lee et al., 2017).  
 
Multiple publications have described various strategies to deliver antigens to 
endogenous DCs in vivo in order to promote antigen-specific tolerance. These 
include the use of vehicles such as nanoparticles or specific receptor targeting 
(Steinman et al., 2003; Tacken et al., 2006; Tacken et al., 2007; Ding et al., 
2008; Kovacsovics- Bankowski et al., 1993). Targeting DC cell surface 
receptors such as DCIR2, expressed on CD8- DCs using DCIR2-specific fusion 
antibodies has been shown to prolong murine skin allograft survival and 
ameliorate EAE, (Tanriver et al., 2010; Tabanksy et al., 2018), whereas, 
targeting DEC-205, expressed on resident CD8+ DCs and migratory CD103+ 
DCs using DEC-205 specific antibodies was shown to promote peripheral CD8+ 




Tanriver et al., (2010) identified targeting DCIR2+ endogenous DCs using a 
murine MHC class I (Kd)-monomer conjugated to an anti-33D1-antibody, 
prolonged MHC-mismatched skin transplant survival in the absence of CD8+ T 
cells, demonstrating that targeting an endogenous DC subset can promote 
tolerance. Their regimen is limited to targeting one specific DC subset and given 
that multiple DC subsets are known to promote tolerance (e.g. DEC-205- 
Bonifaz et al., 2002), there is a need to find specific receptors that are 
expressed on multiple DC subsets to optimise antigen-specific tolerance.   
 
Siglec receptors are expressed on different DC subsets as well as, 
macrophages and B cells. Given their ITIM in their cytosolic portion and 
convenient location on the cell’s surface, these inhibitory receptors are known 
to inhibit/ modulate immune responses. Siglec interactions have been targeted 
on DCs, macrophages and B cells for the purpose of inhibiting immune 
responses. Perdicchio et al., (2016) demonstrated in vitro, that antigen specific 
tolerance was achieved following engaging Siglecs expressed on BM-DCs and 
SPLN-DCs with α2,3 sialic acid-conjugated antigen. Another study found that 
interaction of Siglec E on BM-DCs with the sialic acids present on E.coli led to 
endocytosis of TLR4, thereby decreasing their immune response to E.coli 
infection (Wu et al., 2016). These results were not achieved when sialic acids 
were removed from the surface of E.coli using sialidase or when Siglec E-/- BM-
DCs were used (Wu et al., 2016). In the latter, persistent expression of TLR4 on 
the surface was observed resulting in the release of high levels of pro-
inflammatory cytokines such as TNF-α and IL-6 following exposure to E.coli 
(Wu et al., 2016). This would suggest that Siglecs on BM-DCs are able to 
modify TLR 4 responses upon sialic acid interaction (Wu et al., 2016). Contrary 
to this study Nagala et al., (2018) published that Siglec E on both BM-DMs and 
BM-DCs were not involved in TLR4 signalling in response to LPS, which leaves 
the mechanism of whether Siglecs modulate TLR4 signalling a on-going 
question. Altogether, this supports the idea of targeting Siglecs on DCs can 
impair aberrant effector immune responses. This chapter will focus on targeting 
DCs to determine whether they display a tolerogenic phenotype by assessing 
MHC and costimulatory marker expression and cytokine production, whether 
these DCs can impair CD4+ effector T cell alloreactivity and possibly promote 
Treg induction/ expansion.  
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3.1.2 B cells 
 
Similarly to DCs, targeting Siglec G expressed on B cells with α2,3 sialic acid 
has been shown to down-regulate BCR signalling by decreasing intracellular 
Ca2+ mobilization (Hutzler et al., 2014). This makes Siglecs on B cells an 
attractive target as it is known that B cells contribute to transplant rejection via 
their APC ability to stimulate CD4+ T cells via the indirect pathway of 
allorecognition and production of alloantibodies (Noorchashm et al., 2006; 
Conlon et al., 2012). There are certain B cell subsets which have shown to be 
regulatory these include transitional B cells (T1 (IgMhighCD21−CD23−), and T2 
(IgMhighCD21+CD23+)) and some studies have found that these subsets are 
required for transplant survival (Moreau et al., 2014). Upon BCR engagement, 
transitional B cell subsets are known to undergo apoptosis or cell cycle arrest 
making them an ideal cell subset for tolerance induction by preventing their 
ability to present alloantigens and stimulate Th1 effector alloreponses. As 
mentioned in the introduction (section 1.4.2, pg. 36), T1 B cells are thought to 
undergo apoptosis following BCR engagement (Petro et al., 2002) whereas T2 
B cells are more responsive to antigen stimulation (Chung et al., 2002). They 
also found that these transitional B cells, whether they are CD23+ or CD23-, do 
not upregulate co-stimulatory molecules upon BCR engagement (Cook et al., 
1998; Chung et al., 2002). One study in particular identified that T2 B cells are 
believed to be regulatory and promote allograft survival (Moreau et al., 2014). 
Therefore, this chapter will focus on targeting B cells to determine whether they 
can impair CD4+ effector T cell alloreactivity and possibly promote Treg 
induction and also determine which B cells subsets the sialylated and non-





Macrophages also play a role in transplant rejection, making these cells a valid 
target for transplant tolerance. Macrophages can become activated upon 
recognition of cellular damage via DAMPS caused by the transplantation 
procedure; this activation allows macrophages to phagocytose antigens and act 
as APCs in the context of MHC and stimulate T cells (Li et al., 2019). Similar 
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activation also occurs in response to TLR activation (eg; via LPS stimulation) 
which can result in the production of proinflammatory cytokines such as IL-12. 
Little is known about the role of macrophages and their contribution to chronic 
rejection, however, given their ability to promote inflammation it is not a surprise 
that one study found that accumulation of macrophages were associated with 
cardiac rejection in a rat model (Kanno et al., 2001).  Macrophages can 
contribute to chronic transplant rejection through the release of proinflammatory 
cytokines, eg: TNF- α and IFN- γ, which were shown to cause transplanted 
tissue fibrosis and vascular injury (Mitchell, 2009). Similarly to DCs and B cells, 
macrophages also have a regulatory role (Mregs). One study demonstrated the 
importance of macrophages in a cardiac murine transplant model where CD8+ T 
cells immune responses were inhibited whereas CD4+ Foxp3+ Tregs were 
promoted in the presence of DC-SIGN+ macrophages (Conde et al., 2015). 
Deletion of these macrophages resulted in reduced allograft survival (Conde et 
al., 2015). Therefore, this chapter also determines whether targeting recipient 
macrophages has the ability to dampen proinflammatory cytokines following 
sialylated alloantigen targeting.   
 
The focus of this chapter is to determine whether targeting sialylated alloantigen 
to Siglec-expressing DCs and B cells can impair indirect allorecognition effector 
immune responses and promote Treg induction in vitro. In addition, the 
targeting of macrophages and DCs will also be assessed to determine if these 
cells are resistant to LPS maturation. Overall, should these Siglec expressing- 
APCs be regulatory upon sialylated alloantigen targeting, this targeting regimen 
can be used as a prospective cellular immunotherapy for transplantation. Either 
by administering antigen treated APCs to transplant recipients or by targeting 
endogenous APCs by directly administering these sialylated alloantigen (Sia-Kd) 













In this chapter targeting sialylated alloantigen, α2,3 Sia-Kd and a longer 
construct, α2,3L Sia-Kd, to APCs such as DCs, B cells and macrophages, will 
be undertaken to determine whether targeting Siglecs leads to tolerogenic 
APCs, impaired indirect CD4+ T cell allorecognition and effector immune 
responses using various in vitro assays.  
 
Objectives 
1. Determine what Siglecs are expressed on different APCs including DCs, B 
cells and macrophages. 
2. Identify whether sialylated alloantigens bind to Siglecs expressed on DCs, B 
cells (and subsets) and macrophages in vitro.  
3. Determine whether targeting sialylated alloantigen to Siglecs expressed on 
DCs, B cells and macrophages in vitro promotes an immunosuppressive 
phenotype 
4. Assess whether targeting DCs and B cells influences dampened allogeneic T 
cell responses and/or induced/ expanded CD4+ Foxp3+ Tregs in vitro. 
 
To achieve the objectives, Kd alloantigen peptide, derived from mouse MHC 
class I H-2Kd (CQEGPEYWEEQTQRAK) and was chosen for sialylation (α2,3 
Sia-Kd and α2,3L Sia-Kd). Prof Y van Kooyk (VUMC, collaborator) generated the 
Sia-Kd conjugated with or without a FAM5/6 (FITC) label using an existing 
patented method for this project (Perdicchio et al., 2016). The justification for 
using this MHC class I Kd peptide (derived from donor BALB/c mice) as a major 
alloantigen was that this peptide when presented by MHC class II I-Ab (B6 self-
MHC II), is recognised by a transgenic T cell receptor (TCR) expressed by 
CD4+ T cells isolated from TCR75Rag-/- transgenic mice. Thus recreating the 
indirect allorecognition response where recipient APCs present donor Ags to 
recipient CD4+ T cells (Ali et al., 2016; Honjo, et al., 2000). This established 
‘indirect allorecognition model’ has been used to assess indirect allorecognition 
in vitro and in vivo in murine transplant models (Chai et al., 2015; Ali et al., 







3.3.1 BM-DCs express well characterised DCs surface markers following GM-
CSF expansion  
 
The current study used ex vivo expanded BM-DCs for the analysis of tolerance 
induction in vitro, which is standard practice in the DC field (Helft et al., 2015; 
Smyth et al., 2013). Bone marrow progenitor cells were isolated and expanded 
with GM-CSF using a protocol published by Smyth et al., (2013) and described 
in detail in the methods section (section 2.3.1.1, pg. 50). These cells were 
stained with fluorochrome-conjugated antibodies to the following cell surface 
markers commonly found on BM-DCs; CD11c, MHC II, MHC I, and co-
stimulatory molecules, CD86 and CD80. As expected, viable cells as assessed 
by FSC vs. SSC [Fig.2.2] expressed CD11c, [Fig. 3.1A-B], as previously 
described (Smyth et al., 2013). In addition they expressed, well-characterised 
DCs markers including MHC II, MHC I, and the co-stimulatory molecules CD80 
and CD86 [Fig. 3.1B-C].  Given the aforementioned, it can be concluded that 
the cells isolated from these cultures are immature bone marrow- derived DCs, 
which expressed high levels of MHC II (Hoffmann et al., 2005; Smyth et al., 










































































































Figure 3.1.  BM-DC express CD11c and are MHC IIhigh, MHC Ilow/int, 
CD80low/int and CD86low/int. GM-CSF expanded B6 derived BM-DCs were 









































CD80 and CD86 was assessed using specific fluorochrome-conjugated 
antibodies and flow cytometry. Gating strategy for CD11c+ BM-DCs is 
demonstrated in Fig. 2.2. A. (i) Percentage of CD11c+ BM-DCs. Unstained cells 
served as a control and data was pooled from 3 independent experiments. (ii) 
MFI for CD11c expression on BM-DCs. Unstained cells served as a control. 
Data was pooled from 5 individual experiments. Bar charts representing the 
means +/- SEM. Statistical comparisons performed using unpaired two-tailed 
Student’s t-test B. Data shown are representative pseudocolour dot plots from 
one out of 3 experiments demonstrating phenotype of ex-vivo generated BM-
DCs gated on live cells. C. Bar charts representing the mean MFI expression 
+/- SEM of MHC II, MHC I, CD80 and CD86 on CD11c+ BM-DCs. Data was 
pooled from three independent experiments. Statistical analysis was performed 
by One-way ANOVA and Tukey’s multiple comparisons test. Statistical 
significance was expressed as follows; p< 0.0001****, p<0.05*, NS = p>0.05. 
 
3.3.2. Siglec- expressing BM-DCs and SPLN-DCs bind α2,3 Sia-Kd alloantigen 
peptide in vitro  
 
Siglecs are found on DCs although, according to different studies, the 
expression of Siglec receptors differs between murine endogenous DCs and ex 
vivo generated BM-DCs. For example, Ding et al., (2016), identified Siglec G on 
splenic CD8α+ DCs, Loscko et al., (2011) discovered Siglec H on pDCs and 
Perdicchio et al., (2016) identified Siglec E on BM-DCs. In order to confirm the 
presence of Siglecs on GM-CSF expanded CD11c+ BM-DCs, cells were stained 
with Siglec specific antibodies, and analysed using flow cytometry. Siglec F and 
Sialoadhesin- 1 (CD169), which is an endocytic receptor that is not considered 
inhibitory due to a lack of an ITIM, were highly expressed on BM-DCs, whereas 
there was moderate expression of Siglec E, G and H [Fig. 3.2A]. To assess 
Siglec expression on CD11c+ endogenous spleen derived DCs (SPLN-DCs), 
DCs from B6 spleen were isolated as mentioned in the methods in section 
2.3.1.2 (pg. 52) and stained with Siglec E, F, G, H and CD169 antibodies as 
mentioned previously. Similarly to BM-DCs, Siglecs E, F, G and CD169 were 
expressed on SPLN-DCs, with Siglec H being expressed the least, however this 
marker is known to be primarily expressed on plasmacytoid DCs [Fig. 3.2A-B]. 
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Interestingly, Siglec F was highly expressed in both BM- and SPLN-DCs [Fig. 
3.2]. 
 
In order to determine whether the sialylated alloantigen peptide bind to these 
Siglec expressing-DCs in vitro, B6 derived BM-DCs and SPLN-DCs were 
pulsed with FITC-conjugated α2,3 Sia-Kd (10μg/ml) for 4 hours at 37°C before 
cells were assessed for peptide binding via flow cytometry. BM-DCs pulsed with 
non-sialylated Kd-FITC and untreated DCs served as controls. MFI of FITC 
expression signified peptide-FITC binding on these CD11c+ DCs. Both the Kd-
FITC and α2,3 Sia-Kd-FITC peptides were capable of binding to CD11c+ BM-
DCs and SPLN-DCs, as compared to unpulsed controls [Fig. 3.3 A-B]. 
However, α2,3 Sia-Kd binding to BM-DCs was significantly greater (p= 0.01) to 
Kd peptide binding, perhaps reflecting that each peptide binds to different 
receptors [Fig. 3.3A]. For example, Kd peptide has the ability to bind to MHC 
molecules expressed by these DCs, whereas α2,3 Sia-Kd may be binding to 
both the MHC and Siglec receptors, however this has yet to be confirmed. 
Similar binding results were found using SPLN-DCs, although binding levels 
between sialylated and unsialylated peptides was not statistically different 
(p=0.81), however there was a trend for greater binding of α2,3 Sia-Kd peptide 
as compared to Kd (Fig. 3.3B).  
 
To confirm binding, BM-DCs were visualised using microscopic imaging 
following FITC-peptide incubation. To achieve this cells were grown on cover 
slips as mentioned in section 2.8 (pg. 68) and treated with either Kd-FITC or 
α2,3 Sia-Kd-FITC conjugates as per above. DCs were further stained with DAPI, 
to identify the nucleus. In comparison to the non treated DCs [Fig. 3.3C (i)], as 
expected and as previously demonstrated in Fig. 3.3A  both Kd-FITC and α2,3 
Sia-Kd-FITC peptides were bound to the BM-DCs [Fig. 3.3C (ii-iii)]. Overall, we 
can conclude that sialylated alloantigens bind to Siglec-expressing B6 BM-DCs 
and SPLN-DCs in vitro which were confirmed using flow cytometry and using 
























Figure. 3.2. Siglecs are expressed on B6 BM-DCs and SPLN-DCs. For 
Siglec expression, day 6 or 7 B6 BM-DCs were stained using anti-mouse 
CD11c APC/PE and either anti-mouse Siglec E- FITC, Siglec F- PE, Siglec G- 
APC, Siglec H-PE and CD169-PE. Live cells were gated on FSC, SSC, followed 
by doublet exclusion and CD11c+ cell gating [Fig. 2.2]. Siglecs were then gated 
against CD11c+ DCs according to the gating strategy in Appendix Fig.1. (A). 
MFI of Siglec-expression on CD11c+ BM-DCs. Data was pooled from 3 
independent experiments. (B). MFI of Siglec expression on CD11c+ SPLN-DCs. 
Data was pooled from 3 independent experiments. Statistical analysis was 
performed by One-way ANOVA and Tukey’s multiple comparisons test. 
Statistical significance was expressed as follows; p< 0.0001****, p<0.001***, 
p<0.01**, p<0.05*. Comparisons that were not significantly significant (NS) are 




















































































































Figure 3.3. α2,3 Sia-Kd- FITC binds to BM- and SPLN-DC in vitro. For 










Kd- FITC (green) + 
DAPI (blue) 




either 10 μg/ml Kd-FITC or α2,3 Sia-Kd- FITC peptide. A. (i) Cells were gated on 
CD11c+ cells and presence of FITC staining assessed using flow cytometry. 
Plot is a representative for one experiment out of four. Unpulsed cells were the 
negative controls. B. (i) Peptide binding to BM-DCs, data presented was pooled 
from four independent experiments. (ii) Peptide binding to SPLN-DCs, data 
presented was pooled from 3 independent experiments. Each bar presents MFI 
of FITC +/- SEM. Statistical analysis was performed by one-way ANOVA and 
Tukey’s multiple comparisons test. Statistical significance was expressed as 
follows; p<0.001***, p<0.05*, NS = p>0.05.  C. Microscopic image of peptide-
pulsed B6 BM-DCs at x200 magnification. BM-DCs grown on coverslips were 
pulsed with peptides followed by DAPI staining (blue). (i) pulsed with either no 
peptide, (ii) 10 μg/ml Kd FITC (green) or (iii) 10 μg/ml α2,3 Sia-Kd FITC (green) 
peptides (image on left) and a larger image of one DC (image on right). Images 
represents 1 experiment.  Comparisons were made against the no peptide 
control.  
 
3.3.3 Engaging Siglecs with α2,3 Sia-Kd peptide down-regulated MHC 
expression on BM-DCs  
 
As mentioned in sections 1.4.1- 1.4.1.1 (pg. 24-25), tolerogenic DCs are able to 
promote an immunosuppressive response through the low expression of co-
stimulatory molecules and production of immunosuppressive cytokines such as 
IL-10 (Marin et al., 2018). Therefore, in order to determine whether Siglec 
engagement with α2,3 Sia-Kd peptide modified BM-DCs creating an 
immature/semi-mature 'tolerogenic' DC the levels of MHC I/II and CD80 and 
CD86 co-stimulatory molecules, as well as IL-10 and IL-12 production were 
measured. BM-DCs were pulsed with 10µg/ml α2,3 Sia-Kd peptides for 4 hours, 
Kd-pulsed and unpulsed DCs acted as controls, and cells were stained with 
antibodies to MHC II, MHC I, CD80 and CD86  before being analysed via flow 
cytometry. BM-DCs treated with α2,3 Sia-Kd peptides expressed significantly 
less MHC I in comparison to Kd treated DCs (13.2% decrease, p=0.01) and no 
peptide controls (13.5% decrease, p=0.01), and significantly less MHC II 
molecules in comparison to Kd treated DCs (24.2% decrease, p=0.02) and no 
peptide controls (23.9% decrease, p=0.02) [Fig. 3.4A-B]. In addition, there was 
a trend for less CD80 expression following Siglec engagement, although this 
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was not significant. No difference in CD86 expression following α2,3 Sia-Kd 
treatment DCs was observed [Fig. 3.4C-D]. Lastly, no significant increase in IL-
10 or IL-12 production was observed following treatment, however there 
appears to be a trend indicating lower IL-12 production following sialylated 
alloantigen targeting in comparison to Kd targeted BM-DCs [Fig. 3.5A].  
 
Overall, targeting sialylated alloantigen to Siglecs on BM-DCs leads to down-

























































Figure 3.4. α2,3 Sia-Kd treatment down-regulates MHC I and MHC II on BM-
DCs. B6 BM-DCs were harvested and pulsed with 10μg/ml of either peptide on 
day 6 of culture for 4 hours. Cells were stained for CD11c, MHCI/II or CD80 and 
CD86 fluorochrome-conjugated antibodies and analysed via flow cytometry. 
Cells were gated on live (FSC vs. SSC) CD11c+ cells. A. Fold-change for MFI 
for MHC I expression. B. Fold-change for MFI for MHC II expression. C. Fold-
change for MFI for CD80 expression. D. Fold-change MFI for CD86 expression.  
Each point represents one experiment and data was pooled from 3-4 
independent experiments. Fold-change was calculated by comparing the MFI of 
peptide treated DCs to unpulsed DCs (set to a value of 1). All statistical analysis 
was determined using One-way ANOVA and Tukey’s multiple comparison test. 
Data shown is mean +/- SEM. Statistical significance was expressed as follows; 




















































































Figure 3.5. Kd or Sia-Kd treatment does not increase significant IL-10 or IL-
12 production from BM-DCs.  B6 BM-DCs were pulsed with 10μg/ml of 
described peptide on day 6 of culture for 4 hours. A. IL-12 and B. IL-10 
production by BM-DCs was assessed using a sandwich ELISA. Data is a 
representative of cytokine production (pg/ml) from 3 pooled independent 
experiments and is shown as mean +/- SEM. All statistical analysis was 
determined using One-way ANOVA and Tukey’s multiple comparison test. 
Statistical significance was expressed as follows; NS= p>0.05. NS was 










3.3.4 Siglec engagement with a2,3 Sia-Kd does not inhibit BM-DCs responses 
to LPS 
 
It has been shown previously that murine DCs treated with Sia-OVA and Sia-
MOG peptides were resistant to LPS maturation as measured via reduction of 
intracellular expression of TNF-α and IL-6 following treatment (Perdicchio et al., 
2016). Therefore, suggesting that sialylated antigen targeted DCs had an 
'immature phenotype' under proinflammatory stimulus (Perdicchio et al., 2016). 
This finding was in line with others who have found that 'tolerogenic' DCs are 
resistant to maturation (see section 1.4.1, pg. 24). In one of these studies, BM-
DCs rendered tolerogenic by drug treatment had low expression of MHC class 
II, co-stimulatory molecules and was in favour of producing IL-10 rather than IL-
12 in comparison to control BM-DCs following LPS/ anti-CD40 or TNFα 
stimulation (Smyth et al., 2013). As the Perdicchio et al., (2016) study did not 
present data on the aforementioned, the expression of MHC and co-stimulatory 
molecules as well as IL-12/IL-10 production following LPS stimulation was 
assessed in sialylated alloantigen treated BM-DCs via flow cytometry and 
ELISA, respectively. 
 
Surprisingly, both MHC I and II levels were not increased in un-pulsed BM-DCs 
after LPS stimulation [Fig. 3.6A-B]. This was an unexpected finding and is 
conflicting to Smyth et al., (2013) and Kelleher & Beverley (2001) studies, 
where they found that untreated BM-DCs stimulated with LPS had increased 
expression of MHC molecules. In contrast, CD80 and CD86 levels were 
increased following LPS stimulation in untreated cells (no peptide/LPS p=0.01). 
Pre-treatment with both unsialylated or sialylated peptides did not modify the 
increase in CD80 however, CD86 was slightly reduced by peptide treatment 
(Kd/LPS vs. untreated/LPS, p=0.13) (α2,3 Sia-Kd /LPS vs. untreated/LPS, p 
=0.10) [Fig.3.6 C-D].  
 
The supernatants from these treated BM-DCs were collected for the 
assessment of IL-12 and IL-10 production. Both IL-12 and IL-10 levels were 
increased in response to LPS for all conditions [Fig. 3.6 E-F]. However, 
compared to Kd pulsed and LPS-treated control BM-DCs, α2,3 Sia-Kd treatment 
did not modify cytokine production [Fig. 3.6E].   
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In conclusion, whether sialylated alloantigen targeted BM-DCs are refractory to 
LPS stimulation remains inconclusive given no significant differences in MHC 































































































































































































































Figure 3.6. MHC, co-stimulatory molecules, IL-10 and IL-12 remain 
unchanged between peptide and unpulsed BM-DCs. B6 BM-DCs were 
harvested and pulsed with 10μg/ml peptide on day 6 of culture for 4 hours and 






measured in the culture supernatants using a sandwich ELISA. Cells were also 
stained with anti CD11c, MHCI/II or CD80 and CD86 flurochrome-conjugated 
antibodies and assessed by flow cytometry, to determine MHC and 
costimulatory marker expression. For expression of MHC and costimulatory 
molecules, each dot represents one experiment. Overall, data was pooled from 
4 independent experiments and the error bars represent +/- SEM. Data is 
presented as fold-change of MFI for MHCI/II or CD80/86 expression, in 
comparison to BM-DCs treated with no peptide or LPS (set to a value of 1): A. 
MFI for MHC I expression. B. MFI for MHC II expression. C. MFI for CD80 
expression. D. MFI for CD86 expression. E. Bar chart showing the mean +/- 
SEM concentration of IL-12 (pg/ml) and F. IL-10 (pg/ml) produced in the 
absence or presence of LPS. Data was pooled from 3 independent 
experiments. All statistical analysis was determined using One-way ANOVA and 
Tukey’s multiple comparisons test. Statistical significance was expressed as 
follows; p<0.001***, p<0.01**, p<0.05*, NS= p>0.05. 
 
3.3.5 In vitro targeting of α2,3 Sia-Kd to B6 BM-DC reduces proliferation as well 
as  IL-2 and IFN-γ production of Kd alloantigen- specific CD4+ T cells 
 
Perdicchio et al., (2016), observed that Sia-OVA antigen pulsed DCs 
significantly impaired proliferation of antigen specific responder T cells in 
contrast to DCs pulsed with unsialylated OVA (Perdicchio et al., 2016). To 
determine whether pulsing DCs with a sialylated-alloantigen resulted in a similar 
observation, Kd specific T cells were isolated from TCR75 transgenic Rag -/- 
mice and stimulated with B6 derived BM-DCs pulsed with either 1 or 10 μg/ml of 
Kd or α2,3 Sia-Kd peptides. As mentioned earlier TCR75 CD4+ recognises Kd 
alloantigen presented via B6 I-Ab, modelling demonstrating an indirect T cell 
responses. Controls were DC and T cell co-cultured in the absence of antigen 
and T cells cultured alone. Different DC: T cell ratios were used to optimise the 
assay. T cell proliferation was measured on day 3 via thymidine incorporation 
and IL-2 and IFN-γ cytokine production was measured using IL-2 and IFN-γ 





In comparison to T cells co-cultured with unpulsed DCs, proliferation of TCR75 
T cells was observed in the presence of BM-DCs treated with either 1 and 10 
μg/ml Kd at all DC: T cell ratios [Fig. 3.7A]. By contrast, T cell proliferation to 
BM-DCs pulsed with 1 μg/ml of α2,3 Sia-Kd pulsed BM-DC was significantly 
reduced, however in the presence of BM-DCs pulsed with 10 μg/ml α2,3 Sia-Kd 
an increase in proliferation was seen at the 1:1 and 1:5 DC:T cell ratios 
suggesting that the level of proliferation of T cells is dependent on the 
concentration of the peptide [Fig. 3.7A]. However, comparing T cell proliferation 
induced by both the peptide pulsed BM-DCs indicated that pre-treatment with 
α2,3 Sia-Kd in comparison to Kd peptide resulted in significantly less T cell 
activation [Fig. 3.7A] (See appendix Fig. 2 for all data). 
 
In addition, and complementary to the T cell proliferation observed, IL-2, a 
cytokine involved in T cell expansion, and IFN-γ, an effector T cell cytokine, 
were produced by TCR75 T cells activated with Kd pulsed DCs. Interestingly, 
co-cultures containing BM-DCs pulsed with 1 μg/ml of peptides at a ratio of 1:10 
suggested no significant differences in IL-2, although there was a trend of less 
IL-2 in the presence of sialylated alloantigen [Fig. 3.7B]. Overall, in the 
presence of 1 or 10 μg/ml α2,3 Sia-Kd, there was a significant reduction of IL-2 
in comparison to Kd [Fig. 3.7B]. The low levels of IL-2 may be a result of 
induced/ expanded Tregs utilising this cytokine for their survival. This could 
explain the proliferation data, which may be utilising the IL-2 for their expansion 
[Fig. 3.7B]. This was assessed and the data will be discussed in section 3.3.7. 
Compared to Kd pulsed DCs, reduced IFN-γ levels were also observed when T 
cells were cocultured with BM-DCs pulsed with 10 μg/ml α2,3 Sia-Kd [Fig. 3.7C]. 
 
Therefore, despite high levels of Sia-Kd binding to BM-DCs [Fig. 3.3] there is 
significant suppression of antigen specific T cell proliferation and cytokine 
production. Taken together this data suggests that engaging Siglecs expressed 
on DCs with sialylated Kd peptide resulted in suppression of the expansion and 
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Figure 3.7. Targeting BM-DC Siglecs with Sia-Kd lead to impaired TCR75 
CD4+ T cell proliferation as well as IL-2 and IFN-γ production in vitro. B6 
BM-DCs were pulsed with 1 or 10µg/ml concentrations of either Kd or α2,3 Sia-
Kd peptide and co-cultured with CD4+ cells from TCR 75 Rag -/- mice at 1:1, 1:5 
or 1:10 DC: T ratios. A. T cell proliferation was assessed on day 3 following the 
addition of 3H thymidine for the last 18hrs of the culture. Proliferation is 
expressed as counts per minute (CPM) +/- SD.  Data represents one 
experiment out of 3 performed. Each bar represents a technical triplicate. B. IL-
2 cytokine present in culture supernatants 3 days after co-culture was 
determined using an IL-2 sandwich ELISA. Data is representative for one 
experiment  out of three experiments, +/- SD. C. IFN-γ production of TCR75 
CD4+ T cells stimulated with BM-DCs pulsed with either 10µg/ml Kd or α2,3 Sia-
Kd peptides at a 1:10 DC:T ratio were assessed using a specific ELISA. 
Controls included T cells and unpulsed BM-DCs. Each bar is a representative of 
pooled data from 2 independent experiments, +/- SEM. One-way ANOVA and 
Tukey’s multiple comparisons test was used to compare the means and 
statistical significance was expressed as follows; p<0.0001****, p<0.001***, 
p<0.01**, p<0.05*, NS= p>0.05.   
 
3.3.6 Long construct of α2,3 sialylated alloantigens (α2,3L Sia-Kd) impairs 
proliferation and IL-2 production of indirect alloreactive CD4+ T cells  
 
We also tested the effect of a longer sialylated alloantigen construct known as 
α2,3L Sia-Kd which was provided to us later on in the project.  We were  
informed via personal communication with Prof. van Kooyk lab (Vumc), that the 
longer constructs produced IL-10, these constructs were in the initial stages and 
required further investigation. BM-DCs were treated with either 10 µg/ml of Kd or 
α2,3L Sia-Kd and subsequently co-cultured with CFSE labelled TCR75 T cells. 
Controls were DC and T cell co-culture in the absence of antigen and T cells 
cultured alone. The BM-DC: T ratio of 1:10 was chosen based on the previous 
data in Figure 3.7 where decreased CD4+ T cell proliferation, IL-2 and IFN-γ 
was found with this ratio. Co-cultured cells were incubated for 3 days, after this 
time supernatants were harvested for the assessment of IL-2 cytokine 
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production using an IL-2 specific sandwich ELISA, and proliferation assessed 
by measuring CFSE dilution using flow cytometry. 
 
Like α2,3 Sia-Kd, the α2,3L Sia-Kd peptide impaired indirect allorecognition in 
vitro. Reduced TCR75 CD4+ T cell proliferation was observed in the presence of 
α2,3L Sia-Kd pulsed BM-DCs, in comparison to Kd, controls with responses 
being similarly to the shorter sialylated alloantigen peptide [Fig. 3.7-8]. As 
expected, T cells produced significantly less IL-2 in the presence of α2,3 Sia-Kd 
(p=0.0009) and α2,3L Sia-Kd (p=0.0005) as compared to Kd-treated BM-DCs, 
with no significant difference in IL-2 production between the sialylated 
alloantigens being observed (p=0.9) [Fig. 3.8B]. Therefore, both the short and 
























































































































Figure 3.8. Targeting B6 BM-DCs with α2,3 Sia-Kd and α2,3L Sia-Kd 
suppressed proliferation of TCR75 CD4+ T cells  B6 BM-DCs were pulsed 
with 10µg/ml peptide and co-cultured with CFSE labelled TCR75 CD4+ T cells 
at 1:10 ratio. After 3 days, supernatants were collected and cells were surface 
stained with CD4 antibody, followed by analysis of CFSE proliferation. A. Cells 
were gated on live cells (FSC vs. SSC), doublets were excluded followed by 
gating on CD4+ T cells that were CFSE+ [Fig. 2.9A]. (i) Histogram plots 
demonstrate CFSE dilution of CD4+ TCR75 T cells. Data is a representation of 
one out of three independent experiments. (ii). Histograms represent the mean 
+/- SEM percentage of T cell proliferation.  B. IL-2 production: supernatants 
were collected in order to determined IL-2 cytokine release using IL-2 sandwich 
ELISA. Error bars demonstrate +/- SEM. Data was pooled from 3 experiments. 
Statistical comparisons were performed using One-way ANOVA and Tukey’s 
multiple comparisons. Statistical significance was expressed as follows; 
p<0.0001****, p<0.001***, p<0.01**, p<0.05*. NS= p>0.05 
 
3.3.7 Targeting α2,3 or α2,3L Sia-Kd to Siglecs leads to DCs with a greater 
ability to expand/induce Tregs 
 
In the previous section we highlighted that targeting Siglecs on DCs can impair 
CD4+ T cell proliferation and effector cytokine production, confirming previous 
studies showing that activation through Siglec leads to DCs with a 'tolerogenic' 
function. One way 'tolerogenic' DCs promote tolerance is through the induction/ 
expansion of Tregs, as mentioned earlier in section 1.4.1 (pg. 24), and by 
Perdicchio et al., (2016), who observed that α2,3 Sia-OVA/ MOG peptide 
pulsed DCs were capable of inducing/expanding Tregs (Perdicchio et al., 2016). 
This section focuses on whether the hyporesponsive state of TCR75 T cells 
observed was accompanied by the induction/ expansion of Tregs. TCR75 CD4+ 
T cells were co-cultured with B6 derived BM-DCs pulsed with either 10 µg of Kd , 
α2,3 Sia-Kd or α2,3L Sia-Kd in the presence of IL-2. We initially assessed Treg 
induction using 10μg/ml peptide at 1:5 and 1:10 DC: T ratio, and found that 
10ug/ml peptide at 1:10 ratio gave optimal results [Appendix fig. 4]. The 
percentage of Tregs in the culture was measured 3 days later via flow cytometry 
using a Foxp3 specific antibody. Like the aforementioned study, it was 
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observed that more Foxp3+ Tregs were induced/expanded when TCR75 CD4+ T 
cells were co-cultured with DCs pulsed with either of the Sia-Kd peptides in 
comparison to no peptide (unpulsed controls) and Kd-treated DCs, however 
there were no significant differences in Treg levels between the two sialylated 
alloantigens (p=0.09) [Fig. 3.9B].  
 
T cells co-cultured with sialylated MOG treated- DCs were unable to produce 
significant levels of IL-10, an immunosuppressive cytokine produced by Tregs, 
in contrast to native MOG peptide (Perdicchio et al., 2016). In order to 
investigate whether sialylated Kd treated DCs influenced T cells to produce 
more IL-10, we measured levels of this cytokine from Treg induction co-
cultures. In line with Perdicchio et al., (2016) findings, there was no significant 
production of IL-10 between Kd and both α2,3 Sia-Kd treated DC:T cell co-
cultures (α2,3 Sia-Kd p=0.9) (α2,3L Sia-Kd p=0.4) [Fig. 3.9C] as compared to T 
cell only controls. Interestingly, there was a significant increase of IL-10 with Kd 
(p=0.01) and α2,3 Sia-Kd (p= 0.04) in comparison to DC+ T only control, 
however, as there were no differences in comparison to T cells, it cannot be 
concluded that IL-10 is produced in response to alloantigens [Fig. 3.9C].  
 
Taken together with our previous in vitro observations, the data demonstrates 
that treatment of DCs with sialic acid modified alloantigen may lead to a 
‘tolerogenic’ DC phenotype which results in suppression of alloantigen reactive 
T cells with indirect specificity and induction/expansion of Tregs. We mentioned 
Treg induction as well as expansion as Tanriver et al., (2010), discovered that a 
small endogenous proportion of CD4+ Foxp3+ Tregs (1.74% Tregs) are present 
within TCR75 mice, therefore, Treg induction as well as expansion may be of 
consequence. Overall, this may help to induce tolerance in vivo and will be 




































































Figure 3.9. α2,3 and α2,3L Sia-Kd targeted BM-DCs induced CD4+ Foxp3+ 
Tregs in vitro. B6 BM-DCs were pulsed with 10µg/ml peptide and co-cultured 
with TCR75 CD4+ T cells at 1:10 ratio with subsequent addition of 5U IL-2 at 
day 0. After 3 days, Foxp3 expression in CD4+ T cells was measured following 
intracellular staining and subsequent flow cytometry. A. Cells were gated on live 
cells (FSC vs. SSC), doublets were excluded followed by gating on CD4+ 
versus Foxp3+. B. The numbers indicate fold- increase of CD4+ Foxp3+ T cells 
over DC+ T controls,  which was set to a value of 1.  C. IL-10 production (pg/ml) 
as measured using a sandwich ELISA. Data was pooled from three 
independent experiments. Error bars demonstrate +/- SEM. Statistical 
comparisons between samples were made using One-way ANOVA and Tukey’s 
multiple comparisons test to assess significance between means of samples. 
Statistical significance was expressed as follows; p< 0.0001**** p<0.001***, 






3.3.8 Immunomodulatory molecules ICOS-L and PDL-1 are not induced 
following Siglec ligation 
 
Tolerogenic DCs can decrease T cell proliferation through various cell surface 
marker interactions such as programmed-death-ligand 1 (PD-L1) and inducible 
T-cell costimulator-ligand (ICOS-L), both of which are highly expressed on DCs 
(Tuettenberg et al., 2009; Tanaka et al., 2008). Having demonstrated that Sia-
Kd treatment impaired BM-DCs ability to activate CD4+ T cell proliferation we 
measured the expression of the aforementioned molecules to assess whether 
expression of these inhibitory receptors were involved. BM-DCs were treated for 
4 hours with 10µg/ml Kd, α2,3 Sia-Kd, or α2,3L Sia-Kd and negative control DCs 
remained unpulsed. Cells were then stained with anti-ICOS-L or anti-PD-L1 
conjugated antibodies and surface expression was analysed using flow 
cytometry. The data suggests that there were no significant changes in PD-L1 
[Fig. 3.10A] and ICOS-L [Fig. 3.10B] expression following exposure to either 
Sia-Kd or Kd peptide. Expression of these molecules was the same as untreated 
controls [Fig. 3.10 A and B].  
 
Taken together, Sia-Kd treated BM-DCs do not mediate impaired T cell 































































































Figure 3.10.  Sialylated Kd peptide and Siglec interaction on BM-DCs does 
not affect ICOS-L or PD-L1 expression.  BM-DCs were pulsed with either Kd, 
α2,3 Sia-Kd or α2,3L Sia-Kd DC for 4 hours with 10 µg/ml peptide and analysed 
using flow cytometry. No peptide treated DCs were used as a negative control. 
Cells were gated on live cells (FSC vs. SSC), doublets were excluded followed 
by gating on CD11c+ DCs [Appendix Fig. 5]. Unstained and single stained 
controls were used as negative controls. A. Percentage of CD11c+ BM-DCs 
expressing ICOS-L. B. Percentage of CD11c+ BM-DCs expressing and PD-L1. 
Data was pooled from 3 independent experiments. Statistical comparisons 
between samples were made using One-way ANOVA and Tukey’s multiple 
comparisons test to assess significance between means of samples.  Error bars 






3.4 Targeting B6 B cells with α2,3 and α2,3L sialylated alloantigen  
 
3.4.1 Siglecs expressed on B cells bind to α2,3 Sia-Kd alloantigen 
 
As previously mentioned, B cells are actively involved in allorecognition (Firl et 
al., 2017). Given that these cells also express Siglecs, CD22 and Siglec G, 
targeting alloantigens to these receptors may facilitate transplant tolerance 
(Meyer et al., 2018). To confirm the presence of the aforementioned Siglecs on 
resting splenic derived B cells, cells were stained with anti-CD22 or anti-Siglec 
G antibodies and assessed using flow cytometry. Figure. 3.11 highlights that 
resting B cells express Siglec G and CD22, as expected. It should be noted that 
statistical analysis comparison between B cells Siglec expression could not be 
performed as CD22 expression staining was conducted once, however, we and 
several publications have confirmed expression of this Siglec on B cells (Pillai et 
al., 2012; Torres et al., 1992; Pfrengle et al., 2013; Hutzler et al., 2014).  
 
Next to assess the interaction between these Siglecs and the sialylated 
allopeptide, B cells were incubated with either α2,3 Sia-Kd or control Kd -FITC 
fluorescent conjugates (10µg/ml for 4 hours at 37°C) before uptake was 
assessed via flow cytometry. In comparison to control unpulsed B cells both the 
Kd-FITC and α2,3 Sia-Kd- FITC peptides were capable of binding to B cells [Fig. 
3.12].  Although we observed moderate expression of Siglec G and CD22 on B 
cells, α2,3 Sia-Kd peptide binding to these cells appears to be slightly less 
efficient than that seen with the BM-DCs in Figure 3.3A (1.5 fold increase of 
α2,3 Sia-Kd than Kd- targeted B cells and 1.7 fold-increase binding of α2,3 Sia-
Kd than Kd- targeted BM-DCs). Given the role of transitional B cell subsets in 
promoting murine allograft survival (Moreau et al., 2014), we next assessed 
which B cell subsets were binding to α2,3 Sia-Kd peptide. B cell subsets were 
identified using IgM, CD21 and CD23  surface markers (Chung et al., 2003) 
following the gating strategy by Zhang et al., (2004); Teague et al., (2007) and 
Ledesma-Soto et al., (2012). From the data shown in Fig 3.13, α2,3 Sia-Kd and 
Kd peptide bind to T1 (IgMhighCD21−CD23−), T2 (IgMhighCD21+CD23+), MZ 
(IgMhighCD21hiCD23-) and FO (IgMlowCD21+ CD23+) B cells (Petro et al., 2002; 
Allman and Pillai, 2008; Zouali and Richard, 2011), with increased FITC staining 
being seen on these cells compared to the no peptide control. No significant 
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Figure 3.11. Siglec G and CD22 are expressed on B6 B cells. B cells were 
gated on live cells (FSC vs. SSC), doublets were excluded followed by gating 
on B220+ B cells [Fig. 2.5]. A. FACS plot demonstrating Siglec G and CD22 
expression on B220+ B cells and B220-FITC single stained control. B. MFI of 
Siglec G and CD22 on B220+ cells. Siglec G expression was assessed in 3 







































Figure 3.12. α2,3 Sia-Kd binds to Siglec expressing B cells in vitro. For 
peptide binding studies, B6 spleen derived B cells were pulsed for 4 hours with 
either 10 µg/ml Kd -FITC or α2,3 Sia-Kd -FITC. Control (no peptide) B cells were 
left untreated. A. Live cells were gated on FSC-A vs. SSC-A [Fig. 2.5]  and 
analysed for peptide binding by gating on B220+ cells SSC and measuring the 
B. MFI of FITC using flow cytometry. Data from 3 independent experiments 
were pooled and statistically compared using One-way ANOVA and Tukey’s 
multiple comparisons test. Data shown is mean ± SEM. Statistical significance 
was expressed as follows; p< 0.0001****, p<0.01**, p<0.05. 
B 
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Figure. 3.13 Sialylated and non-sialylated alloantigens bind to transitional, 
MZ and FO B cell subsets A. Gating strategy for B6 spleen derived B cells and 
B cell subset analysis determined by staining cells with antibodies to B220, IgM, 
CD23 and CD21. Live cells were gated on FSC vs. SSC, and B220+ B cells. 
Data is represented as contour plots and representative of one out of three 
independent experiments. For peptide binding analysis, B cells were pulsed for 
4 hours with either 10 µg/ml Kd -FITC or α2,3 Sia-Kd -FITC. MFI of FITC 
expression is shown as a fold-change over the no peptide (set to a value of 1). 
Pulsed B cell subset controls: B. MFI of peptides-FITC bound to T1 B cells. C. 
MFI of peptides-FITC bound to T2 B cells. D. MFI of peptides-FITC bound to 
MZ B cells. E. MFI of peptides-FITC bound to FO B cells. Data shown is mean ± 
SEM and was pooled from 3 independent experiments with statistical 
comparisons being performed using One-way ANOVA and Tukey’s multiple 
comparisons test. Statistical significance was expressed as follows; p<0.0001 
****, p<0.01**, p<0.05*. NS = p>0.05.  
 
3.4.2 In vitro targeting of Kd peptide, α2,3 Sia-Kd or α2,3L Sia-Kd to B6 B cells 
does not stimulate proliferation of antigen specific CD4+ T cells 
 
As previously shown (Section 3.3.5, pg. 94), reduced proliferation and cytokine 
release of Kd- specific CD4+ T cells was observed in the presence of BM-DCs 
pulsed with α2,3 Sia-Kd or α2,3L Sia-Kd peptide. To assess whether targeting 
Siglecs on B cells using the aforementioned peptides, also reduced T cell 
responses, B6 B cells were incubated with 10 µg/ml of either the sialylated-
alloantigens or control Kd peptide before being co-cultured with TCR75 CD4+ T 
cells at a 1:10 ratio. Controls included B and T cell co-culture in the absence of 
peptide and T cells alone. Unlike the strong T cell proliferation observed with Kd 
pulsed DCs (section 3.3.5, pg. 94), B cells treated with Kd or sialylated Kd 
peptide did not induce CD4+ T cell proliferation suggesting that naïve B cells 
were unable to activate these T cells [Fig. 3.14 A]. This was supported by a lack 
of IL-2 or IFN-γ production [Fig. 3.14 B-C].  
 
Despite these findings, the induction/expansion of Tregs by Sia-Kd pulsed B 
cells was assessed. TCR75 CD4+ T cells were co-cultured with B6 derived B 
cells pulsed with 10 µg of Kd or α2,3 Sia-Kd or α2,3L Sia-Kd at a 1:10 B:T ratio. 
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The percentage of Tregs in the culture was measured 3 days later as previously 
described. No Treg induction was observed in any conditions tested [Fig 3.15A].  
Next, IL-10 production was assessed. Surprisingly, TCR75 T cells co-cultured 
with Kd- pulsed B cells, produced significantly more IL-10 in comparison to T 
cell only (p=0.003) and B and T control, (p=0.002) [Fig. 3.15 B]. In comparison 
to the T cells only control, this was not observed with sialylated alloantigen 
treated B cells (α2,3 Sia-Kd p= 0.35, α2,3L Sia-Kd p=0.53), however T cells 
cultured with B cells pulsed with α2,3 Sia-Kd produced more IL-10 in 
comparison to B and T control (p=0.04)  [Fig. 3.15 B]. Overall, T cells released 
more IL-10 when co-cultured with Kd treated B, in comparison to B cells treated 
with sialylated alloantigen (α2,3 Sia-Kd p= 0.01, α2,3L Sia-Kd p=0.02) [Fig. 3.15 
B].  
 
Taken together, sialylated or unsialylated alloantigen treated naïve B cells do 
not stimulate CD4+ T cell proliferation or induce Tregs, however Kd targeted B 
cell appear to produce more IL-10 in comparison to the negative and sialylated 



































































































Figure 3.14 Targeting alloantigens to B6 B cells do did not stimulate 
alloantigen-specific CD4+ T cells proliferation or IL-2 and IFN-gamma 
production. B6 B cells were pulsed with 10µg/ml peptide and co-cultured with 
CFSE labelled TCR75 CD4+ T cells at 1:10 ratio. After 3 days, supernatants 
were collected and cells surface stained with anti-CD4-APC antibody. Cells 
were gated on live cells (FSC vs. SSC), doublets were excluded followed by 
gating on CD4+ T cells and CFSE+ dilution assessed [Fig. 2.9B]. A. (i) Histogram 
FACS plots demonstrating the percentage of CD4+ TCR75 T cells proliferation. 
Data is a representation for one out of three independent experiments. (ii) 
Percentage proliferation of TCR75 T cells in response to targeted B cells. Error 
bars demonstrate +/- SEM pooled from 3 independent experiments. B. IL-2 
(pg/ml) and C. IFN- γ (pg/ml) present in culture supernatants were analysed for 
using either an IL-2 or IFN- γ specific sandwich ELISA. Data represent mean ± 
SEM cytokines from 3 experiments and statistical analysis was performed using 





























































































Figure 3.15. α2,3 Sia-Kd targeted B cells do not induce CD4+ Foxp3+ Tregs 
in vitro. B6 B cells were pulsed with 10µg/ml peptide and co-cultured with 
TCR75 CD4+ T cells at 1:10 ratio with subsequent addition of 5U IL-2 at day 0. 
After 3 days, expression of Foxp3 was measured by intracellular antibody 
staining and subsequent flow cytometry analysis. A. Fold-change of CD4+ 
Foxp3+ T cells in comparison to B+T controls (set to a value of 1). B. IL-10 
release from T cells co-cultured with pulsed/unpulsed B cells was assessed 
using a IL-10 specific ELISA. Data is a representative of three pooled 
experiments. Statistical comparisons were made using a One-way ANOVA and 
Tukey’s multiple comparisons test to determine statistical significance between 






3.5 Targeting B6 macrophages with α2,3 and α2,3L sialylated alloantigen  
3.5.1 Targeting alloantigen to Siglec-expressing macrophages reduced IL-12 
production in presence of LPS  
Aside from DCs and B cells, macrophages also play a role in transplant 
rejection. These cells express Siglecs (Pillai et al., 2012) such as Siglec F, 
which was the predominant Siglec expressed on M-CSF expanded BM-derived 
macrophages (BM-DM) [Fig 3.16A]. However they also express CD169 and low 
levels of Siglec E and H, as assessed using flow cytometry [Fig 3.16A]. Like the 
aforementioned cells in this chapter, both Kd and α2,3 Sia-Kd FITC peptides 
bind to macrophages [Fig. 3.16B]. Surprisingly, we noticed that Kd peptide, and 
not α2,3 Sia-Kd, preferentially binds to macrophages, although not significant, 
which is opposite to what we have observed with DCs and B cells [Fig. 3.16B] 
[Fig.3.12] [Fig.3.3 A-B]. This was quite an interesting finding given that Siglec 
expression between DCs and macrophages were quite similar. It would be 
interesting to determine whether the same Siglecs expressed on different APCs, 
have a particular binding affinity/strength to different structures of sialic acids.  
To determine whether targeting Siglecs on macrophages with α2,3 Sia-Kd or 
α2,3L Sia-Kd could render them refractory to LPS stimulation, macrophages 
were pulsed with α2,3 Sia-Kd, α2,3L Sia-Kd or Kd peptides whilst control cells 
were left untreated [Fig. 3.16C]. After 4 hours, cells were treated for 24 hours 
with 200 ng/ml of LPS. Supernatants from the cultures were collected and IL-12, 
which is produced by proinflammatory macrophages, was measured using a 
sandwich ELISA. Without LPS stimulation, no differences in the production of 
IL-12 were observed between the control and peptide targeted BM-DMs [Fig. 
3.16C]. Following LPS stimulation, untreated (no peptide) BM-DMs (p=0.0003), 
BM-DMs treated with Kd (p=0.04) and α2,3L Sia-Kd (p=0.04) produced more IL-
12 in response to LPS stimulation, however, this was not observed in α2,3 Sia-
Kd pulsed macrophages (p=0.25) [Fig 3. 16C]. This would suggest that α2,3 
Sia-Kd targeted macrophages may be resistant to LPS maturation [Fig. 3.16C]. 
Amongst the LPS-treated BM-DMs, there was also a general decrease in IL-12 
production for peptide targeted BM-DMs in comparison to no peptide-treated 
BM-DMs. [Fig.3. 16C]. 
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Overall, Siglec-expressing macrophages can bind to sialylated alloantigen 
leading to modification of their cytokine production following LPS stimulation in 
the case of α2,3 Sia-Kd. Whether these targeted macrophages can impair 
indirect alloreactive T cell proliferation and promote Treg induction in vitro 
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Figure 3.16. Sia-Kd binds to Siglec expressing macrophages in vitro. A.  
Siglec expression on F4/80+ BM-DMs was assessed via flow cytometry using 
antibodies specific to mouse Siglec E, F, H and CD169. Live cells were gated 
on forward scatter (FSC), side scatter (SSC) [Fig. 2.4]. B. For peptide binding 
studies, B6 BM-DMs were pulsed with either 10 µg/ml Kd -FITC or α2,3 Sia-Kd -
FITC and (i) peptide binding assessed by gating on F4/80+ cells and measuring 
the MFI of FITC expression using flow cytometry. Controls cell were untreated 
BM-DMs.(ii) Each bar represent pooled data for MFI of FITC and error bars 
demonstrate +/- SEM, n=3. C. IL-12 production (pg/ml) produced by day 6 BM-
DMs pulsed with 10 µg/ml of the various peptides shown in the presence or 
absence of 200 ng/ml LPS for 24 hours. Unpulsed (no peptide) served as 
negative control. Each bar represents pooled cytokine data from 3 independent 
experiments. Statistical comparisons were made using a  One-way ANOVA and 
Tukey’s multiple comparisons test. Data shown is mean ± SEM. Statistical 























The main focus of this chapter was to determine whether 2,3 Sia-Kd or the 
longer 2,3 Sia-Kd constructs (2,3L Sia-Kd) target Siglecs expressed on DCs, 
B cells and macrophages and whether this interaction can modulate indirect 
allorecognition in vitro.  The data in this chapter suggests that targeting these 
Siglec receptors using sialylated alloantigens modifies both innate and adaptive 
immunity leading to a hyporesponsive environment.  
 
We initially addressed whether Siglecs were expressed on DCs, B cells and 
macrophages and confirmed that Siglec F, CD169 and Siglec E were 
predominantly expressed on BM-DCs, SPLN- DCs and BM-DMs and Siglec G 
and CD22 were expressed on B cells (Pillai et al., 2012). In fact, we found that 
Siglec F was highly expressed on the aforementioned DCs and macrophages. 
Currently, there are very few publications demonstrating Siglec F expression 
and the functional role of this receptor on BM-DCs.  Siglec F expression is 
mostly associated with macrophages present in the lung and eosinophils (Feng 
& Mao, 2012; Zhang et al., 2004). It has been reported that Siglec F is 
expressed on BM-DCs, SPLN-DCs as well as BM-DMs, however the authors 
did not present this data (Tetano et al., 2007). One study confirmed expression 
of Siglecs E on both murine splenic DC and macrophages, but did not observe 
Siglec F expression on either B6 or BALB/c cells (Zhang et al., 2004).  Similarly 
to their study, Siglec expression on cells derived from B6 mice which were 
housed under SPF-free conditions was assessed using flow cytometry and we 
also confirmed Siglec E expression on macrophages and splenic DCs.  It 
remains uncertain as to why Siglec F expression is varied amongst studies, 
possibly due to the varied methodologies for generating ex vivo expanded BM-
DCs.  
 
We did not assess Siglec G expression on BM-DMs, however according to 
previous literature, we expect our macrophages to also express Siglec G (Chen 
et al., 2014). In line with previous literature we were able to confirm that Siglecs 
CD22 and Siglec G were expressed on splenic B cells (Meyer et al., 2018; 
Müller & Nitschke, 2014). We did not examine expression of these Siglecs on B 
cell subsets, however Zhang et al., (2004) confirmed their expression, using 
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flow cytometry, on transitional and MZ/ FO B cells subsets. These authors 
demonstrated low but detectable expression of Siglec E on T2 and MZ B cells, 
while Siglec E expression on T1 B cells were negligible. Siglec F was not 
detected in any of the B cells subsets. It has yet to be determined whether 
Siglec E receptor has any functional role on B cells, but the former study did 
observe that Siglec E levels remained unchanged when B cells were stimulated 
in vitro (findings were not published) (Zhang et al., 2004). As future work, Siglec 
E levels could be assessed on B cells subsets to confirm Zhang et al., (2004) 
study.  
 
CD169 is a Siglec expressed on murine macrophages (van Dinther et al., 
2018), and has also been reported to be expressed on human DCs, (Puryear et 
al., 2013). We confirmed CD169 expression on BM-DMs and surprisingly on 
BM-DCs. This raises the question of the phenotype similarity of ex vivo 
generated BM-DMs and BM-DCs. Both cells are known to express CD11c; 
however F4/80 is predominantly expressed on macrophages. We also observed 
CD169 expression on SPLN-DCs, therefore, by gating on CD11c+ cells, it may 
be a possibility that macrophages are being pooled within the DC population 
during analysis; this could explain CD169 expression detected. Others have 
also questioned the purity of GM-CSF expanded BM-DCs. Helft et al., (2015) 
published phenotype data of GM-CSF expanded murine BM-DCs and 
concluded that these cells were comprised of a heterogeneous population of 
CD11c+ MHC II+ DC and macrophages. There are several distinctions in the 
preparation of BM-DCs culture between the current and aforementioned study, 
one being that in our study, BM cells were initially depleted of B220+, MHC II+, 
CD4+ and CD8+ cells prior to culture with GM-CSF, this was not mentioned in 
Helft et al., (2015) study. Additionally, our BM cells were cultured in DC media 
which was fully replenished on day 2 and 4 as opposed to the protocol in Helft 
et al., (2015). Therefore, given the differences in the protocols used, it cannot 
be fully confirmed that our ex-vivo expanded BM-DCs comprise of a 
heterogeneous population of DCs and macrophages, and therefore expression 
of CD169 on murine BM-DCs may be a novel finding to this study. As future 
work, F4/80+ cells can be measured using flow cytometry to determine purity of 





In addition, 2,3 Sia-Kd or 2,3L Sia-Kd alloantigens targeted to BM-DCs were 
unable to stimulate TCR75 T cell proliferation or effector cytokines IL-2 and IFN-
γ production in comparison to Kd- pulsed BM-DCs. Sialylated alloantigen treated 
BM-DCs were dominant at inducing/ expanding Foxp3+ Tregs, this finding was 
considerably opposite to what was observed with Sia-Kd treated B cells. Unlike 
BM-DC targeting, B cells were not able to stimulate T cell proliferation or Treg 
induction/ expansion; however, there was an increase of IL-10 released from 
TCR75 T cells cultured with Kd-pulsed B cells.  
 
A study by Perdicchio et al., (2016) confirmed that sialylated OVA protein 
antigen had the capability of binding to Siglec E expressed on BM-DCs. In their 
study, they were able to confirm a decrease in sialylated antigen binding to 
Siglec E-/- DCs in comparison to Siglec E expressing WT DCs, whereas no 
significant difference in binding was observed between the Siglec E -/- and WT 
DCs when non-sialylated antigen was tested (Perdicchio et al., 2016). In fact, 
these authors observed that there was preferential binding of sialylated antigen 
to B6 BM-DCs in comparison to non-sialylated antigen. In keeping with their 
data, we also observed that 2,3 Sia-Kd preferentially binds to Siglec-
expressing BM-DCs and SPLN-DCs in comparison to Kd. However we did not 
assess whether this was via Siglec E or the other Siglecs found- this can be 
addressed as future work using Siglec KO mice. Given the differential binding 
between Kd and 2,3 Sia-Kd, the data suggests that the Kd peptide may have 
the ability to bind to MHC molecules whereas 2,3 Sia-Kd, may be binding to 
both the MHC and Siglec receptors. 
 
We extended the work of Perdicchio et al., (2016) and assessed the binding of 
α2,3 sialylated peptide antigen to Siglecs expressed on B cells and 
macrophages. α2,3 sialylated alloantigens were preferentially expressed by 
BM-DCs and B cells in comparison to the unsialylated equivalent, however, this 
was not the case with BM-DMs. This was an intriguing observation given that 
Siglec expression found on DCs and macrophages were similar. This may 
possibly suggest that Siglecs expressed on different APCs, have a particular 
binding affinity/strength to different structures of sialic acids. It appears that the 
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level of α2,3 Sia-Kd binding may also correlate with the Siglec expression. It 
was suggested in a review that Siglec E  binds moderately to 2,3 and 2,6  
sialic acids, whereas Siglec F binds moderately to 2,3 sialic acids but weakly 
to  2,6  sialic acids (Crocker et al., 2007). In addition, Siglec G also has the 
ability to bind to both linkages of sialic acids (Chen et al., 2014), but in order to 
fully confirm which Siglecs the peptides are binding to it would be important to 
utilise Siglec E, F and G knock-out mice or use blocking antibodies. 
 
As mentioned in Chapter 1 (section 1.4.1.1, pg. 25) DCs can be rendered 
'tolerogenic' in a number of ways, Tol-DCs generally express low levels of MHC 
and co-stimulatory molecules, inhibitory receptors and produce anti-
inflammatory cytokines. Interestingly, treatment with sialylated alloantigen but 
not alloantigen resulted in the down-regulation of MHC molecules and no 
increase in PD-L1 and ICOS-L, suggesting that PD-L1 and ICOS-L receptors 
are not modulated following α2,3 sialylated alloantigen targeting. It is known 
that DCs express sialic acids on their surface where they are conveniently 
placed for interactions with receptors such as Siglecs (Silva et al., 2016). One 
study demonstrated the importance of sialic acids and tolerogenic DCs; by 
removing sialic acids on the surface of DCs using sialidase, murine splenic DCs 
became mature (Silva et al., 2016). Their study also compared expression of 
MHC I/II and CD80/86 on splenic DCs and discovered that DCs treated with 
sialidase had increased expression of these molecules (Silva et al., 2016). This 
would suggest that sialic acids are required for the maintenance of tolerogenic 
quiescent DCs and this would support our findings where MHC I and II 
molecules were down-regulated upon sialylated alloantigen targeting. Unlike 
Silva et al., (2016) study, we did not notice any changes in CD80/86 
expression, however, differences in CD80/86 were only noticed following LPS 
treatment. Our findings are somewhat in line to Perdicchio et al., (2016) study, 
where they observed no changes of co-stimulatory marker expression as a 
consequence of Sia-antigen uptake by DCs- although their study did not publish 
this data but did mention this in their discussion. They still found that Sia-
antigen –treated DCs were able to promote tolerance in vitro and in vivo despite 




Heavily sialylated pathogens down-regulate pro-inflammatory immune 
responses following interaction with Siglecs- this is their mechanisms to evade 
the host’s immune systems for their survival. For example, sialylated 
Trypansoma cruzi are able to evade the host immune system through 
interaction with Siglec E expressing DCs leading to significant reduction in IL-12 
(Erdmann et al., 2009). This inhibitory effect was reversed when T.cruzi was 
desialylated (Erdmann et al., 2009). Unlike the former study, we observed no 
differences in this pro-inflammatory cytokine production from BM-DCs in 
response to sialylated alloantigen. It is a possibility that IL-12 is not the correct 
readout for assessing sialylated antigen targeted DC’s capacity to become 
refractory to LPS stimulation. One study demonstrated that sialylated OVA 
antigens targeted to DCs under LPS stimulation were able to impair 
proinflammatory cytokines such intracellular TNF-α and IL-6 (Perdicchio et al., 
2016). In fact previous literature states that Siglec E-/- BM-DCs stimulated with 
E.Coli LPS, sustained high levels of TNF-α and IL-6, suggesting that these 
cytokine levels are modulated via Siglec E (Wu et al., 2016). Therefore and as a 
future investigation TNF-α and IL-6 could be assessed.  
 
It was recently demonstrated that the sialylated structures on the flagellum 
derived from Campylobacter jejuni, were able to engage with Siglec 10 on host 
human monocyte-derived DCs and Siglec G on murine BM-DCs (Stephenson et 
al., 2014). This interaction led to a profound increase of IL-10 mediated by 
MyD88 and p38 MAPK signalling, which supported an anti-inflammatory 
environment favouring the survival of C.jejuni within the host (Stephenson et al., 
2014). Therefore these studies demonstrate that targeting Siglecs on DCs that 
are stimulated via TLRs, are able to dampen proinflammatory immune 
responses. It appears that Siglec G and Siglec E have a role in controlling IL-10 
and IL-12 from DCs in response to TLR signalling, however, our results 
demonstrate quite low levels of Siglec E and Siglec G expression on BM-DCs. 
Therefore, this may explain the little difference in IL-12/ IL-10 release when 
Siglecs are engaged with Sia-Kd and stimulated with LPS. On the other hand, 
Stephenson et al., (2014) and Erdmann et al., (2009) studies are based on 
sialylated pathogens and their interactions with DCs, which is significantly 
different to the current study (targeting DCs with sialylated alloantigens and LPS 
derived from E.coli). First of all, in the current study BM-DCs were treated with 
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peptide for 4 hours prior to LPS stimulation which lasted for 24 hours, as 
opposed to Stephenson et al., (2014), where cytokines were measured 8 hours 
post infection. The next issue is that the “stimulatory capacity’ of the LPS used 
is questionable, given that MHC molecules were not up-regulated in response 
to LPS, as a result we cannot conclude that DCs were fully activated in 
response to the LPS used.  
 
Boyd et al., (2009), demonstrated that inhibitory receptors Siglec E present on 
macrophages dampens TLR signalling as a result of NF-κB attenuation in the 
presence of LPS stimulation and Siglec E cross-linking Ab targeting. NF-kB is a 
transcription factor that is upregulated following TLR4 activation, this results 
upregulation of genes encoding for proinflammatory cytokines such as TNF-α or 
IL-6 (Zhang and Ghosh, 2001).  We have seen that BM-DMs treated with 2,3 
Sia-Kd  and LPS, released less IL-12 in comparison to BM-DMs treated with 
LPS alone, a finding similar to all other peptide plus LPS treated BM-DMs. 
However, the difference is that BM-DMs targeted with 2,3 Sia-Kd alloantigen 
and LPS, displayed similar low levels of IL-12 in comparison to BM-DMs treated 
with 2,3 Sia-Kd alone, which was not observed in the other peptide treated 
BM-DMs.  Therefore,  2,3 Sia-Kd targeted macrophages can suppress IL-12 
production under LPS stimulation. What surprising was that unlike 2,3 Sia-Kd,  
BM-DMs treated 2,3L Sia-Kd and LPS displayed increased levels of IL-12 in 
comparison to BM-DMs treated with 2,3L Sia-Kd alone . This finding  reflects 
what was found by Nagala et al., (2018), where no significant role of Siglec E in 
TLR4 signalling was identified in response to LPS. To fully confirm this, other 
read-outs may be necessary such as NF-κB signalling given Boyd et al., (2009) 
findings.   
 
Targeting antigens to specific cell surface receptors on DCs has been shown to 
dampen antigen specific effector T cell responses through T cell deletion or 
anergy as well as inducing/ expanding Tregs. For example, DCIR2+ DCs 
targeted using an anti-DCIR2 antibody fused to MOG peptide promoted 
tolerance through expansion of antigen specific Tregs (Tabansky, et al., 2018). 
Chappell et al., (2014) showed when targeting antigen to blood dendritic cell 
antigen 2 (BDCA2) expressed on plasmacytoid DCs led to impaired antigen-
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specific CD4+ T cell proliferation even following antigen re-challenge (Chappell, 
et al., 2014). Therefore, it was not surprising that targeting Siglecs on BM-DCs 
with 2,3 Sia-Kd and 2,3L Sia-Kd would lead to impaired Kd- alloantigen 
specific T cell (TCR75 CD4+ T cells) responses and the induction/expansion of 
Tregs. As mentioned before, the CD4+ T cell indirect alloresponse plays a vital 
role in chronic-mediated rejection (Ali et al., 2015). CD4+ T cells from TCR75 
Rag-/- mice were especially useful at determining whether targeting Siglecs 
impaired effector T cells responses that contribute to chronic rejection mediated 
by indirect allorecognition. Using these TCR75 CD4+ T cells as a model for 
indirect allorecognition, our data provides strong support to a study by 
Perdicchio et al., (2016), where they demonstrated that targeting SPLN-DCs 
with sialylated OVA protein and MOG peptide impaired antigen specific T cell 
proliferation and effector cytokine production and induce antigen-specific Tregs. 
It should be taken to account that the aforementioned study identified their 
findings by targeting Siglecs on SPLN-DCs, whereas we identified similar T cell 
responses by targeting BM-DCs. Therefore, the data is this chapter can be 
extrapolated to the findings of Perdicchio et al., (2016) study.   It was found in 
this study following α2,3 sialylated alloantigen targeting, IL-10 production was 
increased but at low levels, this may be due to the lack of increased ICOS-L 
levels of Sia-Kd treated BM-DCs (Tuettenberg et al., 2009).  In addition, IL10-
producing Tr1 cell may not contribute significantly to the population of Tregs 
that have been induced.  
 
B cells are also known for their ability to present alloantigen indirectly to T cells 
as demonstrated by Reichardt et al., (2007), who found that pulsing naïve B 
cells with OVA antigen in vitro promoted the induction of antigen specific Tregs 
(Reichardt et al., 2007). In the peptide binding experiments for this study, it was 
observed that all the alloantigen peptides (sialylated and un-sialylated) were 
capable of binding to T1, T2, MZ and FO B cells subsets with no significant 
differences in binding between the peptides. This may be a possible result of 
the α2,3 Sia-Kd peptide binding to the MHC instead of the Siglec. B cell targeted 
with alloantigens did not stimulate T cell proliferation or effector cytokine 
production. CD4+ Foxp3+ Tregs were not induced/ expanded, however T cell co-
cultured with Kd-targeted B cells produced the most IL-10. An explanation to this 
outcome may be due to sialic acids linkage that is being targeted to the B cells, 
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as Siglec CD22 preferably binds to α2,6 Sia and Siglec G has the ability to bind 
to α2,6 sialic acids, we will address whether the former targeting will provide a 
more substantial immune response in the next chapter.  
 
Overall, targeting Siglec-expressing DCs with 2,3 Sia-Kd or 2,3L Sia-Kd 
impairs CD4+ T cell proliferation, effector cytokine production, and induction 
CD4+ Foxp3+ Tregs, this was not observed when Siglecs were targeted on B 
cells. An explanation as to why α2,3 Sia-Kd and 2,3L Sia-Kd targeted DCs 
have an increased capability to induce Tregs  in comparison to targeted B cells, 
could be that B cell Siglec CD22 can sometimes be ‘masked’ by other α2,6 
sialylated ligands present on the surface of the same cell in cis interaction. This 
therefore limits their availability to bind to other ligands such as our α2,3 Sia-
peptide (Razi and Varki, 1998), however this requires further investigation. It is 
not yet established as to whether Siglec G has a similar ‘masking’ mechanism.  
 
The next chapter will focus on targeting DCs, B cells and macrophages with 
2,6 sialylated alloantigens. As mentioned earlier in Chapter 1 (section 1.5, pg. 
38), certain Siglecs expressed on different cells have preference for sialic acids 
linkages, for example Siglec E binds to α2,3 Sia and α2,6 Sia, Siglec F prefers 
to bind to α2,3 Sia and CD22 only binds to α2,6 Sia (Crocker et al., 2007). 
Targeting using different sialic acids linkages will be appeal to a larger variety of 
Siglecs expressed on different cells, thus increasing the potential to hit various 
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As described in Chapter 3, Siglecs F, E, CD169 and G were expressed on DCs 
and macrophages, whilst CD22 and Siglec G were found on B cells. Also 
mentioned previously, these Siglec receptors have a specificity for certain 
linkages of sialic acids such as α2,3 and/or α2,6 or α2,8-linked sialic acids. For 
example, Crocker et al., (2007), suggested that Siglec E has moderate binding 
to both α2,3 and α2,6 sialic acids, whilst Siglec F has a preference for α2,3 
sialic acids, CD22 binds to α2,6 sialic acids and Siglec G has the capacity to 
recognise α2,3 and/or α2,6 sialic acids (Crocker et al., 2007; Pillai et al., 2012). 
It is also established that CD22 on B cells interact with α2,6- linked sialic acids 
which can impair BCR signalling by decreasing Ca2+ mobilization (Hutzler et al., 
2014). Therefore, targeting APCs with different sialylated constructs may 
optimise the inhibitory function of these peptides by targeting multiple Siglec 
receptors.  
 
Given the findings from Chapter 3 demonstrating that targeting Siglec 
expressing DCs with α2,3 sialylated alloantigen impaired proliferation of indirect 
alloreactive T cells and induced Tregs, we investigated whether α2,6-linked 
sialic acid- modified Kd alloantigen have the same efficacy. Similarly to Chapter 
3, the findings from this chapter will determine whether targeting APCs using 
















4.2 Aims:  
 
Similarly to Chapter 3, this chapter focuses on targeting Siglecs expressed on 
DCs, B cells and macrophages using an α2,6-linked sialic acid modified Kd 
alloantigen, to observe whether this targeting regimen can modulate indirect 
alloresponses in vitro and induce Tregs.  
 
Objectives 
1. Identify whether α2,6 Sia-Kd alloantigens bind to recipient DC, B cells and 
macrophages in vitro. 
2. Determine whether targeting Siglecs with α2,6 Sia- alloantigen peptides on 
these APCs dampened allogeneic T cell responses in vitro and promotes Treg 



























4.3.1. α2,6 Sia-Kd binds to Siglec-expressing BM-DCs 
 
It has been reported that α2,6-linked sialic acids preferentially bind to Siglecs 
expressed on B cells, however according to Perdicchio et al., (2016), these 
sialic acids are also able to bind to Siglec-expressing BM-DCs and promote a 
tolerogenic immune response. In fact, these authors reported that α2,6-linked 
sialic acid conjugated OVA antigen was able to bind to Siglec E on DCs 
(Perdicchio et al., 2016). Given their data, the binding of α2,6 Sia-Kd-FITC 
alloantigen peptides to Siglecs expressed on BM-DCs was assessed in vitro. B6 
derived BM-DCs were incubated with FAM5/6 (FITC) fluorochrome-conjugated 
alloantigen peptides; either Kd or α2,6 Sia-Kd (10μg/ml for 4 hours at 37°C) 
before cells were assessed via flow cytometry. Untreated BM-DCs served as a 
control. Peptide binding was determined by assessing the MFI of FITC 
expressed on CD11c+ DCs. As expected both the Kd-FITC and α2,6 Sia-Kd-
FITC peptides were capable of binding to CD11c+ DCs. Compared to controls 
(no peptide treatment), there was a 2.8 fold increase in FITC expression for Kd 
treated BM-DCs and a 3.2 fold increase for α2,6 Sia-Kd pulsed BM-DCs [Fig. 
4.1]. However, unlike the α2,3 Sia-Kd-FITC (please refer to Fig. 3.3B (i)), no 
significant difference in the amount of Kd-FITC and α2,6 Sia-Kd binding was 
found [Fig.4.1].  
 
In conclusion, α2,6 sialylated alloantigens bind to Siglec expressing BM-DCs, 
although there is less binding of α2,6 sialylated alloantigen as compared to α2,3 
sialylated alloantigen. This may reflect the type and the abundance of Siglec 
receptors expressed as well as reflecting their binding capacity [Fig 3.3A, Fig. 






































Figure. 4.1. α2,6 Sia-Kd binds to Siglec-expressing BM-DCs in vitro. For 
peptide binding studies, B6 BM-DCs were pulsed for 4 hours with either 10 
μg/ml Kd - FITC or α2,6 Sia-Kd FITC at 37° C incubation and analysed for 
peptide binding by gating on CD11c+ cells [Fig. 2.2]  and measuring the MFI of 
FITC using flow cytometry. Data was pooled from 3 independent experiments. 
No peptide treated DCs were included as controls. Statistical comparisons 
performed using One-way ANOVA and Tukey’s multiple comparisons test. 
Statistical significance was expressed as follows; p<0.01**, NS= p>0.05. 
 
4.3.2 α2,6 Sia-Kd targeted DCs impair indirect allorecognition and induce Tregs 
 
Perdicchio et al., (2016), reported that B6 SPLN-DC targeted with α2,6 Sia-
MOG peptide were capable of inducing/expanding more Foxp3+ Tregs from 
MOG antigen-specific CD4+ T cells (2D2 T cells) than DCs treated with α2,3 
Sia-MOG. They also found no difference in IL-10 production when 2D2 T cells 
were co-cultured with α2,6 Sia-MOG, α2,3 Sia-MOG or MOG peptide treated 
DCs. However, a decrease in IFN-γ production was observed when these T 
cells were stimulated with α2,3/ α2,6 sialylated MOG pulsed DCs in comparison 
to MOG peptide alone (Perdicchio et al., 2016). Taken together, this data 
highlighted that both α2,6 and α2,3 Sia-MOG have the ability to reduce antigen-
specific effector responses and induce Foxp3+ Tregs (Perdicchio et al., 2016). 
To address whether targeting Siglecs on BM-DCs with α2,6 Sia-Kd impair, 
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antigen specific CD4+ T cell proliferation, cytokine production (IL-2 and IFN-γ) 
and were also capable of inducing/ expanding Tregs, the following experiments 
were conducted:  CFSE labelled TCR75 T cells were co-cultured with B6 
derived BM-DCs pulsed with either 10µg of α2,6 Sia-Kd or control Kd peptide at 
a 1:10 DC:T ratio for 3 days and T cell proliferation, CFSE dilution, was 
investigated. Culture supernatants were harvested to allow measurement of IL-
2 and IFN-γ production. In addition, and in separate cultures, Tregs 
induction/expansion was measured as previously described. Supernatants from 
these co-cultures were harvested to measure IL-10 using sandwich ELISA.  
 
As expected, and as previously shown, proliferation of TCR75 T cells was 
observed when these CD4+ T cells were co-cultured with Kd pulsed BM-DCs 
(Fig 4.2A). T cell proliferation was impaired when these cells were co-cultured 
with α2,6 Sia-Kd pulsed BM-DCs, which was similar to what was seen following 
α2,3 Sia-Kd DC treatment [Fig. 4.2A (ii)]. In addition, both IL-2 and IFN-γ 
production by TCR75 T cells was limited in response to α2,6 Sia-Kd pulsed DCs 
[Fig. 4.2B-C]. No T cell proliferation or cytokine production was observed in 
control groups; T cell plus unpulsed DCs and T cell alone. 
 
As expected Foxp3+ Tregs were induced/expanded when Kd specific CD4+ T 
cells were co-cultured with DCs pulsed with α2,6 Sia-Kd peptides, however 
there were no significant differences in IL-10 production between groups 
[Fig.4.3]. This finding was similar to what was observed by Perdicchio et al., 
(2016), where IL-10 production from 2D2 CD4+ T cells in response to sialylated 
and non-sialylated MOG was not significant [Fig. 4.3].  Overall, it appears that 
all the sialylated constructs are able to impair alloreactive T cell responses in 






























































































Figure 4.2. Targeting B6 BM-DCs with α2,6 Sia-Kd suppressed proliferation 
and cytokine production of TCR75 CD4+ T cells  B6 BM-DCs were pulsed 
with 10µg/ml peptide and co-cultured with CFSE labelled TCR75 CD4+ T cells 
at 1:10 ratio. After 3 days, supernatants were collected and cells surface 
stained with CD4 antibody, followed by analysis of CFSE proliferation. A. Cells 
were gated on live cells (FSC vs. SSC); doublets were excluded followed by 
gating on CD4+ T cells that were CFSE+ [Appendix Fig. 3A]. (i) Histogram plots 
demonstrate CFSE dilution of CD4+ TCR75 T cells. Data is a representation of 
one out of three independent experiments. (ii). Plot demonstrates a graphical 
comparison of TCR75 CD4+ T cell proliferation with all sialylated constructs (B6 
BM-DCs pulsed with α2,3 Sia-Kd, α2,3L Sia-Kd or α2,6 Sia-Kd). Data represents 
the mean +/- SEM percentage of T cell proliferation and was pooled from 3 
independent experiments. B. IL-2 production: supernatants were collected in 
order to determined IL-2 cytokine release using IL-2 sandwich ELISA. Error 
bars demonstrate +/- SEM. Data was pooled from 3 experiments. C. 
Supernatants were collected in order to determined IFN-  cytokine release 
using IFN- sandwich ELISA. Error bars demonstrate +/- SEM. Data was pooled 
from 3 experiments. Statistical comparisons were performed using One-way 
ANOVA and Tukey’s multiple comparisons. Statistical significance was 



























































































Figure 4.3. Siglec targeting with α2,6 Sia-Kd induces CD4+ Foxp3+ Tregs in 
vitro. B6 BM-DCs were pulsed with 10µg/ml peptide and co-cultured with 
TCR75 CD4+ T cells at 1:10 ratio with subsequent addition of 5U IL-2 at day 0. 
A.  After 3 days, the expression of Foxp3 was measured via intracellular 
staining and subsequent flow cytometry. FACS plot is a representative for one 
of 4 experiments. B. The numbers indicate fold-increase of CD4+ Foxp3+ T cells 
compared to DC+T cultures (set to a value of 1). Data was pooled from 4 
independent experiments. C. IL-10 release from T cells co-cultured with 
pulsed/unpulsed B cells. IL-10 production was assessed using sandwich ELISA. 
Data is a representative of three pooled experiments and error bars present +/- 
SEM. Statistical comparisons were made using One-way ANOVA and Tukey’s 
multiple comparisons test and was expressed as follows; p<0.001***, p<0.01**, 
ns=p>0.05.  
 
4.3.3. ICOS-L and PD-L1 expression remain unchanged following α2,6 Sia-Kd 
targeting 
 
As mentioned in section 3.3.8 (pg. 104), levels of ICOS-L and PD-L1 on DCs 
were not affected by treatment with α2,3 Sia-Kd or α2,3L Sia-Kd sialylated 
alloantigens. Next we assessed whether Siglec:α2,6 Sia-Kd interaction could 
increase the expression of these molecules. Untreated BM-DCs and DCs 
treated with 10µg/ml Kd or α2,6 Sia-Kd were stained with ICOS-L or PD-L1 
conjugated antibodies and analysed using flow cytometry. The results were in 
line with our previous findings. No significant difference in PD-L1 and ICOS-L 
expression was observed following the addition of the α2,6 sialylated peptide, 
and there was no significant difference with unsialylated peptide [Fig. 4.4]. In 
conclusion, ICOS-L and PD-L1 expression does not play a role in limiting T cell 













































































Figure 4.4. α2,6 Sia-Kd peptide treated BM-DCs do not affect ICOS-L or PD-
L1 expression.  B6 derived BM-DCs targeted with no peptide, Kd or α2,6 Sia-
Kd were pulsed for 4 hours with 10 µg/ml peptide  at 37°C incubation and 
analysed using flow cytometry. Cells were gated on live cells (FSC vs. SSC), 
doublets were excluded followed by gating on CD11c+ DCs [Fig. 2.2].  A. 
Numbers indicate the percentages of the total cell population of cells expressing 
CD11c and PD-L1 or B. ICOS-L. Data was pooled from 3 independent 
experiments. Error bars represent +/- SEM. Statistical comparisons were made 
use One-way ANOVA and Tukey’s multiple comparisons test and was 










4.4  Targeting B6 B cells with α2,6 sialylated alloantigen  
 
4.4.1 α2,6 Sia-Kd binds to B cells  
 
CD22 and Siglec G present on B cells are capable of binding to α2,6 sialic acid 
(Pillai et al., 2012; von Guten et al., 2008; Meyer et al., 2018). Therefore, we 
wanted to determine whether α2,6 Sia-Kd was capable of binding these 
receptors. B6 splenic derived B cells were incubated with either α2,6 Sia-Kd-
FITC or control Kd-FITC fluorescent conjugates and binding was assessed via 
flow cytometry. As expected, in comparison to unpulsed B cells, alloantigens Kd 
and α2,6 Sia-Kd significantly bound to B cells (p=0.0084 and p=<0.0001, 
respectively). However, α2,6 Sia-Kd preferentially binds to B cells in comparison 
to native Kd (p=<0.0001), suggesting that the α2,6 sialic acid linkage to the 
alloantigen may allow this constructs to bind to Siglecs (Siglec G and CD22) 
with a specific preference for this sialic acid [Fig. 4.5]. Overall, we have shown 
that in line with the published literature (Mahajan et al., 2016; Razi et al., 1998), 































Figure 4.5. α2,6 Sia-Kd binds to Siglec expressing B cells in vitro. B6 B 
cells were isolated from spleens, followed by treatment with or without peptide. 
For peptide binding studies, B6 B cells were pulsed for 4 hours with either 10 
µg/ml Kd FITC or α2,6 Sia-Kd FITC at 37°C incubation and analysed for peptide 
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binding by gating on B220+ cells and measuring the MFI of FITC using flow 
cytometry. For the negative controls, cells were not treated with peptide. Live 
cells were gated on forward scatter (FSC), side scatter (SSC) [Fig. 2.5]. 
Statistical comparisons were made using One-way ANOVA and Tukey’s multiple 
comparisons test and data was pooled from 3 independent experiments (n=3). 
Data shown is mean ± standard deviation (SEM). Statistical significance was 
expressed as follows; p<0.0001****, p<0.01**. 
 
Next we determined which specific subset of B cells α2,6 Sia-Kd peptide binds 
to. Previous experiments in Chapter 3 demonstrated that α2,3 Sia-Kd binds to 
T1 (IgMhighCD21−CD23−), T2 (IgMhighCD21+CD23+), MZ (IgMhighCD21hiCD23-) 
and FO (IgMlowCD21+CD23+) B cell subsets. To assess whether Siglecs 
expressed on these B cell subsets also recognised the α2,6 Sia-Kd peptide, B6 
splenic derived B cells were incubated with either α2,6 Sia-Kd-FITC or control 
Kd-FITC fluorescent conjugates and uptake assessed via flow cytometry. Like 
the α2,3 sialylated peptide, α2,6 Sia-Kd peptide significantly binds to T1, FO and 
MZ B cell subsets [Fig. 4.6], however it appears that only α2,6 Sia-Kd binds 
significantly to T2 as opposed to Kd (p=0.03) and unpulsed B cells (p=0.006)  
[Fig. 4.6C]. These observations suggest that the high level of α2,6 Sia-Kd 
binding, seen in Fig 4.5 may be specific to a few B cell subsets (particularly T2 






































Figure. 4.6 Sialylated and non-sialylated alloantigens bind to T1, T2, MZ 
and FO B cell subsets A. Gating strategy for B cells subset analysis. Live cells 
were gated on forward scatter (FSC), side scatter (SSC) and B220+ B cells. 
Subsets were determined by staining cells with antibodies to IgM, CD23 and 
CD21. Data is represented as contour plots and representative one out of three 
independent experiments.  (B-D) B cells were pulsed for 4 hours with either 10 
µg/ml Kd FITC or α2,6 Sia-Kd FITC and B cell subsets B. T1 B cells. C. T2 B 
cells. D. MZ B cells. E. FO B cells were analysed for peptide binding by gating 
on B220+ , IgM, CD23 and CD21 B cells and measuring the MFI of FITC using 
flow cytometry. Controls cell were not treated with peptide. No peptide control 
was set to a value of 1 and peptide targeted B cells were compared against no 
peptide control as fold-change. Data was pooled from 3 independent 
experiments to look for B cell binding and statistical comparisons were made 
use One-way ANOVA and Tukey’s multiple comparisons test (n=3). Data shown 
is mean ± SEM). Statistical significance was expressed as follows; p<0.01**, 
p<0.05*, NS= p>0.05.  
 
4.4.2 Targeting Siglecs on B6 B cells with α2,6 Sia-Kd peptides in vitro does not 
stimulate T cell proliferation or induce/expand Tregs 
 
We have previously demonstrated in Chapter 3 that engaging Siglecs on naïve 
B cells with α2,3 Sia-Kd led to B cells with no capacity to activate antigen 
specific T cells or induce/expand Tregs. In order to assess whether α2,6 Sia-Kd 
treatment resulted in a similar or different observation, CFSE- labelled TCR75 T 
cells were stimulated with B6 derived B cells at a 1:10 B: T ratio and B cells 
were pulsed with Kd or α2,6 Sia-Kd peptides. T cell activation was assessed by 
CFSE dilution and the production of cytokines IL-2 and IFN-γ. Tregs 
induction/expansion was measured as previously described.  
 
As expected naïve B cells did not induce T cell proliferation or cytokine release 
regardless of the presence of sialylated or non-sialylated alloantigens 
[Fig.4.7A]. In addition, α2,6 Sia-Kd and Kd-treated B cells did not induce Tregs 
[Fig. 4.8A], however and similarly to the data in Chapter 3, TCR75 T cells 
cocultured with Kd-pulsed B cells produced significantly more IL-10 in 
comparison to T cells activated with unpulsed B cells (p=<0.0001) [Fig. 4.8B]. In 
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conclusion, B cells targeted with Kd peptide favour IL-10 production more than 
α2,6 Sia-Kd-treated B cells, however naïve B cells do not activate TCR75 cells 






































































Figure. 4.7. Targeting Siglecs on B6 B cells does not stimulate 
alloantigen-specific CD4+ T cells proliferation. B6 B cells were pulsed with 
10µg/ml peptide and cocultured with CFSE labelled TCR75 CD4+ T cells at 1:10 















CD4 antibody, followed by analysis of CFSE proliferation. A. Cells were gated 
on live cells (FSC vs. SSC), doublets were excluded followed by gating on CD4+ 
T cells that were CFSE+ [Fig. 2.9 B]. (i) Histogram plots demonstrate CFSE+ 
CD4+ T cell proliferation.  Data is a representation for one out of three 
independent experiments. (ii). Percentage of T cell proliferation. Error bars 
demonstrate +/- SEM and data represents 3 independent experiments. B. 
Supernatants were analysed for IL-2 using a sandwich ELISA. C. Supernatants 
were analysed for IFN- γ production using sandwich ELISA. ELISA data was 
pooled from 3 independent experiments, n=3. Data shown is mean ± SEM. 
Statistical comparisons were performed using One-way ANOVA and Tukey’s 























































































Figure. 4.8. Kd targeted B cells produce more IL-10 in vitro.  B6 B cells were 
pulsed with 10µg/ml peptide and cocultured with TCR75 CD4+ T cells at 1:10 
ratio  with subsequent addition of 5U IL-2 at day 0. After 3 days, expression of 
Foxp3 was measured by intracellular staining and subsequent flow cytometry. 
A. The numbers indicate fold- increase of CD4+ Foxp3+ T cells from B+ T 
control. Data was pooled from 3 independent experiments (n=3). B. IL-10 
release from T cells co-cultured with pulsed/unpulsed B cells. IL-10 production 
was assessed using sandwich ELISA. Data is a representative of three pooled 
experiments and error bars present +/- SEM. Statistical comparisons were 
made using One-way ANOVA and Tukey’s multiple comparisons test and was 








4.5 Targeting B6 macrophages cells with α2,6 sialylated alloantigen  
4.5.1 α2,6 Sia-Kd peptides bind Siglec-expressing macrophages  
We have previously observed that α2,3 Sia-Kd binds to Siglec-expressing BM-
DMs which did not result in IL-12 cytokine production following LPS treatment 
(Chapter 3). To assess whether α2,6 Sia-Kd peptide binds to B6 macrophages 
and whether this binding impacted IL-12 production, BM-DMs were targeted as 
previously mentioned in section 4.3.1 (pg. 130). Binding of α2,6 Sia-Kd and Kd 
to B6 derived BM-DMs in vitro was observed by flow cytometry [Fig.4.9A]. 
Unlike α2,3 Sia-Kd targeting, there were no significant differences in binding 
between the peptides [Fig 4.9A].  
Next, to determine whether targeting macrophages with α2,6 Sia-Kd altered IL-
12 cytokine profile in the presence of LPS stimulation, macrophages were 
pulsed with Kd or α2,6 Sia-Kd peptides (unpulsed BM-DMs were controls), 
followed by a 24 hour LPS stimulation at a concentration of 200 ng/ml. 
Supernatants from the cultures were collected in order to measured IL-12 via 
ELISA. Interestingly, BM-DMs stimulated with LPS and Kd or α2,6 Sia-Kd 
alloantigens released less IL-12 in comparison to BM-DMs pulsed with LPS 
alone, suggesting that peptide treatment affected BM-DMs ability to respond to 
LPS stimulation (Kd, p= 0.02, α2,6 Sia-Kd p= 0.02) [Fig. 4.9B].  
In summary, peptide targeted BM-DMs that were also stimulated with LPS 
produced less IL-12 in comparison to BM-DMs treated with LPS alone, a finding 
similar to Chapter 3, section 3.5.1, pg. 115. However, targeting Siglecs on BM-
DMs using α2,6 sialylated alloantigens does not limit IL-12 production, 
demonstrated by an increase of this proinflammatory cytokines in response to 
LPS, thus demonstrating an opposite finding to α2,3 Sia-Kd targeted BM-DMs 
































































































Figure. 4.9. α2,6 Sia-Kd binds to Siglec expressing macrophages in vitro 
and produces less IL-12 when treated with alloantigens.  A. For peptide 
binding studies, B6 BM-DMs were pulsed for 4 hours with either 10 µg/ml Kd 
FITC or α2,6 Sia-Kd FITC and peptide binding analysed by gating on F4/80+ 
cells and measuring the MFI of FITC using flow cytometry. For the negative 
controls cell were not treated with peptide. Live cells were gated on forward 
scatter (FSC), side scatter (SSC) [Fig. 2.4]. Bar graphs showing the MFI of 
FITC expression on F4/80+ BM-DMs following peptide binding. Error bars 
demonstrate +/- SEM and data represents 3 pooled independent experiments. 
B. BM-DMs were pulsed with 10μg/ ml peptide for 4 hours and some cells 





macrophages in culture were harvested for the measurement of IL-12 using 
sandwich ELISA. Each bar represents mean ± SEM IL-12 (pg/ml) pooled data 
from 3 independent experiments (n=3). Statistical comparisons were made 
using One-way ANOVA and Tukey’s multiple comparisons test to determine 
statistical significance. Statistical significance was expressed as follows; 

































The data in this section demonstrated that targeting B6 BM-DCs with α2,6 Sia-
Kd impaired T effector cell  proliferation, induced Tregs and decreased 
proinflammatory cytokines production. However, these findings were not due to 
ICOS-L and PD-L1 expression on BM-DCs. These findings were not found 
when B cells were targeted with α2,6 Sia-Kd. In addition, Siglec expressing 
macrophages targeted with α2,6 Sia-Kd are not resistant to LPS maturation as 
demonstrated by the IL-12 readout.  
 
Different Siglecs are expressed between DCs, B cells and macrophages, for 
example Siglecs CD22 and Siglec G are expressed on B cells, whereas Siglecs 
CD169, E, F, G are expressed on DCs and macrophages (Pillai et al., 2012). 
The abundance and expression of various Siglecs on one cell remains to be 
determined, but given that some of these Siglecs share the same specificity for 
α2,6 sialic acids, we can assume that differential levels of α2,6 Sia-Kd binding 
will be expected amongst the APCs. As expected and due to the expression of 
Siglecs G and CD22 on B cells which have specificities to α2,6 sialic acids, 
there was significant and preferential binding of α2,6 Sia-Kd to B cells in 
comparison to the unsialylated peptide. This was not seen when BM-DCs and 
BM-DMs were tested. Siglecs F and CD169 are highly expressed on both cells 
(Chapter 3) and these Siglecs are known to preferentially bind to α2,3-linked 
sialic acids, and Siglec F in particular binds weakly to α2,6-linked sialic acids 
(Crocker et al., 2007), therefore the binding profiles may reflect the type of 
Siglecs that are present on BM-DCs and BM-DMs. Siglec E is said to have the 
ability to bind moderately to both α2,3/ α2,6 linked sialic acids. Although we 
have confirmed expression of Siglec E on DCs, their expression levels were not 
as high as Siglec F and CD169. Therefore, the expression of Siglecs and their 
specificity towards sialic acid linkages may provide some explanation as to why 
α2,6 Sia-Kd binding to BM-DCs and BM-DMs was not as prominent as α2,3 Sia-
Kd binding, when comparisons are made to Kd-peptide binding (Chapter 3). 
Regardless of this result, we still assessed the capacity of α2,6 Sia-Kd targeted 




Tregs were induced when BM-DCs were targeted with α2,6 Sia-Kd supporting a 
study by Perdicchio et al., (2016). In fact, according to Perdicchio et al., (2016), 
targeting Siglec E-/- BM-DCs with α2,6 Sia-OVA drastically reduced the 
proportions of induced Foxp3+ Tregs in comparison to WT BM-DCs. This may 
imply that interactions between α2,6 Sia-Kd and Siglec E on our B6 BM-DCs 
contributes to the increase of Foxp3+ Tregs, and this could be confirmed, as 
future work, by assessing Tregs induction potentials between Siglec E-/- BM-
DCs and WT BM-DCs. Given that various Siglecs are present on DCs, it 
remains to be determined if any of the other Siglecs are involved in Treg 
induction.     
 
B cell Siglecs are able to interact with α2,6- linked sialic acids and in turn impair 
BCR signalling by decreasing Ca2+ mobilization and limiting B cell activation 
(Hutzler et al., 2014). Therefore, this chapter addressed whether these Siglecs 
could be targeted with α2,6 sialylated alloantigens to promote tolerance and 
identified that targeting these B cells with sialylated constructs did not affect T 
cell responses or induce/ expand Tregs as seen with Sia-Kd targeted BM-DCs. 
However, literature states that B cell Siglecs are well-defined as receptors for 
preventing autoimmunity, for example Jellusova et al., (2010) demonstrated that 
double-deficient Siglec G and CD22 knockout murine B cells contributed to 
systemic autoimmunity. When these Siglecs were absent on B cells these 
authors noticed the development of B cell proliferation in response to TLR 
stimulation and an increase in IgG autoantibodies associated with glomerular 
damage in the kidneys (Jellusova et al. 2010). B cell associated Siglecs are 
known to be inhibitory making them potential receptors to promote tolerance, 
especially since these receptors can interact with sialic acids both in cis and 
trans (Meyer et al., 2018).  
 
Siglecs are present on transitional B cells (Zhang et al., 2004), we addressed if 
targeting Siglecs on B cells can promote immunoregulatory T cell function, and 
whether transitional, MZ or FO B cells play a role. In the current study, binding 
of both Kd and α2,6 Sia-Kd was observed in T1, T2, MZ and FO B cell subsets. 
However, unlike α2,3 Sia-Kd, we identified that α2,6 Sia-Kd, binds more to T2 
subsets as demonstrated by the increase of FITC MFI in comparison to Kd 
peptide. This finding is quite promising as it demonstrates that this sialylated 
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peptide has more binding potential to a subset of B cells which are known for 
promoting  tolerance (Moreau et al., 2014). Regardless of this interaction and 
similarly to α2,3 Sia-Kd targeting in Chapter 3, no T cell proliferation or Treg 
induction was observed.  
 
In comparison to other studies, there are several distinctions in the methodology 
which may explain our findings. It was initially thought that targeting naïve B 
cells may not be sufficient to stimulate T cells proliferation, however, one study 
demonstrated that naïve B cells targeted with OVA, were able to stimulate OT-II 
CD4+ T cells proliferation in vitro (Reichardt et al., 2007). Their experiments 
consisted of targeting naïve B cells with OVA overnight and again 4 hours 
before use, followed by co-culture with OT-II T cells for a further 72 hours at a 
1:1 B:T ratio (Reichardt et al., 2007). What was notably interesting was that OT-
II T cells cocultured with OVA-pulsed naïve B cells produced significant 
amounts of IL-2 and IFN-γ, whereas these cytokines were negligible in our 
experiments. However,  significant differences between studies are the origin of 
the T cells for the co-cultures (OT-II versus TCR75) and the antigen (OVA 
whole protein versus Kd peptide). In 1995, one study showed that peptide 
antigens where more efficiently presented via DCs to naïve CD4+ T cells rather 
that it’s protein form, whereas proteins Ags acquired via B cells were more 
efficient at initiating an immune response in comparison to protein targeted DCs 
(Constant et al., 1995a; Constant et al., 1995b).  Therefore, as a future 
experiment, we can target B cells with whole MHC monomers as opposed to 
peptide, so that the antigen processing mechanism is similar to a whole OVA 
protein.   
 
In the aforementioned study, they observed an increase of IL-10 was found in 
supernatants containing B and T cells, which is in line with our findings from T 
cell co-cultured with Kd-pulsed B cells (Reichardt et al., 2007). In our study, it 
was interesting to see that regardless for a lack of T cell proliferation or Treg 
induction, IL-10 was found in supernatants with Kd-pulsed B cells and TCR75 T 
cells. This raised the question as to whether the IL-10 is being released by B 
cells or the TCR75 T cells. This was addressed by Reichardt et al., (2007), 
where they found that B cells were the actual source of IL-10 in the B/T 
supernatants, therefore this may provide some explanation to our IL-10 data. 
152 
 
Overall, targeting naïve B cells with OVA protein antigens can promote antigen-
presentation and stimulate T cells proliferation. Therefore as future work, the B 
cell experiments in the study could be adapted to Reichardt et al. (2007) study, 
and be repeated by targeting B cells with whole MHC monomer protein (+/- 
sialylation) rather than a peptide, which is similar to the aforementioned study 
whole protein targeting strategy. This way, we will be able to establish whether 
targeting Siglecs on B cells can modulate indirect allorecognition, which was 
observed when BM-DCs were targeted.  
 
Lastly, as mentioned in the previous Chapter 3, Siglec E expressing 
macrophages have been shown to limit TLR cytokine production following LPS 
stimulation (Boyd et al., 2009). It was interesting to see in their study following 
LPS activation, Siglec E receptors were up-regulated and inhibitory SHP-1 and 
SHP-2 were recruited to the receptor (Boyd et al., 2009). With respect to Boyd 
et al., (2009) observations for upregulation of Siglec E receptors following LPS 
stimulation, as a future experiment, it may also be worth targeting macrophages 
with sialylated alloantigen following LPS activation to determine whether 
activated macrophages with more Siglec E expression can become ‘tolerogenic’ 
and that proinflammatory cytokines such as IL-12 production, TNF-α and IFN-γ 
are dampened. Conversely, one study identified no differences in pro-
inflammatory cytokines such as TNF-α release following LPS stimulation when 
WT versus Siglec E-/- macrophages were compared, further questioning 
whether Siglec E has a definitive role at controlling LPS stimulation (Nagala et 
al., 2018). The present study did not look at the levels of TNF-α following 
targeting, however it would be interesting to measure this cytokine so that 
comparisons can be made to the aforementioned studies. This study measured 
the levels of IL-12 and we noticed that macrophages that were treated with α2,6 
Sia-Kd produced less IL-12 in comparison to the no peptide controls. Similarly to 
the macrophage data in Chapter 3, all peptide targeted BM-DMs stimulated with 
LPS produced less IL-12 in comparison to BM-DMs treated with LPS alone. 
However, unlike α2,3 Sia-Kd targeted BM-DMs where there was no significant 
difference in IL-12 production between +/- LPS groups, there was an increase 
of IL-12 production following LPS activation of BM-DMs treated with α2,6 Sia-Kd  
and LPS in comparison to the non-LPS treated counterpart. This suggests that 
α2,3 sialylated peptides may have an immunomodulatory effect in the presence 
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of LPS in comparison to α2,6 sialylated peptides. However, there is very little 
literature to support these findings other than Boyd et al., (2009) study. 
Nevertheless, there are significant differences to the aforementioned study and 
the current study such as their use of  targeting Siglec E with a cross-linking Ab 
and their readouts such as TNF-α and IL-6, where we only assessed IL-12 
(Boyd et al., 2009).  Also, we cannot rule out the possibility that α2,6 Sia-Kd is 
binding to CD169 on macrophages, which is a Siglec that does not contain an 
ITIM, therefore limiting interaction with other inhibitory Siglecs. This is debatable 
as CD169 preferably binds to α2,3 linked sialic acids as opposed to α2,6 linked 
sialic acids (Pillai et al., 2012; Macauley et al., 2014).  
 
Overall, targeting α2,6 Sia-Kd to Siglecs expressed by BM-DCs modulated 
indirect allorecognition in vitro in favour of impaired T cell proliferation and 
induction/expansion of Tregs. This was also seen when BM-DCs were targeted 
with α2,3/ α2,3L Sia-Kd. There were clear differences in peptide binding profiles 
to DCs, macrophages and B cells between the sialylated constructs, indicating 
that some of these constructs prefer to bind to specific Siglec receptors. 
However, in this chapter, targeting Siglecs on B cells and macrophages with 
α2,6 Sia-Kd did not promote an immunoregulatory function.  
 
One of the aims of this project was to determine whether targeting different 
Siglecs on APCs by targeting with different sialylated alloantigens could 
promote an immunoregulatory environment that could potentially support 
allograft survival. As mentioned in Chapters 3-4, targeting BM-DCs in vitro with 
all the sialylated constructs demonstrated this by impairing CD4+ T cell 
proliferation, effector cytokine production and distinctly induced/ expanded 
Foxp3+ Tregs. We conclude that all the sialylated alloantigens used in this study 
may have the ability to instruct DCs to promote alloantigen-specific tolerance. 
What is yet to be confirmed is whether similar results can be obtained if BM-
DCs or SPLN-DCs can targeted with all sialylated constructs at once to see 
whether this generates a more immunoregulatory environment, with a further 
increased proportion of Tregs, as opposed to targeting with one construct 
alone. In addition, it would also be necessary to determine whether Siglec- 
expressing BM-DMs can impact T cells proliferation and the development of 

















TARGETING SIGLECS ON BATF3- 
DEPENDENT DCs PROLONGS SKIN 
TRANSPLANT SURVIVAL AND LEADS TO 


















Immunosuppressive drugs are effective at prolonging organ transplant survival 
on a short-term basis by reducing the incidences of acute rejection. However, 
this treatment fails to prevent chronic rejection and is associated with a number 
of side effects as outlined in the general introduction (Chapter 1). In order to 
promote graft survival without the use of ISD, several laboratories have opted to 
use cellular immunotherapeutic approaches to promote tolerance and reduce 
the incidences of chronic rejection. Some of these approaches include 
modifying donor (direct pathway) and recipient (indirect pathway) DCs to limit 
effector immune responses, the use of depletion antibodies and the induction/ 
expansion of Tregs (Morelli & Thomson., 2014).  
 
Of relevance to this thesis is the literature looking at inhibiting the indirect 
allorecognition pathway, the pathway known to contribute to chronic rejection 
(Brennan et al., 2009), via manipulating DCs. In the context of allograft survival 
various methods have looked at manipulating recipient DCs or targeting 
endogenous DCs to induce tolerance. These have included treating transplant 
recipients with syngeneic/ autologous DCs that have been rendered 
'tolerogenic' ex vivo, administering donor-alloantigen loaded recipient DCs or 
target endogenous DCs with alloantigens in situ. These treatments have proven 
to be successful in prolonging solid organ transplants in murine models 
(Tanriver et al., 2010; Divito et al., 2010; Morelli et al., 2014).  
 
Peche et al., (2005) assessed the capacity of recipient-derived DCs to modulate 
allograft rejection in a rat model; they compared a non-adherent subpopulation 
of recipient derived BM-DCs with an adherent population of BM-DCs (Peche et 
al., 2005). They found that immature adherent BM-DCs induced significant 
heart allograft survival when introduced back into the recipient (Peche et al., 
2005). Divito et al., (2010) and Morelli et al., (2014) both described that ex vivo 
expanded alloantigen pulsed-recipient DCs were short-lived when reintroduced 
into the host and that their immunomodulatory effects were dependent on the 
recipient endogenous DCs. These cells acquired and presented alloantigen 
from the injected DCs leading to deletion of alloreactive effector T cells and the 
promotion of CD4+ Foxp3+ Tregs, both of which were required for transplant 
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survival. However, maintaining the ‘tolerogenic’ state of ex vivo-generated DCs 
that are administered in vivo can be challenging and there are also issues with 
generating tolerogenic DCs on a large scale for clinical use such as the 
expense (Hu and Wan, 2010).  
  
An alternative method to inhibit the indirect pathway is to target alloantigens to 
endogenous DCs. These cells are inactivated/quiescent and are present in the 




The aim of this chapter is to assess whether targeting sialylated alloantigen to 
Siglecs expressed on endogenous DCs promotes transplant tolerance by 
inhibiting the indirect pathway of allorecognition. 
 
To achieve this, the following objectives were undertaken: 
1. Determine whether Siglecs expressed by endogenous DCs bind sialylated Kd 
peptide following intravenous administration.  
2. Assess whether targeting Siglecs on specific DC subsets promotes transplant 
tolerance. 
 
The in vivo experiments in this chapter were adapted from a previous 
publication using an established skin transplant model (Honjo et al., 2000; 
Tanriver et al., 2010). Similarly, Tanriver et al., (2010) established that targeting 
33D1-Kd constructs to DCIR2 receptors on endogenous DCs successfully 
prolonged MHC I mismatch skin allograft B6.Kd (B6 strain expressing H-2Kd 
transgene) survival in the absence of direct CD8+ T cells. 
 
This study has so far highlighted that targeting BM-DCs in vitro with sialylated 
alloantigen led to impaired indirect CD4+ T cell allorecognition and the 
expansion/ induction of CD4+ Foxp3+ Tregs. In this chapter we sought to 
determine whether targeting Siglecs on DCs, in vivo, induced transplant 
tolerance. If successful this would support the use of administering sialylated 






5.3.1 Sialylated alloantigen peptides bind to endogenous DCs and B cells in the 
SLOs when administered intravenously 
 
We have previously confirmed Siglec expression on both B6 derived splenic 
DCs and B cells as well as the ability of α2,3 Sia-Kd and α2,6 Sia-Kd peptides to 
bind to these cells in vitro. Before beginning the transplant experiments, we first 
determined whether the i.v. administered sialylated and non-sialylated Kd 
peptides are capable of binding to these cells in the SPLN and LNs, two organs 
that are essential for antigen presentation and immune cell interaction (Modino 
et al., 1996). To assess alloantigen peptide binding in vivo, B6 mice were 
injected i.v. with 10μg of either Kd-FITC, α2,3 Sia-Kd-FITC, α2,6 Sia-Kd-FITC or 
saline as a negative control. SPLNs and LNs were harvested 2 hours after 
administration. This time point was selected to allow circulation of the peptides 
to reach the SLOs and was chosen based on based on previous studies (Mann 
et al., 2017; Whitney et al., 2011).   
 
Splenocytes and LN cells were stained with either anti-CD11c antibodies to 
identify DCs or anti-B220 antibodies to identify B cells. Cells were then analysed 
using flow cytometry and peptide binding was determined by measuring the MFI 
of FITC expressed on these cells. The data suggests that following i.v. injection 
Kd, α2,3 Sia-Kd and α2,6 Sia-Kd peptides bind to DCs resident in the LNs, 
although the data is not statistically significant, a trend of increased FITC 
expression is observed [Fig. 5.1C (i)].  In addition, both sialylated and non-
sialylated alloantigen peptides bind to B cells; however this again appears to be 
preferentially in LNs rather than in the SPLN [Fig. 5.2]. Therefore, it can be 
concluded that it is possible for the peptides to bind to DCs and B cells in the 
LNs in vivo following intravenous injection. It should be noted that the binding of 
α2,3L Sia-Kd in vivo could not be assessed as we did not have a fluorochrome-









































































































SPLN and LN harvest 
CD11c cell surface stain/ FACS 
analysis 
 
B6 2 hours 
Saline, 10µg K
d











Figure. 5.1. Sialylated and unsialylated allopeptides bind to DCs in the 
lymph node following intravenous administration. A. B6 mice (2-4 mice per 
group) received 10μg/200μl saline of either Kd –FITC,  α2,3 Sia-Kd –FITC, α2,6 
Sia-Kd –FITC or 200 µl saline (no peptide control) via i.v. injection. B. Two hours 
post injection mice were sacrificed; (i) spleens and (ii) LNs were harvested and 
DCs were identified by staining for CD11c expression. Doublets were initially 
excluded, followed by live cells gating based on forward scatter (FSC) and side 
scatter (SSC). The MFI of FITC expression on CD11c  was analysed. C. MFI of 
FITC was expressed as fold-change against saline treated mice which was set 
to a value of 1. (i) saline, Kd-FITC, α2,3 Sia-Kd-FITC or α2,6 Sia-Kd-FITC 
peptide binding to SPLN-DCs.  (ii) saline, Kd-FITC, α2,3 Sia-Kd-FITC or α2,6 
Sia-Kd-FITC peptide binding to SPLN-DCs.  Error bars demonstrate +/- SEM. 
Each dot is a representative of 1 mouse per condition. Statistical comparisons 
were performed using One-way ANOVA and Tukey’s multiple comparisons. 
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Figure 5.2. Sialylated alloantigen preferentially binds to Siglecs expressed 
on lymph node B cells following intravenous administration. A. B6 mice (2-
3 mice per group) received 10μg/200μl saline of either Kd –FITC,  α2,3 Sia-Kd –
FITC, α2,6 Sia-Kd –FITC or 200 µl saline (no peptide control) via i.v. injection. 
B. Two hours post injection mice were sacrificed; (i) spleens and (ii) LNs were 
harvested and B cells identified by stained for B220 expression. Doublets were 
initially excluded, followed by live cells gating based on forward scatter (FSC) 
and side scatter (SSC). The median fluorescence intensity (MFI) of FITC 
expression on B220  was analysed. C. MFI of FITC was expressed as fold-
change against saline treated mice which was set to a value of 1. (i) saline, Kd-
FITC, α2,3 Sia-Kd-FITC or α2,6 Sia-Kd-FITC peptide binding to SPLN-B cells.  
(ii) saline, Kd-FITC, α2,3 Sia-Kd-FITC or α2,6 Sia-Kd-FITC peptide binding to 
LN- B cells.  Error bars demonstrate +/- SEM. Each dot is a representative of 1 
mouse per condition. Statistical comparisons were performed using One-way 
ANOVA and Tukey’s multiple comparisons. Statistical significance was 
expressed as follows; p<0.01**, p<0.05*. NS= p>0.05. 
 
5.3.2. Treating recipient B6 mice with Sia-alloantigens 10 days before a B6.Kd 
skin transplant did not prolong allograft survival  
 
Having established that BM-DCs pulsed with Sia-Kd conjugates can impair 
indirect alloreactive CD4+ T cell proliferation, cytokine release and induce/ 
expand Foxp3+ Tregs in vitro, we investigated whether targeting these APCs in 
vivo prolonged allograft survival using an established skin transplant model 
designed to measure the indirect pathway of allorecognition (Tanriver et al., 
2010). Here, B6 recipient mice were transplanted with skin taken from mice 
expressing native BALB/c- derived Kd MHC I molecule (B6.Kd donor mice) 
(Honjo et al., 2004). One of the mechanisms to assess whether the indirect 
pathway of allorecognition is being modified was to assess the levels of 
alloantibodies produced in response to donor alloantigens. Suave et al., (2004), 
identified that IgG alloantibodies are produced by B cells with the help of CD4+ 
helper T cells with indirect allospecificity and the direct pathway is insufficient to 
generate these alloantibodies. Tanriver et al. (2010), assessed the levels of Kd-
specific alloantibodies in recipient mice and found that mice treated with 33D1-
Kd monomer to target DCIR2 subset of endogenous DCs had significantly 
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reduced alloantibodies in comparison to mice treated with saline alone. 
Therefore, in this chapter we will assess the levels of Kd-specific alloantibodies 
to determine whether sialylated alloantigen targeting impacts indirect 
allorecognition in vivo as it does in vitro.  
 
To assess the efficacy of Siglec targeting in vivo, B6 mice were treated with 10 
µg of either α2,3 Sia-Kd, or control peptide Kd 10 days before receiving a Kd skin 
transplant. Control mice received saline only. We reasoned that treating animals 
with the alloantigen peptides 10 days prior to transplant would allow sufficient 
time for antigen-specific Tregs to develop. For example, Kretschmer et al., 
(2005) administered one infusion of anti-DEC-205 fused with hemagglutinin 
peptide antigen for 14 days to allow the development of antigen-specific Tregs 
from adoptively transferred CD4+ CD25- Rag2−/− 6.5 TCR-transgenic Thy-1.2+ 
cells into Thy-1.1+ BALB/c recipients. Perdicchio et al., (2016) however, 
administered sialylated antigen 7 days prior to OVA/poly(I:C)/anti-CD40 
treatment, and also observed increase in Tregs with Sia-OVA treated mice. 
Therefore, it was decided to administer peptides on day 10, which 
approximately lies between 7-14 days and is also the same time-point Tanriver 
et al., (2010) adopted to administer Kd alloantigen in mice. In addition and 
similarly to Tanriver et al., (2010) study, mice were treated with anti-CD8 
antibody on the day of transplant (day 0) and one day following to remove the 
CD8+ T cells with direct allorecognition for Kd [Fig. 5.3 A-B].  
 
Despite peptide and anti-CD8 treatment, no prolongation of Kd skin allograft 
survival was observed as compared to saline treated mice. The mean survival 
time (MST) of grafts for α2,3 Sia-Kd and Kd treated recipients was 13 days 
compared to 11.5 days for saline treated recipient mice [Fig 5.3A]. Although we 
did not observe allograft survival, we can conclude that our targeting regimen is 
not priming the animal as peptide and saline treated mice rejected with the 
same kinetics [Fig. 5.3].  
 
Tanriver et al., (2010) established that contradictory to their ex vivo data, 
targeting a specific subset of DCs with Kd peptide coupled to a 33D1 antibody to 
B6 recipients 14 days before transplant did not prolong B6.Kd skin graft survival, 
but did observe significantly decreased Kd-specific alloantibodies in comparison 
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to untreated controls. As mentioned above, B cells which produce 
alloantibodies are primed by the CD4+ T cells mediated indirect pathway of 
allorecognition, therefore a reduction of these alloantibodies is a hallmark for 
the inhibition of the indirect pathway (Suave et al., 2004). To determine whether 
our targeting regimen is suppressing the indirect alloresponse, serum was 
collected from transplanted recipients 4 weeks post-transplant and analysed for 
donor-specific (Kd) alloantibodies. As expected in saline treated mice, following 
transplantation, Kd-specific alloantibodies were observed which  bound to B6.Kd 
splenocytes as opposed to B6 splenocytes [Fig. 5.3C]. Interestingly, there was 
a decrease in the development of alloantibodies in both Kd (p=0.0004) and α2,3 
Sia-Kd (p=0.003) peptide treated recipients in comparison to the saline controls, 
however no significant difference was observed between the two peptide 
treated groups (p=0.9) [Fig. 5.3C]. These observations suggest that indirect 
CD4+ T cells are being ‘modified’ once DCs are targeted with alloantigens prior 
to transplantation, as determined by the reduction of alloantibodies, however 
the rejection seen may be mediated by CD8+ T cells directly recognising Kd on 
graft tissue following their transient removal. To assess this, we repeated the 
treatment regimen and transplant with prolonged infusions of anti-CD8 
antibody, on days -1, 0, +7 and +14 post transplant. These time points were 
according to Tanriver et al., (2010) depletion regimen to ensure total depletion 
of CD8+ T cells. However, despite this additional treatment no significant 

























































































Figure 5.3. Graft survival was not prolonged when B6 mice were treated 
with α2,3 Sia-Kd 10 days before transplant, however alloantibodies were 







strategy. B6 mice (5 mice/group) received either 10µg/200µl saline of α2,3 Sia-
Kd or Kd (i.v.). Control mice received 200µl saline i.v. only. One day following 
peptide treatment, mice received B6.Kd (Kd) skin transplant. Additionally mice 
received 250µg of anti-CD8 antibody (clone YTS169) (i.p.) on days -1 and 0.  
Mice were monitored daily and skin deemed rejected when 90% necrosis of 
donor skin was reached. B. Data are shown as percentage of mice with 
surviving grafts (days) as demonstrated by MST (NS= p> 0.05 log-rank Mantel- 
Cox test). C. The development of Kd specific IgG Abs in serum derived from 
recipient mice was assessed against B6.Kd and B6 (control) target cells by flow 
cytometry 4 weeks following transplantation.  Alloantibody for each individual 
mouse was detected using goat anti-mouse IgG-FITC and data is expressed as 
MFI of FITC binding to CD3+ target T cells. Each dot represents one mouse and 
horizontal line between data points represents the mean MFI.  Statistical 
comparisons performed using One-way ANOVA and Tukey’s multiple 
comparisons test. Statistical significance was expressed as follows; 
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Figure 5.4. Graft survival was not prolonged when B6 mice were treated 
with α2,3 Sia-Kd 10 days before transplant, despite prolonged anti-CD8 
treatment. A. Diagrammatic representation of the targeting and transplant 
strategy.  B6 mice (3-5 mice/group) received either 10µg/200µl saline of α2,3 
Sia-Kd or Kd iv. Control mice received 200µl saline i.v. only. One day following 
peptide treatment, mice received B6.Kd (Kd) skin transplant. Additionally mice 
received 250µg of anti-CD8 antibody (clone YTS169) on days -1, 0, +7 and 
+14.  Mice were monitored daily and skin deemed rejected when 90% necrosis 
of donor skin was reached. B. Data are shown as percentage of mice with 
surviving grafts (days) as demonstrated by MST (*p< 0.05 log-rank Mantel- Cox 








5.3.3. Targeting Siglecs in vivo with α2,3 Sia-Kd one day prior to a transplant 
prolonged allograft survival  
 
As graft prolongation was not observed when alloantigens were administered 
10 days prior to transplant, we decided to administer the peptide one day before 
as an alternative, especially since the half-life of these novel sialylated 
alloantigen peptides were not known. To this end B6 mice were administered 
with α2,3 Sia-Kd or α2,6 Sia-Kd as well as control Kd peptide 1 day before a 
B6.Kd skin transplant. Control mice received only saline. All mice additionally 
received weekly anti-CD8 treatment [Fig. 5.5A]. Skin transplant survival was 
monitored daily, and mice were bled 4 weeks post transplant to measure 
alloantibodies. B6 mice treated with α2,3 Sia-Kd  had significant skin graft 
prolongation (MST: 16 days, p=0.002) compared to saline treated mice (MST: 
11 days) and Kd treated mice (MST: 13 days) [Fig.5.5B]. In addition, there was 
no difference between Kd and saline treated mice [Fig. 5.5B]. In comparison to 
saline treated mice, this was not observed when the α2,6 Sia-Kd (MST: 13, 
p=0.6) was administered [Fig. 5.5B].  
 
In addition, and as expected targeting B6 mice with Kd or sialylated alloantigens 
impaired CD4+ indirect allorecognition pathway, leading to the reduction of Kd 
specific alloantibodies [Fig. 5.5C]. Overall, there was no significant difference in 
alloantibody production between the sialylated alloantigens, despite differences 
in graft survival. Although not statistically significant, there was a trend towards 
reduced alloantibodies with following sialylated alloantigen treatment in 
comparison to Kd.  
 
Taken together, we concluded that targeting Siglecs with α2,3 Sia-Kd peptide 
one day before transplant, prolonged MHC I -mismatched skin grafts in the 
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Figure 5.5. Graft survival was prolonged when B6 mice were treated with 
α2,3 Sia-Kd one day before transplant. A. Diagrammatic representation of the 
targeting and transplant strategy. B. B6 mice (5-7 mice/group) received either 
10µg/ 200µl saline of α2,3 Sia-Kd or α2,6 Sia-Kd or Kd (i.v.). Control mice 
received 200µl saline i.v. only. One day following peptide treatment, mice 
received B6.Kd (Kd) skin transplant. Additionally mice received 250µg  of anti-
CD8 antibody (clone YTS169) on days -1, 0, +7 and +14.  Mice were monitored 
daily and skin deemed rejected when 90% necrosis of donor skin was reached. 
Data are shown as percentage of mice with surviving grafts (days).  Mean 
survival time (MST) is shown. (*p> 0.05 (log-rank Mantel- Cox test)). C. The 
development of Kd specific IgG Abs in serum derived from recipient mice was 
assessed against B6.Kd and B6 (control) target T cells by flow cytometry 4 
weeks following transplantation.  Alloantibody for each individual mouse was 
detected using goat anti-mouse IgG-FITC and data is expressed as MFI of FITC 
binding to CD3+ target T cells. Each dot represents one mouse and horizontal 
line between data points represents the mean MFI.  Statistical comparisons 
performed using One-way ANOVA and Tukey’s multiple comparisons test. 
Statistical significance was expressed as follows; p<0.0001****, p<0.001***, 




5.3.4 Targeting recipient DCs with α2,3 Sia-Kd prolonged skin allograft survival 
in B6.Rag2-/- recipients  
 
As it is observed that sialylated and unsialylated alloantigens bind to DCs as 
well as B cells in vivo, the question that arose was which of these APCs was 
driving the skin graft prolongation. To investigate whether skin graft 
prolongation is observed in recipient mice when B cells are absent but the DC 
subsets were present, we conducted our targeting experiments in Rag deficient 
mice, which lack T and B cells. Brennan et al., (2009) used an immunodeficient 
B6.Rag 2-/- model to assess the role of indirect CD4+ T cell allorecognition in 
skin transplant rejection. These authors assessed rejection of BALB/c skin on 
B6.Rag-/- mice reconstituted with TCR75 CD4+ T cells and noted that fully 
mismatched skin was rejected at approximately 10 days post transplant 
(Brennan et al., 2009). We modified this model slightly and chose to inject B6 
rather than TCR75, derived CD4+ T cells, as a slightly slower rejection was 
observed with B6 CD4+ T cells [Appendix Fig. 6]. We reasoned that this would 
allow us a window of time to see differences between the treatments. When T 
cells are injected into an immunodeficient host such as Rag-/- mice, T cells are 
able to spontaneously undergo homeostatic proliferation, thereby increasing the 
T cell pool (Tanchot et al., 1997; Surh & Sprent, 2000). The concern was that 
mice that were administered with Kd alloantigen and TCR75 T cells followed by 
a  BALB/c (WT mice that express H2-Kd MHC I) skin graft will have accelerated 
rejection due to the proliferation of Kd specificity of the T cells.  We have 
previously shown in Chapter 3, increased T effector proliferation in vitro in 
response to Kd-pulsed DCs, therefore, we hypothesised that rejection would be 
too quick to measure. As a result a trial transplant experiment was conducted to 
compare BALB/c skin graft rejection between mice that were administered with 
TCR75 T cells  (Brennan et al., 2009) versus B6 CD4+ T cells. In comparison to 
B6.Rag2-/- mice receiving TCR75 T cells, a slightly slower pace of rejection, 
delayed by 2 days, was observed in mice that received B6 CD4+ T cells, 
therefore, we opted to use the latter T cells [Appendix Fig. 6].  
 
B6.Rag 2-/- mice were injected with saline,10µg Kd, α2,3 Sia-Kd, α2,3L Sia-Kd or 
α2,6 Sia-Kd peptides and 0.5 x 106 B6 CD4+ T cells one day before receiving a 
BALB/c skin transplant [Fig 5.6A]. In comparison to saline treated mice (MST: 
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11 days), Kd peptide treatment significantly prolonged fully mismatched skin 
graft survival (MST: 13.5, p=0.02). However, this prolongation was significantly 
enhanced when recipient mice were treated with α2,3 Sia-Kd (MST: 25, p= 
0.0005) but not α2,3L Sia-Kd or α2,6 Sia-Kd [Fig. 5.6B]. Overall, this data 
suggests that targeting Siglecs on DCs in mice devoid of B cells, with α2,3 Sia-
alloantigens prolonged graft survival in B6.Rag 2-/- mice reconstituted with B6 
CD4+ T cells, however this was not observed with the other sialylated peptides 
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Figure 5.6. Allogeneic graft survival was prolonged in B6.Rag 2 -/- mice 
following α2,3 Sia-Kd treatment. A. Diagrammatic representation of the 
targeting and transplant strategy. B. B6.Rag 2-/- mice (3-6 mice/ group) received 
0.5 x 106 B6 CD4+ T cells (i.v.) and either Kd 10µg/200µl saline or α2,3 Sia-Kd 
10 µg/200µl saline, α2,3L Sia-Kd 10 µg/200µl saline or α2,6 Sia-Kd 10 µg/200µl 





peptide treatment, mice received BALB/c skin transplant. Mice were monitored 
daily and skin deemed rejected when 90% necrosis of donor skin was reached. 
Data are shown as percentage of mice with surviving grafts (days).  MST is 
shown. (*p> 0.05 (log-rank Mantel- Cox test). Statistical significance was 
expressed as follows; p<0.001***, p<0.05*, NS= p> 0.05. 
 
5.3.5. Targeting α2,3 Sia-Kd to recipient mice devoid of CD8α+ DCs and 
CD103+ DCs did not prolong transplant survival 
 
The data so far suggests that targeting Siglec-expressing DCs, rather than B 
cells, with α2,3 Sia-Kd prolongs transplant survival. To further assess the 
contribution of endogenous DC subsets we repeated the experiments using 
B6.Batf3-/- knockout mice as transplant recipients. These mice lack the CD8α+ 
and CD103+ DCs, but have all the other DC subsets (eg; CD8α-DCs, CD11b), 
macrophage and B cell compartments (Hildner et al., 2008). Firstly, we 
confirmed the binding of the Kd and α2,3 Sia-Kd FITC peptides to B6.Batf3-/- 
splenic DCs in vitro [Fig. 5.7]. As expected α2,3 Sia-Kd and Kd peptides bound 
to CD11c+ cells present in the B6.Batf3-/- spleen, which is consistent with our B6 
data [Fig. 5.7].  
 
Next, B6.Batf3-/- mice were administered with sialylated and non-sialylated Kd 
peptides either 1 or 10 days prior to a Kd skin transplant and rejection was 
measured [Fig. 5.8- 5.9]. In these experiments we tested only the α2,3 Sia-Kd 
peptide. Contrary to the B6 transplant recipients, α2,3 Sia-Kd treatment of 
B6.Batf3-/- mice 1 day before the transplant did not lead to graft prolongation 
with rejection times being comparable to mice treated with Kd or saline. The 
MST of the transplant in mice treated with saline or Kd peptide was 12 days 
whilst for α2,3 Sia-Kd treated individuals the MST was 10 days [Fig. 5.8B]. 
Similar observations were also made in B6.Batf3-/- mice treated with peptide 
alloantigens 10 days before transplant [Fig. 5.9B], suggesting that administering 
peptides at different time points has no impact on transplant outcome in these 
mice. Interestingly, B6.Batf3-/- mice treated with peptides had reduced 
alloantibodies, suggesting that the indirect pathway is still impaired but  a 
reduction of alloantibodies is simply not enough to prolong allograft survival 
[Fig. 5.8- 5.9]. In summary, targeting Siglecs on either CD8α+ DCs and/or 
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CD103+ DCs with α2,3 Sia-Kd  may have led to prolonged allograft survival as 



























Figure 5.7. Alloantigen peptides bind to B6.Batf3-/- SPLN-DCs. B6.Batf3 -/- 
SPLN-DCs were pulsed for 4 hours with 10 µg/ml peptide-FITC at 37°C 
incubation and analysed using flow cytometry. A. Live cells were gated on 
forward scatter (FSC), side scatter (SSC). B. MFI of peptide-FITC bound cells 










































Figure 5.8. Targeting Siglecs expressed on B6. Batf3-/- DCs with α2,3 Sia-
Kd does not prolong allograft survival. A. Diagrammatic representation of the 
targeting and transplant strategy. B. B6.Batf3-/- mice (5 mice/group) received 
either 10µg/200µl saline of α2,3 Sia-Kd or Kd i.v. Control mice received 200µl 
saline i.v. only. One day following peptide treatment, mice received B6.Kd (Kd) 
skin transplant. Mice were monitored daily and skin deemed rejected when 90% 
necrosis of donor skin was reached. Data are shown as percentage of mice with 







































The development of Kd specific IgG Abs in serum derived from recipient mice 
was assessed against B6.Kd and B6 (control) target T cells by flow cytometry 4 
weeks following transplantation.  Alloantibody for each individual mouse was 
detected using goat anti-mouse IgG-FITC and data is expressed as MFI of FITC 
binding to CD3+ target T cells. Each dot represents one mouse and horizontal 
line between data points represents the mean MFI.  Statistical comparisons 
performed using One-way ANOVA and Tukey’s multiple comparisons test. 













































































Figure 5.9. Targeting Siglecs expressed on Batf3-/- DCs with α2,3 Sia-Kd 
does not prolong allograft survival. A. Diagrammatic representation of the 
targeting and transplant strategy. B. B6.Batf3-/- mice (10-11 mice/ group) 
received either 10µg/200µl saline of α2,3 Sia-Kd or Kd i.v. Control mice received 
200µl saline i.v. only. Ten days following peptide treatment, mice received 
B6.Kd (Kd) skin transplant. Mice were monitored daily and skin deemed rejected 
when 90% necrosis of donor skin was reached. Data are shown as percentage 
of mice with surviving grafts (days), MST is shown. (*p> 0.05 (log-rank Mantel- 
Cox test)). C. The development of Kd specific IgG Abs in serum derived from 
recipient mice was assessed against B6.Kd and B6 (control) target T cells by 
flow cytometry 4 weeks following transplantation.  Alloantibody for each 
individual mouse was detected using goat anti-mouse IgG-FITC and data is 
expressed as MFI of FITC binding to CD3+ target T cells. Each dot represents 
one mouse and horizontal line between data points represents the mean MFI.  
Statistical comparisons performed using One-way ANOVA and Tukey’s multiple 
comparisons test. Statistical significance was expressed as follows; p<0.001***, 






















This chapter examined the possibility of promoting murine skin allograft survival 
by targeting DCs and B cells with sialylated alloantigens in situ. This chapter 
confirmed that Kd and α2,3 and α2,6 Sia-Kd peptides are capable of binding to 
lymph node-derived DCs, and B cells in vivo following intravenous 
administration. In addition, α2,3 Sia-Kd peptide targeting to B6. Batf3-dependent 
DC subsets, one day before a transplant, induced prolongation of skin graft 
survival in the absence of direct CD8 T cell responses. Moreover, both 
sialylated and non-sialylated alloantigens pre-treatment led to reduced 
alloantibodies in comparison to saline treated mice. 
 
Siglec expression and peptide binding to splenic DC and B cells was confirmed 
in vitro, however,  the in vivo was less clear-cut.  This study initially identified 
that alloantigen peptides (sialylated or unsialylated) administered intravenously 
were capable of binding to splenic and lymph node DCs and B cells, however 
data was not statistically significant. As a future experiment, in order to refine 
this experiment and to perhaps allow better detection,  harvesting the SPLN 
and LNs at a shorter time-point post peptide infusion such as 30 minutes (Mann 
et al., 2017), as opposed to 2 hours may be required. However, as we have 
observed a trend of increase in MFI of FITC in peptide-treated mice, we can 
suggest that peptides are binding to DCs and B cells in SLOs in vivo. 
 
It has yet to be confirmed whether the sialylated peptides are binding to Siglecs 
present on APCs and whether they bind to particular Siglecs on APC subsets 
such Siglec G on CD8α+ DCs (Ding et al., 2016), CD169 on M2 macrophages 
(Thornley et al., 2014) or Siglec E on T2 and MZ B cells (Zhang et al., 2004). It 
has yet to be investigated what other Siglecs are expressed on APC subsets 
and whether there is differential Siglec expression between APCs in LNs and 
SPLN. It was important to prove the presence of these peptides in SLOs such 
as the SPLN and LNs which are two of the essential organs where antigen 
presentation occurs and are also known for being the site for where cell 
trafficking and trapping of antigens from the bloodstream and peripheral tissues 
takes place, enabling them to interact with immune cells and initiate an adaptive 
immune response (Modino et al., 1996). It was especially important to confirm 
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the presence of these peptides in the lymph nodes as this is the site known for 
tolerance induction (Ochando et al., 2005; Dijke et al., 2008). During 
allorecognition, alloantigens derived from the graft can enter the SLOs via 
donor DCs, alloantigen-bound recipient DCs, exosomes carrying alloantigens or 
soluble antigens (Ng & Chalasani, 2010). However, there is an added 
complexity to transplantation; the pace of rejection can be dependent on the 
type of graft and the location of where the alloimmune response mainly occurs, 
the SPLN or the LNs. In a review by Ng and Chalasani (2010), they mention 
that the primary site for allorecognition for skin allografts are the LNs because 
once vascularisation occurs, the donor lymphocytes from the transplanted 
organs move via the lymphatics to the draining lymph nodes. The spleen also 
plays a role in rejection (particularly in heart allografts), however, Streilein and 
Wiesner (1977) found that splenectomised wild-type mice rejected skin grafts 
faster than mice with SPLNs, suggesting that the components of the spleen 
may have an immunoregulatory role, which remains to be determined.  
 
One of our major findings was that targeting α2,3 sia-alloantigen to Siglecs on 
DCs resulted in transplant survival. Using B6. Batf3-/- mice we observed that 
engaging Siglecs on CD8α+ and CD103+ DC subsets (which require Batf3 
transcription factor for their development) might have resulted in this outcome. 
CD8α+ DCs are primarily found in lymphoid tissues, whereas CD103+ DCs can 
be found in tissues such as the skin draining LNs, mesenteric LNs, lung and 
intestine (Edelson et al., 2010). Both these DC subsets are efficient for cross-
presentation of antigens and CD8+ T cell immunity and are a source of IL-12 
required for Th1 responses (Bedouj et al., 2009; Mashayekhi et al., 2011; 
Martinez- Lopez et al., 2015). In a murine transplant setting, one study reported 
that donor-derived CD103+ DCs present in donor skin grafts were responsible 
for allograft rejection, by carrying donor MHC molecules and stimulating direct 
allorecognition (Borges et al., 2018). On the contrary, these Batf3-dependent 
DCs have been shown to promote tolerance such as CD103+ DCs present in 
the gut are important cells involved in Treg induction leading to mucosal 
tolerance (Matteoli et al., 2010). In addition, targeting antigen to CD8α+ rather 
than CD8α- DC subsets has been shown to promote antigen-specific T cell 
tolerance both in vitro and in vivo, however under proinflammatory conditions 
these CD8α+ DC were shown to promote Th1 responses (Manicassamy & 
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Pulendran 2011). As mentioned in the aforementioned review, one study 
identified that intraperitoneal administration of anti-DEC205 Ab conjugated to 
OVA antigen to mice (targeting DEC-205 CD8α+ DCs) induced Foxp3+ cells 
from adoptively transferred CD4+ Foxp3- cells (Yamazaki et al., 2008). 
Therefore, this particular subset of DCs may be required to promote tolerance 
and additionally, the aforementioned study supports our findings where mice 
deficient of CD8α+ DCs are unable to prolong allograft survival when 
administered with sialylated alloantigen.  
 
CD8α- DC subsets on the other hand are more efficient at promoting CD4+ T 
cell responses and also display multiple functions according to where they 
reside (Hasegawa & Matsumoto, 2018; Tanriver et al., 2010). It was interesting 
to see that according to Tanriver et al., (2010), where targeting CD8α- DCs 
alone by targeting 33D1 established long-term allograft skin survival, whereas 
we did not see this when B6.Batf3-/- mice (devoid of CD8α+ DC subset) were 
targeted. However, an important difference which may contribute to the 
contrasting findings is that the aforementioned study targeted B6 mice and 
established tolerance using a 33D1-Kd monomer as opposed to 33D1-Kd 
peptide (Tanriver et al., 2010). They reasoned that targeting with a monomer as 
opposed to a peptide, will help to target a wider range of CD4+ TCRs, rather 
than a single TCR epitope specific to a peptide, therefore as future work, 
sialylated MHC monomer may be used as an alternate targeting regimen 
(Tanriver et al. 2010).  
 
Overall, various subsets of DCs when targeted independently can promote 
tolerance such as CD4+ CD8- DCs (DCIR2+ DCs) (Tanriver et al., 2010) and 
DEC-205 DCs (Yamazaki et al., 2008). CD103+ DCs is another subset with the 
potential to promote tolerance when targeted. For example,  Idoyaga et al., 
(2013) showed that migratory CD103+ DCs were able to generate MOG 
antigen-specific CD4+ Tregs from adoptively transferred MOG-specific CD4+ T 
cells in vivo, following s.c. administration of an anti-DEC monoclonal antibody 
engineered to conjugate to MOG. Although targeting these DC subsets has led 
to tolerance induction in other models, it is a possibility that in our model 
CD103+ DCs as well as CD4+CD8- DCs and/ or CD11b+ DCs are required, 
perhaps through the generation of Tregs, which may lead to allograft survival in 
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our transplant model. We suggest a role for CD103+ DCs, as B6 mice that were 
administered with anti-CD8 antibody, which depletes CD8 positive cells 
including CD8α+ DCs (Smyth et al., 2013), had surviving allografts following 
sialylated Kd administration. On the contrary, we still cannot rule out the 
possibility of sialylated peptides binding to CD8α DCs+, especially since we 
confirmed the presence of the peptides in the SPLN and LNs in this Chapter. 
   
It has been demonstrated by Tanriver et al., (2010), that targeting a subset of 
endogenous murine DCs (DCIR2) with an MHC I monomer conjugated to a 
33D1-crosslinking antibody promotes B6.Kd skin graft tolerance. In contrast they 
observed that targeting B6 WT mice with 33D1 antibody conjugated with a Kd 
monomer alone (without anti-CD8 depletion to deplete CD8+ direct alloreactive 
cells) did not prolong allograft survival when administered 14 days prior to 
transplant but did lead to decreased alloantibodies. These findings are similar to 
what we observed where B6 mice were targeted with sialylated or non-
sialylated peptide 10 days before the transplant did not improve transplant 
survival but did reduce alloantibodies. These alloantibodies can contribute to 
rejection through interactions such as with Fc gamma RIII on NK cells leading to 
antibody dependent cellular cytotoxicity, complement fixation forming antigen- 
antibody bound complexes to form foreign antigens recognised by APCs (Smith 
& Colvin, 2012). Importantly, these alloantibodies are known for being produced 
by B cells which have been activated via indirect allospecific CD4+ T cells, 
therefore suggesting that similarly to our in vitro data, the T cell mediated 
indirect pathway of allorecognition is still being suppressed in our transplant 
models which is evident by the decrease in alloantibodies (Sauve et al., 2004; 
Steele et al., 1996).  
 
Our results suggest that targeting DCs with α2,3 Sia-Kd rather than α2,3L Sia-
Kd or α2,6 Sia-Kd can promote allograft survival. We reasoned that this may be 
due to the binding capacity of these constructs as we have seen in Chapters 3 
and 4, where α2,3 Sia-Kd binding to BM-DCs was greater in comparison to Kd 
targeted BM-DCs, whereas there were no differences in binding between α2,6 
Sia-Kd and Kd-binding to BM-DCs. Therefore, allograft survival may be due to 
α2,3 Sia-Kd binding to particular Siglecs on DCs that have an increased affinity 
to α2,3 sialic acids rather than α2,6 sialic acids. However in Chapter 3, no 
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significant differences in Kd and α2,3 Sia-Kd peptide binding was observed in 
SPLN-DCs which are endogenously found, therefore it is controversial to 
explain allograft survival based on peptide-binding to DCs in vitro.  A review by 
Crocker et al., (2007), suggested that Siglec E has moderate binding to both 
α2,3 and α2,6 sialic acids, however Siglec F binds moderately to α2,3 sialic 
acids and interestingly, binds weakly to α2,6 sialic acids. Taking into account 
the data in this Chapter 5 and Chapter 3 where Siglec F was highly expressed 
on BM and SPLN-DCs than Siglec E and the review by Crocker et al., (2007); 
transplant survival may be due to interactions between α2,3 Sia-Kd and Siglec F 
and on to a lesser extent, Siglec E. Future investigations may include Siglec 
knockout mice which could help fully confirm the interaction of Siglec E/F and 
this sialylated peptide and their role in allograft survival.   
 
The lack of transplant survival seen following administration of α2,6 Sia-Kd may 
be due to it interacting with Siglec E, suggesting that targeting this Siglec does 
not lead to transplant survival. This finding is in contrast to a study by 
Perdicchio et al., (2016) where they demonstrated that the interaction of Siglec 
E and α2,6- sialylated antigens induced Foxp3+ Tregs in vitro. However, the 
obvious difference between the experiments is that the aforementioned 
experiment was carried out using Siglec E-/- BM-DCs in vitro and we tested our 
sialylated constructs in an vivo transplant model. In addition, their study did not 
compare directly α2,6 and α2,3 Sia-OVA/MOG constructs in vivo, therefore 
given our findings it is possible that α2,3 sialylated constructs may be better 
than α2,6 sialylated constructs at promoting immunosuppressive immune 
responses in an in vivo transplant model. Conversely, Perdicchio et al., (2016), 
did demonstrate the potential of targeting mice with α2,6 sialylated antigens to 
promote tolerance in vivo, in an autoimmune setting. They established that 
targeting endogenous DCs using α2,6 Sia-OVA in vivo, followed by OVA/ 
PolyI:C/ anti-CD40 sensitization, decreased proportions of T effectors and 
increased Tregs. Taken together they were able to demonstrate that targeting 
Siglec E can modulate DCs under pro-inflammatory conditions (Perdicchio et 
al., 2016).  
 
The data in this chapter demonstrated that targeting Siglecs on B cells in vivo 
with sialylated alloantigens did not have a significant role in prolonging allograft 
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survival. In recipient mice lacking B cells which are  B6.Rag2-/- mice 
reconstituted with B6 CD4+ T cells, α2,3 Sia-Kd pre-treatment prolonged 
allograft survival. Surprisingly, despite the inhibitory role of B cell Siglecs and 
their for preference for α2,6- linked sialic acids (demonstrated in Chapter 4), 
(Crocker et al., 2007; Pillai et al., 2012), targeting B6 mice with α2,6 Sia-Kd did 
not prolong allograft survival. Therefore, targeting B cell Siglecs in situ does not 
promote allograft survival.  
 
The next question is, if targeting B cells does not prolong allograft survival by 
influencing them to become regulatory, how can the reduction of alloantibodies 
be explained? We observed that B6 and B6.Batf3-/- mice targeted with sialylated 
or non-sialylated peptide had reduced alloantibodies despite the different 
transplant survival outcome. These alloantibodies are produced by B cells 
which have been activated via indirect allospecific CD4+ T cells, therefore 
suggesting that similarly to our in vitro data, the T cell mediated indirect 
pathway of allorecognition is still being suppressed in our transplant models as 
evident by the decrease in alloantibodies (Sauve et al., 2004; Steele et al., 
1996).  
 
To date it has not been demonstrated that targeting B cell Siglecs with α2,6 
sialic acids induces Tregs, but instead it has been shown that activation of BCR 
signalling is impaired. B cell Siglecs have ITIMs that recruit SHP-1 tyrosine 
phosphatases to inhibit BCR signalling (Meyer et al., 2018). One study found 
that targeting Siglec CD22 on B cells with an α2,6 Sia construct, that is also 
capable of binding to the BCR, was capable of impairing Ca2+ influx into the 
cytosol of B cells, thereby reducing B cell activation (Courtney et al., 2009). This 
study is described more in detail in Chapter 7. As we have seen that sialylated 
alloantigens bind to B cells in vitro and in vivo, it is a possibility that B cells are 
not being activated upon sialylated alloantigen, which is a consequence of B 
cell Siglec targeting that Meyer et al., (2018) and Courtney et al., (2009), 
mentioned. Therefore, a lack of B cell activation may explain a reduced 
generation of alloantibodies when B6 transplant recipient mice were 
administered with sialylated alloantigen. This conclusion is questionable given 
that Kd targeted mice also had reduced alloantibodies, therefore this reduction 
may be of consequence for T cell deletion which will be addressed in Chapter 6.  
185 
 
B cells have shown to be involved in allograft survival, particularly transitional B 
cells. Moreau et al., (2014) discovered that B cells transferred from tolerant 
mice who accepted MHC I mismatched skin allografts, were able to prolong 
allograft survival and significantly reduce production of alloantibodies against 
donor grafts. Additionally they identified that T2 and MZ B cells were amongst 
the tolerogenic B cell pool, with T2 B cells being able to suppress proliferation 
of T cells that have been activated with CD3/CD28 stimulation (Moreau et al., 
2014). This would suggest that transitional B cells play a role in MHC I-
mismatched allograft survival. We have demonstrated in Chapter 4, that α2,6 
Sia-Kd preferentially bind to T2 subsets in vitro over Kd- pulsed B cells, 
demonstrating the potential of this construct to targeting tolerogenic B cells. To 
address whether B cells are truly required for allograft survival following 
sialylated alloantigen targeting, B6 WT mice which have all innate and adaptive 
lymphocyte compartments; were targeted with alloantigens. As expected, α2,3 
Sia-Kd targeting still prolonged allograft survival, however, α2,6 Sia-Kd targeting 
did not, despite the presence of B cells. Therefore, targeting B cell Siglecs in 
situ does not promote allograft survival, and our in vitro data in Chapters 3 and 
4 reflects this.  
 
Overall, it has been demonstrated for the first time that MHC mismatch skin 
allograft survival and an inhibition of the CD4+ T cell indirect allorecognition 
pathway can be achieved following sialylated alloantigen targeting. In this 
Chapter we did not address the mechanism behind the prolongation in vivo. 
However, literature focused on peptide-induced tolerance in models such has 
EAE, have found T cell anergy, Treg induction and impaired effector T cell 
proliferation (Maldono et al., 2015; Ghetts et al., 2012). Perdicchio et al., (2016) 
showed that sialylated OVA antigen targeted to endogenous Siglec-expressing 
DCs in vivo, decreased T effector proportions and increase Foxp3+ Tregs. 
Similar mechanisms could be at play following α2,3 Sia-Kd targeting and will be 





















CHAPTER 6: T CELL DELETION AND 
INCREASE OF CD4+ CD62L+ FOXP3+ 
REGULATORY T CELLS CONTRIBUTE TO 
GRAFT PROLONGATION FOLLOWING α2,3 


















This chapter focuses on investigating the underlying mechanisms for transplant 
survival following α2,3 sialylated alloantigen targeting to Siglecs expressed on 
DCs, as outlined in Chapter 5.  
 
As described in Chapter 1,  various mechanisms to induce tolerance exist such 
as T cell deletion and Treg induction/ expansion. Deletion can occur both in the 
thymus (central tolerance) and in the periphery (peripheral tolerance) as a 
means of promoting self-tolerance by removing self-reactive T cells.  In a 
transplant setting, T cell deletion is a process whereby alloreactive T cells that 
have the potential to mature and elicit effector function against the transplanted 
tissue are killed. Mentioned in a review by Li et al. (2001), the proportions of 
direct alloreactive T cells responding to MHC-mismatched grafts, is greater in 
frequency than T cells responding to nominal antigens. Therefore, the 
increased frequency of MHC responsive alloreactive T cells contributes to 
transplant failure. One approach to deplete these alloreactive T cells is to target 
alloantigen to receptors on specific DCs in vivo. Tanriver et al., (2010) found 
that when DCs were targeted with Kd alloantigen in vivo, using an antibody to 
33D1 conjugated to-Kd monomer, reduced numbers of adoptively transferred 
TCR75 T cells in comparison to mice treated with saline alone. This would 
suggest that alloantigen targeted to CD8α- DCs in vivo promoted deletion of 
alloreactive specific T cells leading to murine skin graft prolongation (Tanriver et 
al., 2010), and one of the focuses of this chapter is to assess whether T cell 
deletion contributes to allograft survival following alloantigen targeting.  
 
The presence of CD4+ Tregs in a transplanted organ is associated with 
prolonged graft survival (Shaban et al., 2018; Yu et al., 2011; Shinoda et al., 
2014). This has led to many laboratories designing protocols to achieve 
transplant tolerance by expanding these cells ex vivo and in vivo. For example, 
studies have found that the adoptive transfer of expanded recipient-derived 
Tregs is an effective approach to induce tolerance in mouse transplant models 
(Ratnasothy et al., 2019; Tsang et al., 2008). It is also known that Treg 
proportions can be increased in vivo and help prolong allograft survival as 
opposed to adoptively transferred Tregs. For example, Magee et al., (2019), 
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recently showed that by blocking Notch-1 signalling using anti-Notch-1 to block 
induction of endogenous naïve CD4+ T cells to Th cells; Foxp3+ Tregs 
proportions were increased and MHC-mismatched allograft survival was 
prolonged. 
 
Tregs which are CD62Lhigh, have shown to be highly immunosuppressive 
(Ermann et al., 2005; Fu et al., 2004; Lange et al., 2011). Ermann et al., (2005), 
identified in a murine GVHD model, CD62L+ Tregs were able to accumulate in 
recipient LNs and SPLNs and inhibit expansion of alloreactive T cells in contrast 
to the CD62L- Tregs. This would suggest that these CD62L+ migratory Tregs 
have an advantage over their CD62L- counterparts as they have the ability to 
enter sites where alloantigen presentation by recipient DCs occurs such as the 
SPLN and LNs (Ermann et al., 2005). Demonstrated in Chapters 3 and 4, in 
vitro targeting of BM-DCs with sialylated alloantigens consistently induced CD4+ 
Foxp3+ Tregs, therefore, this chapter will assess whether this outcome was 
observed in vivo in transplant recipients. The proportions of CD62L+ Tregs in 
recipient mice will determine whether these particular Tregs are assisting in 




To dissect the mechanisms of tolerance behind skin allograft survival following 
Siglec targeting with α2,3 alloantigen construct.  
 
In order to address this aim, the following objectives were undertaken: 
1. Assess whether in vivo deletion of alloreactive T cells, Kd-antigen specific 
CD4+ T cells (TCR75 T cells), occurs in mice administered with α2,3 sialylated 
alloantigens. 
2. Measure the proportions of Foxp3+ Tregs in transplanted recipient mice and 
assessing their phenotype (CD62L+). 
 
In Chapters 3 and 4 we demonstrated that targeting BM-DCs with α2,3, α2,3L 
and α2,6 sialylated alloantigen in vitro impairs proliferation of TCR75 T cells and 
induced/expanded Tregs. Having demonstrated that targeting Siglecs using 
sialylated constructs impaired indirect allorecognition in vitro, the constructs 
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were tested in murine skin transplant models in Chapter 5. Only pre-treatment 
with the α2,3 sialylated construct induced transplant prolongation highlighting 
that in vitro and in vivo findings can differ. Some of the other significant findings 
in the aforementioned Chapter demonstrated that B6 WT and B6 Rag-/- mice 
treated with α2,3 Sia-Kd one day before transplant prolonged allograft survival, 
whereas B6.Batf3-/- mice (devoid of CD8α+ DCs and CD103+ DCs) treated with 
the same peptide did not prolong transplant survival. This data suggested that 
targeting Siglecs on the aforementioned DCs with α2,3 Sia-antigens may 
contribute to prolonging the graft.  
 
Despite these differences, the generation of alloantibodies produced by B cells 
that have been activated via the indirect pathway CD4+ T cell help, were 
profoundly decreased in B6 WT and Batf3-/- mice in response to Kd and all Sia-
Kd peptide treatments prior to transplantation (Suave et al., 2004). This would 
suggest that in both models, the indirect pathway of allorecognition is impaired; 
however the reduction of alloantibody production may not be a significant 
contributor to allograft survival in this study given the data in Chapter 5. Aside 
from the similarity of alloantibody generation between models and targeting 
regimens, there is a clear difference in immune response mediated by Kd and 
Sia-Kd which is demonstrated by the transplant data in Chapter 5. Therefore, 
this chapter will focus on whether other mechanisms such T cell deletion assist 
in transplant survival following α2,3 Sia-Kd targeting and the contribution of 
CD62L+ Foxp3+ Tregs.  
 
In terms of clinical relevance, this chapter will provide some input into 
understanding the mechanisms of allograft survival following of targeting Siglec 












6.3. Results  
 
6.3.1 Indirect alloantigen-specific CD4+ T cells are deleted following peptide 
targeting in vivo  
 
One of the main mechanisms that led to both central and peripheral tolerance is 
deletion of antigen specific T cells, which is possible to achieve in murine 
models by immunizing mice at a steady state with soluble antigen or peptide. 
Tanriver et al., (2009), found that adoptively transferring TCR75 CD4+ T cells 
into naïve recipient B6 mice followed by administration of 33D1 Ab- Kd peptide 
24 hours later, resulted in TCR75 CD4+ T cell deletion without altering the 
endogenous Treg pool (Tanriver et al., 2009). Therefore, in the current study, 
we determined whether antigen-specific deletion is one of the mechanisms 
contributing to allogeneic skin transplant survival following α2,3 Sia-Kd 
treatment seen in Chapter 5. B6 and B6.Batf3-/- mice received 2 x 106 TCR75 
CD4+ T cells (Thy1.1) intravenously, 24 hours prior to 10µg/ml Kd or α2,3 Sia-Kd  
peptide administration. Control mice received T cells and saline only. Both the 
spleens and lymph nodes from these mice were harvested 10 days later and 
the presence of TCR75 CD4+ T cells was assessed using an anti-Thy1.1 
antibody. As expected, less Thy1.1+ CD4+ T cells were present in B6 mice 
treated with Kd in comparison to mice treated with saline only [Fig. 6.1B (i)]. In 
addition, α2,3 Sia-Kd alloantigen peptide treatment led to reduced TCR75 CD4+ 
T cells. However, there were no significant differences in the number of Thy1+ T 
cells between the sialylated and non-sialylated peptides (p=0.98) [Fig. 6.1B (i)]. 
Similar results were observed when B6.Batf3-/- mice were used [Fig. 6.1C (i)], 
demonstrating deletion of TCR75 T cells in response to α2,3 Sia-Kd (p=0.03) 
and Kd (p=0.02) in comparison to saline.  
 
In line with the findings of Tanriver et al., (2010), Kd treatment did not 
significantly alter the endogenous Treg pool in either of the mouse strains [Fig.  
6.1]. In addition, treatment with α2,3 Sia-Kd in both mouse strains resulted in a 
similar finding. Therefore, antigen-specific deletion may be one of the 
mechanisms contributing to graft survival, or contributing to a reduction of 
alloantibodies by depleting the proportions of Th cells engaging with 
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alloantibody-producing B cells. However, as B6.Batf3-/- mice did not induce graft 
survival following targeting but were able to delete antigen-specific T cells, 




















































 T cells purified from 















































Figure 6.1. CD4+ T cells are deleted following peptide targeting, however, 
CD4+ Foxp3+ Tregs numbers remain unchanged.  B6 or B6.Batf3-/- mice 
were administered with 2 x 106 TCR75 T cells (Thy1.1) one day before mice 
received Kd 10µg/200µl saline or α2,3 Sia-Kd 10 µg/200µl saline,  i.v. No 
peptide controls received 200 µl saline i.v. only. Ten days later spleens and 
lymph nodes were harvested and stained for CD4, Thy1.1 and Foxp3. A. Live 
cells were gated on forward scatter (FSC), side scatter (SSC) then CD4 versus 
Thy1.1 cells. B. (i). Number of cellular events of  CD4+ Thy1.1+ T cells in B6 
mice (n=3 mice per group). (ii). Percentage of CD4+ Foxp3+ Tregs in B6 mice 
(n=2 mice per group). C. (i). Number of cellular events of CD4+ Thy1.1+ T cells 
in B6.Batf3-/- mice  (n=2 mice per group). (ii). Percentage of CD4+ Foxp3+ Tregs 
B6. Batf3-/- mice (n=2 mouse per group). Each data point represents one 
mouse. Error bars represent +/- SEM and horizontal line between data points 
represent mean. Statistical comparisons performed using One-way ANOVA and 
Tukey’s multiple comparisons test. Statistical significance was expressed as 
follows; p<0.05*, NS= p>0.05. 
 
6.3.2. α2,3 Sia-Kd administration increased proportions of CD4+ CD62L+ Foxp3+ 
Tregs 
 
Ermann et al., (2005), Fu et al., (2004) and Lange et al., (2011), have described 
that CD62L+ Foxp3+ Tregs are more suppressive than CD62L- Tregs. In order to 
determine whether CD4+ CD62L+ Foxp3+ Tregs were contributing to graft 
prolongation observed in Figure 5.5A, B6 mice transplanted with B6.Kd skin 
grafts following administration of peptide alloantigens, Kd, α2,3 Sia-Kd and α2,6 
Sia-Kd one day before transplant, were bled two weeks post transplant and 
CD4, CD62L and Foxp3 expression analysed via flow cytometry. An increased 
proportion of CD4+ CD62L+ Foxp3+ Tregs was observed in α2,3 Sia-Kd  treated 
mice (mean= 4.01%) in comparison with mice treated with Kd (mean= 1.66%), 
saline (mean= 1.63%), which was not seen when the recipients mice were 
treated with α2,6 Sia-Kd (mean= 0.68%) [Fig.6.2-3]. In fact, it was observed that 
mice treated with Kd had increased ability of inducing/ expanding of 
CD4+CD62L- Foxp3+ Tregs [Fig. 6.3B]. As demonstrated in Chapter 5, B6 mice 
treated with α2,3 Sia-Kd, had significant graft survival, which may be due to an 
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increase of CD62L+ Tregs. Whereas, B6 mice treated with Kd and α2,6 Sia-Kd 
peptide did not have increased transplant survival nor CD62L+ Tregs, but 
interestingly had increased proportions of CD62L- Tregs [Fig. 6.2 & Fig. 6.3 A]. 
This would suggest that targeting Siglecs on endogenous CD8α+ and CD103+ 
DCs with α2,3 Sia-Kd in vivo increases CD62L+ Tregs which may be a 


























































































Figure 6.2. Gating strategy for peripheral CD4+ CD62L+ Foxp3+ Tregs. B6 
mice (4-5 mice/group) received either 10µg/200µl saline of α2,3 Sia-Kd or α2,6 
Sia-Kd or Kd i.v. Control mice received 200 µl saline i.v. only. One day following 
peptide treatment, mice received B6.Kd (Kd) skin transplant. Additionally mice 
received 250 µg  anti-CD8 (clone YTS169) on days -1, 0, +7, +14 and were 
bled 14 days post-transplant to look for percentage Treg proportions by staining 
with CD4, CD62L and Foxp3. A. Live cells were gated on forward scatter (FSC), 
side scatter (SSC) followed by gating on CD4+ T cells. Contour FACS plots 
indicate CD62L+/- vs. Foxp3+/- T cells. B. Control mice received 200 µl saline iv 
only. C. Kd 10 µg/200µl saline. D. α2,6 Sia-Kd 10µg/200µl saline or  E. α2,3 Sia-




































































































Figure 6.3. Targeting Siglecs on DCs in vivo with α2,3 Sia-Kd one day 
before transplant treatment leads to significant increase of peripheral 
CD4+ CD62L+ Foxp3+ Tregs. B6 mice (4-5 mice/group) received either α2,3 
Sia-Kd 10µg/200µl saline or α2,6 Sia-Kd 10µg/200µl saline or Kd 10 µg/200µl 
saline (i.v.). Control mice received 200 µl saline (i.v.) only. One day following 
transplant, mice received B6.Kd (H2b + Kd) skin transplant. Additionally mice 
received 250 μg anti-CD8 (clone YTS169) on days -1, 0, +7 and +14. Recipient 
mice were bled 14 days post-transplant and the percentage of Treg assessed 
by staining with CD4, CD62L and Foxp3. Live cells were gated on forward 
scatter (FSC), side scatter (SSC), followed by gating on CD4, CD62L and 
Foxp3 [Fig. 6.2]. A. Percentage of CD4+ CD62L+ Foxp3+ Tregs. B. Percentage 
of CD4+ CD62L- Foxp3+ Tregs. Statistical comparisons performed using One-
way ANOVA and Tukey’s multiple comparisons test. Error bars represent mean 
± SEM and each bar represents 4-5 pooled mice.  Statistical significance was 
expressed as follows; p<0.001***, p<0.01**, p<0.05*.NS = p>0.05.  
 
6.3.3. Targeting α2,3 Sia-Kd to Siglecs expressed on Batf3-/- DCs did not induce 
CD4+ CD62L+ Foxp3+ Tregs  
 
We observed that unlike B6 WT mice, B6.Batf3-/- recipients treated with α2,3 
sialylated alloantigen one day before transplantation did not have prolonged 




reflect transplant survival in these mice, B6.Batf3-/- recipients were bled 2 weeks 
post peptide and B6.Kd skin transplant and CD4, CD62L and Foxp3 were 
analysed using flow cytometry. Unlike B6 recipient mice, there was no 
significant increase in the percentage of CD62L+ Tregs observed over untreated 
mice (saline mean= 2.6%, Kd mean= 2.5%, α2,3 Sia-Kd mean= 4.38%) [Fig. 6.4 
A and B]. Therefore, targeting Siglecs on CD8α- CD11b+ DCs with α2,3 Sia-Kd 
does not result in an increase in CD62L+ Tregs numbers, suggesting that 
Siglecs expressed on Batf3-dependent DC subsets may be required for the 
prolongation seen via the induction/expansion of CD62L+ Tregs.  
 
Overall, our data suggests that targeting Siglecs expressed on cDC1s, either 
resident CD8α+ or migratory CD103+ DCs with α2,3 Sia-Kd increased CD4+ 
CD62L+ Foxp3+ Tregs whilst targeting cDC2s, such as resident CD8α- (CD4+) 
CD11b+ with sialylated or unsialylated alloantigens leads to antigen specific T 

































































Figure 6.4. Gating strategy for peripheral CD4+ CD62L+ Foxp3+ Tregs in 
B6.Batf3-/- mice. B6.Batf3-/- mice (4-5 mice/group) received either 10µg/200µl 
saline of α2,3 Sia-Kd or α2,6 Sia-Kd or Kd (i.v.). Control mice received 200 µl 
saline (i.v.) only. One day following peptide treatment, mice received B6.Kd (Kd) 
skin transplant. Mice were bled 14 days post-transplant to look for percentage 
Treg proportions by staining with CD4, CD62L and Foxp3. A. Live cells were 
gated on forward scatter (FSC), side scatter (SSC) followed by gating on CD4+ 
T cells. Contour FACS plots indicate CD62L+/- vs. Foxp3+/- T cells. B. Control 
mice received 200 µl saline (i.v.) only. C. Kd 10 µg/200µl saline. D. α2,3 Sia-Kd 

































































Figure 6.5. CD8α+ and CD103+ DCs may be required for the development 
of peripheral CD4+ CD62L+ Foxp3+ Tregs following α2,3 Sia-Kd targeting 
and B6.Kd skin transplant. Batf3-/- mice (3-5 mice/group) received either α2,3 
Sia-Kd 10µg/200µl saline or Kd 10 µg/200µl saline (i.v.). Control mice received 
200 µl saline (i.v.) only. One day following transplant, mice received B6.Kd (H2b 
+ Kd) skin transplant. Recipient mice were bled 14 days post-transplant to look 
for percentage Treg proportions by staining with CD4, CD62L and Foxp3. A.  
Percentage of CD4+ CD62L+ Foxp3+ Tregs (n=5). B. Percentage of CD4+ 
CD62L- Foxp3+ Tregs (n=5).  Statistical comparisons performed using One-way 
ANOVA and Tukey’s multiple comparisons test. Data shown is mean ± SEM. 
Statistical significance was expressed as follows; p<0.001***, p<0.01**, 
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This chapter examined the underlying mechanisms contributing to allograft 
survival following targeting Siglec-expressing DCs with α2,3 Sia-Kd. This 
chapter identified that similarly to Tanriver et al., (2010), mice treated with 
alloantigens showed profound deletion of Kd-specific T cells with no deletion of 
CD4+ Foxp3+ Tregs. In fact recipient B6, but not B6.Batf3-/- mice, treated with 
α2,3 Sia-Kd prior to transplantation had a signifiant increase of CD4+ CD62L+ 
Foxp3+ Tregs in peripheral blood. These preliminary observations suggests that 
targeting Siglecs on DCs subsets with 2,3 Sia alloantigens expands/induces 
CD62L+ expressing Tregs which may contribute to the prolonging transplant 
survival seen in Chapter 5.  
  
The expression of CD62L homing receptor on Tregs allows these Tregs to 
migrate to sites such as the LNs to initiate suppression, and these cells have 
been found to be more suppressive than their CD62L- counterparts, which could 
be the reason for graft prolongation following α2,3 Sia-Kd targeting (Ermann et 
al., 2005; Fu et al., 2004). The spleen and the LNs are two organs that are 
essential for the interaction between alloantigen acquired APCs such as DCs 
and priming of alloreactive T cells. Therefore, the migratory capacity of CD62L+ 
Tregs to secondary lymphoid organs is pivotal for the inhibition of priming of 
naïve alloreactive T cells at these sites, as demonstrated by Ochando et al., 
(2005). These authors determined that administration of anti-CD62L antibody to 
cardiac allograft recipient mice exacerbated rejection due to impaired 
accumulation of CD4+ CD25+ Tregs in LNs, SPLN and blood. Siglecs targeted 
with α2,3 Sia-Kd in situ increased CD62L+ Tregs in the blood (although we did 
not check the SPLN and LNs for these Tregs), however although graft survival 
was prolonged, we did not observe indefinite skin graft survival. This suggests 
that this targeting regimen may be a useful complimentary therapy to increase 
CD62L+ Tregs or expand CD62L+ Tregs from adoptively transferred Tregs, 
which can improve allograft survival, but additional strategies such as sialylating 
an MHC monomer instead of an MHC peptide in order to induce indefinite skin 





The importance of CD103+ DCs for promoting tolerance was demonstrated by 
Bain et al., (2017), where reducing CD103+ DCs decreased the proportion of 
inducible Tregs in vivo and in vitro. For example, one study found that murine 
mesenteric LN CD103+ DCs have a role of converting naïve T cells into Foxp3+ 
Tregs which was dependent on TGF-beta and retinoic acid (Coombes et al., 
2007). These authors also described that CD103 and CCR7 expression on 
these migratory DCs were essential to migrate to the intestine and mediate 
control of induced-colitis (Coombes et al., 2007). In addition, expression of 
Indoleamine 2,3-dioxygenase (IDO), which is involved in tryptophan catabolism 
and in limiting T cell activation, by CD103+ DCs was essential for the 
development of Foxp3+ Tregs (Matteoli et al., 2010). However, CD103+ DCs 
may also function in organs other than the intestine. In fact, Batf3-dependent 
dermal CD11blow/- Langerin+ CD103+ DCs present in the skin (Edelson et al., 
2011) generates Tregs (Hasewgawa et al., 2018). In another study donor 
CD103+ DCs migrate to host LNs from the donor skin allograft and drive the 
direct pathway of allorecognition leading to transplant rejection (Borges et al., 
2018). Borges et al., (2018), identified that donor-derived CD103+ DCs are the 
prime APCs carrying donor MHC II which migrate to recipient LNs and drive 
direct allorecognition and instigate murine skin graft rejection.  
 
Interestingly, CD103+ DCs have been shown to express Siglec F (Bain et al., 
2017). It is therefore possibility that in our study, targeting Siglec F on migratory 
CD103+ DCs (Bain et al., 2017) using α2,3 Sia-Kd may have induced the 
CD62L+ Tregs seen in the blood of B6 mice. Idoyaga et al., (2013) showed that 
dermal CD103+ DCs generated MOG antigen-specific CD4+ Tregs in vivo 
following administration of an anti-CD103 monoclonal antibody (s.c.) 
engineered to express MOG. Their study aligns with our findings that targeting 
endogenous Batf3-dependent DCs induces Foxp3+ Tregs, which may be a 
contributing factor for allograft survival as seen with α2,3 Sia-Kd targeting. What 
would be interesting to assess is the presence of sialylated peptides in non-
lymphoid organs where CD103+ DCs reside such as the lungs, skin and 
intestine (Edelson et al., 2010), especially since these DCs are migratory. That 
said, CD103+ DCs do not limit their function to non-lymphoid organs; they have 
also be found in the skin draining lymph nodes at both a steady and inflamed 
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state, therefore in this study peptides present in the lymph nodes may be in the 
vicinity of CD103+ DCs resulting in a possible interaction (Ginhoux et al., 2007).  
 
The next question is, do CD8α+ DCs play a role in prolongation following Siglec 
targeting? Depletion of CD8+ cells with routine administration of anti-CD8 
antibody has been used in various murine transplant models as a means of 
assessing the indirect pathways of allorecognition (Tanriver et al., 2010). This 
treatment also depletes cross-presenting CD8α+ DCs (Smyth et al., 2013). In 
our transplant experiments, anti-CD8 antibody treatment was given on the same 
day of peptide treatment, but, following peptide treatment, therefore, it is a 
possibility that sialylated alloantigens would have already bound to CD8α+ DCs 
before anti-CD8 was administered. It is questionable to rule out the possibility of 
sialylated peptides binding to CD8α DCs+, especially since we confirmed the 
presence of the peptides in the SPLN and LNs in Chapter 5.   
 
In both WT and B6.Batf3-/- mouse models, antigen-specific CD4+ T cells were 
deleted following administration with either sialylated or unsialylated peptides, 
Therefore, antigen-specific T cell deletion may also be one of the mechanisms 
involved in the reduction of alloantibodies in our model, an observation very 
similar to that published by Tanriver et al., (2010). A possible explanation is that 
i.v. injection of peptides contributed to thymic tolerance. Although we injected 
our peptides i.v., so that they reach the SPLN and LNs, we cannot rule out the 
possibility that they entered other organs within the body such as the thymus, 
although we have yet to confirm this. It is possible that the Kd allopeptides were 
presented via MHC II by thymic DCs to developing thymocytes. This theory is 
supported by one study by Garrovillo et al., (1999) which suggested that 
acquired thymic tolerance and indirect allorecognition exists in the thymus, they 
first targeted immunodominant MHC I peptide to recipient rat BM-DCs in vitro 
and injected these cells via intrathymic injection which was then followed by a 
heart transplant (Garrovillo et al., 1999). Donor type allografts were indefinitely 
accepted, whereas unrelated donor were acutely rejected, therefore inducing 
alloantigen specific tolerance (Garrovillo et al., 1999). However, a significant 
difference between our study and the aforementioned study is that they injected 
antigen-pulsed BM-DCs intrathymically, whereas the current study administered 
peptides systemically. Therefore, the thymic tolerance theory in our study is 
206 
 
questionable, especially given the concentration of peptide used. Several 
studies have reported thymic tolerance via injecting high doses of peptides 
systemically, for example Liblau et al., (1996) demonstrated that 750µg, but not 
75µg, of influenza virus hemagglutinin (HA peptide) administered intravenously 
induced thymic tolerance by depleting CD4 and CD8 thymocytes and inducing 
peripheral tolerance in the SLOs by antigen specific deletion and anergy. In 
addition repetitive intravenenous administration of 750μg  HA peptide was also 
shown to induce depletion of CD4 and CD8 thymocytes in mice, whereas a 
single dose of this peptide did not induce long-lasting tolerance (Bercovici et al., 
1999).  As we only administered 10µg of peptide once per mouse, and not 
intrathymically, we suggest that thymic deletion may not be involved however 
we can substantiate this by isolating the thymus from Kd-FITC targeted mice 
and assessing binding on thymic DCs using flow cytometry. Altogether, we do 
not have experimental evidence to suggest thymic tolerance; nevertheless this 
can be addressed as future work with thymectomized mice. 
 
It is possible that targeting Siglecs F with Sia-Kd inhibited allorecognition by 
modifying DCs leading to peripheral tolerance, via a combination of peripheral 
deletion and an increase in CD4+ CD62L+ Foxp3+ Tregs. This is in contrast to 
Kd peptide administration of which only induced peripheral deletion, which was 
not enough to significantly prolong allograft survival. Overall, two tolerance 
inducing mechanisms could be contributing to allograft survival following Siglec 
interaction with α2,3 sialylated alloantigen, which are induction/ expansion of 
CD4+ CD62L+ Foxp3+ Tregs and antigen-specific deletion. Other tolerance 
inducing mechanisms such as anergy could also be at play, but this could not 













































7.1. Final discussion  
 
7.1.1 Can sialylated alloantigen targeting to APCs inhibit indirect 
allorecognition?  
 
Chronic transplant rejection remains a persistent obstacle for long-term 
transplant survival. As previously mentioned, ISD can be administered prior or 
post-transplant and are effective at prolonging the survival of the transplant on a 
short-term basis. However, these treatments fail to prevent chronic mediated 
rejection, instead, there is an increase of opportunistic infections and 
malignancies (Sampaio et al., 2012; Munoz-Price et al., 2004; Razonable et al., 
2013). In order to promote graft survival without the use of ISD, 
immunotherapeutic approaches targeting specific immune cell interactions that 
contribute to chronic allograft rejection are being investigated.  
 
One of the pathways known to contribute to chronic rejection is the indirect 
pathway of allorecognition (Stanford et al., 2003; Hornick et al., 2000). Immune 
cells that are known to contribute to indirect allorecognition are DCs and B cells 
that can contribute to initiating this pathway. Upon recognition and processing 
of alloantigens by recipient DCs/ B cells, alloantigens are presented to recipient 
T cells. These T cells can then instruct follicular B cells via CD40/ CD40L 
interaction to differentiate into alloantibody producing B cells or memory B cells 
(Steele et al., 1996). It is also established that DCs have the ability to present 
antigen which are in its native state to B cells to influence humoral immune 
responses to T-independent antigens, via receptors such as Fc receptor, 
FcgRIIB on DCs (Bergtold et al., 2005; Wykes et al., 1998; Qi et al., 2006). Qi et 
al., (2006) identified that DCs that had acquired antigen, could present this to B 
cells in LNs and using imaging studies they discovered B cells that captured the 
antigen, were activated and migrated towards the T-B border to initiate immune 
response. Therefore, not only can DCs present antigen to T cells, then can also 
present antigens to B cells. In addition to DCs, macrophages are also known to 
contribute to rejection, for example by releasing proinflammatory cytokines, eg: 
TNF- α and IFN- γ, which were shown to cause transplanted tissue fibrosis and 




As mentioned previously in this thesis, DCs, B cells and macrophages share a 
group of inhibitory receptors, known as Siglecs and various studies have 
demonstrated the role of these receptors in inhibiting immune cell interactions 
(Pillai et al., 2012). Inhibitory Siglecs are expressed on both human and murine 
cells where 14 human and 9 murine Siglecs have been identified (Bornhӧfft et 
al., 2018). To date, it has not been established whether targeting Siglec 
receptors on APCs can modify the indirect pathway of allorecognition and 
induce transplantation tolerance. Therefore, this thesis investigated targeting 
Siglecs on recipient DCs, B cells and macrophages using a sialylated MHC I 
alloantigen peptide (an established alloantigen used to assess indirect 
allorecognition in vitro and in vivo) (Tanriver et al., 2010) to modify the indirect 
pathway of allorecognition and to promote organ transplant survival. The overall 
goal of this study was to determine whether targeting Siglec expressing antigen 
presenting cells using sialylated MHC I Kd alloantigen peptide could modify 























The present study's objectives and key findings were: 
 
1. To test the possibility of improving skin transplant survival by targeting 
Siglec-expressing cells using Sia-alloantigen (Kd) peptide as model 
alloantigens. 
 
Findings: Siglec -expressing BM-DCs, but not B cells targeted with Sia-Kd 
alloantigens in vitro had impaired abilities to promote CD4+ T cell proliferation 
however, they induced/expanded CD4+ Foxp3+ Tregs [Fig. 7.1A-B]. Targeting 
BM-DMs with α2,3 sialylated alloantigens decreased IL-12 in the presence of 





















Figure. 7.1. Graphical representation for the outcome from targeting DCs, 
B cells and macrophages with Sia-Kd in vitro. A. Targeting BM-DCs in vitro 
with α2,3 Sia-Kd impaired MHC I and MHC II expression and inhibited TCR75 T 
cell proliferation and IFN-γ and IL-2 production. BM-DCs targeted with all 
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sialylated alloantigens induced/ expanded CD4+ Foxp3+ Tregs from naïve 
TCR75 T cells. B. B6 B cells targeted with alloantigens did not stimulate TCR75 
CD4+ T cell proliferation or induce/ expand CD4+ Foxp3+ Tregs. C. Targeting B6 
BM-DMs with α2,3 Sia-Kd impairs IL-12 production even in the presence of LPS.   
 
2. To identify whether specific DC subsets, B cells or macrophages are 
targeted by sialylated alloantigen and whether this contributes to 
transplantation outcome.  
 
Findings: Skin allograft survival occurred following pre-treatment with α2,3 Sia-
Kd [Fig. 7.2 A-B]. Siglec-expressing B cells may not be required for allograft 
survival following sialylated alloantigen targeting, however DCs were required 
[Fig. 7.2]. Targeting Siglecs on Batf3-dependent DCs with α2,3 Sia-Kd prolongs 
allograft transplant survival and reduced alloantibodies [Fig. 7.2].  
 
3. If improved transplant outcome occurs, to assess what are the 
mechanisms of ‘tolerance’ following targeting recipient APCs with 
sialylated alloantigen.  
 
Findings: In vivo targeting of Sia-Kd alloantigen to DCs leads to T cells with 
indirect specificity deletion, without deleting the Treg pool. Mice with prolonging 
allograft following α2,3 Sia-Kd targeting have increased proportions CD4+ 





























Figure. 7.2. Graphical representation for the transplant outcome following 
α2,3 Sia-Kd targeting in vivo. A.B6.Rag2-/- mice devoid of B cells and 
reconstituted with B6 CD4+ T cells have prolonging skin graft survival following 
α2,3 Sia-Kd targeting. B. B6 WT mice, that consists of all DC subsets and 
administered with  α2,3 Sia-Kd and anti-CD8 had increased allograft survival, 
CD4+ CD62L+ Foxp3+ Tregs in peripheral blood and reduced alloantibodies. C. 
Batf3- dependent CD8α+ and CD103+ DCs are required for allograft survival 
following α2,3 Sia-Kd targeting.  
 
Chapters 3 and 4 highlight the ability of sialylated alloantigen targeted BM-DCs 
to promote alloantigen-specific tolerance in vitro. As mentioned in Perdicchio et 
al., (2016) study, α2,6 sialylated antigen interaction with Siglec E on BM-DCs 
promoted induction of Tregs in vitro.  Perdicchio et al., (2016), did not publish 
data on the effect of α2,3 Sia-OVA on Siglec E-/- BM-DCs or whether their 
constructs are interacting with Siglec F, however as suggested by Crocker et 
al., (2007), this linkage of sialic acids bind to Siglec E and F, therefore α2,3 Sia-
Kd may be binding to Siglec E and/or Siglec F to mediate their 
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immunoregulatory effects. However, in order to fully confirm this, the binding of 
our constructs need to be tested on Siglec E and F knockout DCs.  
 
We have confirmed in vitro that both α2,3 and α2,6 sialylated Kd constructs bind 
to BM-DCs, however there is preferential binding for α2,3 Sia-Kd compared to 
α2,6 Sia-Kd. As mentioned in Chapter 5, the differences in binding may reflect 
the type of Siglecs these constructs are binding to. It is known that Siglec E has 
moderate binding to α2,3 and α2,6 sialic acids, however Siglec F binds 
moderately to α2,3 sialic acids and interestingly, binds weakly to α2,6 sialic 
acids (Crocker et al., 2007). Therefore, as Siglec F is highly expressed on BM-
DCs and SPLN DCs it is possible that this resulted in the increased binding of 
α2,3 Sia-Kd observed. Whereas α2,6 sialylated Kd binds to Siglec E on BM-
DCs, which is not as highly expressed as Siglec F. Currently, there are very few 
publications demonstrating Siglec F expression and functional role of this 
receptor on BM-DCs.  Siglec F expression is mostly associated with 
macrophages, namely present in the lung and eosinophils (Feng & Mao, 2012; 
Kiwamoto et al., 2014), though it has been reported that Siglec F is expressed 
on BM-DCs and BM-DMs (which we have confirmed), however the authors did 
not present this data in their publication but did mention this in their discussion 
(Tetano et al., 2007). We cannot rule out the possibility of sialylated alloantigen 
binding to MHC as well as Siglecs, however to fully confirm the binding profiles, 
in vitro peptide binding experiments can be repeated on both B6 WT DCs and 
MHC I/II DCs derived from MHC KO mice.   
 
The next question raised is whether Siglecs have the ability to present 
sialylated alloantigens. Tateno et al., (2007) demonstrated that Siglec F can 
mediate endocytosis of anti-Siglec F antibody and sialylated ligands such as 
bacterium Neisseria meningitides. They discovered that the ITIM of Siglec F 
mediated endocytosis which is dependent on ADP-ribosylation factor 6 (ARF6) 
(Tateno et al., 2007), similarly, peptide-MHC II complexes that enter DCs also 
require ARF6+ tubular endosomes (Walseng et al., 2008). To further support 
that sialylated alloantigens are involved in antigen-presentation, Perdicchio et 
al., (2016), investigated whether native and sialylated OVA protein antigens had 
different intracellular routes that could impact MHC presentation and T cell 
activation (Perdicchio et al., 2016). It was revealed that sialylation did not alter 
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the intracellular route within the DC, in fact, both native and sialylated antigen 
had higher colocalization with lysosomal (LAMP-1) compartment rather than the 
endosomal (EEA-1) (Perdicchio et al., 2016). By observing the intracellular 
route of the antigens, they found that both Sia-OVA and OVA protein were 
present within the same compartments where MHC II-peptide complexes are 
formed, thus confirming that irrespective of sialylation, antigens are presented 
via self MHC II to CD4+ T cells (Perdicchio et al., 2016). In order to confirm that 
Sia-Kd binding and the intracellular fate of the conjugates is also not affected, 
peptide binding and intracellular routing of Sia-Kd-FITC could be assessed 
using confocal microscopy. 
One significant difference between the current study and Perdicchio et al., 
(2016) study is that the aforementioned study targeted BM-DCs with a sialylated 
whole OVA protein as well as MOG peptide, whereas we are targeted DCs with 
a sialylated MHC-derived peptide. Their study did confirm that both sialylated 
proteins and sialylated peptide antigens promoted tolerance in vitro and in vivo, 
however they did not confirm the intracellular routing of sialylated MOG peptide 
antigen which has yet to be investigated. A particular difference between 
protein and peptide antigens could be a slightly enhanced and quicker immune 
response with peptides as opposed to whole proteins. In 2013, Rosalia et al 
(2013), identified that in comparison to whole OVA proteins, OVA peptides 
constituting of 24 amino acids were more efficiently and quickly processed by 
murine DCs and presented via MHC molecules I/II to T cells. Therefore, when 
considering sialylated alloantigens as a potential therapy, it may be worth 
testing sialylated whole MHC monomer to decipher whether this enhances the 
impaired alloreactive immune responses observed with peptide. Sialylated 
alloantigens targeting may be useful for human therapy, especially since human 
leukocytes also express inhibitory Siglecs and studies have suggested a role of 
these receptors in inhibiting effector immune responses.   
 
The human homologue of Siglec F is Siglec 8, both of which are known to be 
expressed on eosinophils and impair effector functions of eosinophils in allergic 
inflammation (Gao et al., 2010; Kiwamoto et al., 2014). The question is; given 
that these Siglecs function similarly on eosinophils in humans and mice, does 
Siglec F have similar inhibitory mechanisms to Siglec 8 in humans and can 
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targeting this Siglec in humans prevent effector alloreactivity? It is known that 
Siglec F is expressed on eosinophils, but we have confirmed their expression 
on murine BM-DCs and SPLN-DCs, and it would be interesting to know whether 
Siglec 8, which expression is established on eosinophils, is expressed on 
human monocyte-derived DCs and has a similar inhibitory function. Unlike 
murine Siglec F which can bind to α2,3 sialylated ligands, Siglec 8 only binds 
strongly with sulphated ligands such as Sialyl-Lewis X which comprises a 
combination of sialic acid, fucose and an N-acetyllactosamine (Kiwamoto et al., 
2012). Therefore, when targeting sialylated alloantigen to humans, different 
glycans attached to the alloantigen should be taken into consideration.  
 
Perdicchio et al., suggested that sialylated antigen loaded DCs mediate their 
tolerogenic effects via contact-dependent mechanisms, not via soluble 
mediators. They addressed this using Transwell chambers, where OVA-pulsed 
DCs and naïve OT-II T cells were placed on the lower Transwell and were 
separated from Sia-OVA pulsed DCs or OVA pulsed DCs, which were placed 
on the top well of the Transwell. They identified no difference in IFN-γ 
production of OT-II CD4+ T cells when either OVA or Sia-OVA pulsed DCs were 
placed on the top Transwell, suggesting that tolerogenic effects were not 
influenced by soluble mediators released by Sia-OVA pulsed DCs, but instead 
are mediated via contact-dependent mechanisms (Perdicchio et al., 2016).  
Several surface molecules such as MHC, PD-L1 and ICOS-L were assessed in 
Sia-alloantigen and Siglec contact dependent immune modification.  
 
Markers such as PD-L1 were increased on murine BM-DCs that were made 
tolerogenic using agents such Dexamethasone and Minocycline (antibiotic used 
to generate TolDCs) (Lee et al., 2017),  and interaction of PD-L1 on DCs and  
PD-1 on T cells resulted in down-regulation of T cell activation (Brown et al., 
2002). Their study recognised that blockade of PD-L1 on monocyte-derived 
DCs enhanced CD4+ T cell proliferation in MLRs in vitro (Brown et al., 2002). In 
vivo, Sander et al., (2005) found that blocking PD-L1 ligand accelerated skin 
graft rejection in an MHC II-mismatched transplant model; in fact PD-L1 
blockage enhanced T cell proliferation. PD-L1 expression on BM-DCs treated 
with sialylated and non-sialylated alloantigen targeted BM-DCs remained 
unchanged, suggesting that the inhibition in T cell proliferation may not be 
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mediated by PD-L1 or Siglec signalling does not lead to upregulation of PD-L1. 
The latter conclusion remains inconclusive, given that human macrophages 
expressing Siglec 9 and once engaged with hypersialylated tumours, can up-
regulate PD-L1 expression in order to evade host effector immune responses 
(Beatson et al., 2016). Therefore as future work, it would be interesting to 
assess PD-L1 expression on BM-DMs following Sia-Kd engagement.  
 
ICOS-L present on DCs interacts with ICOS expressing CD4+ T cells and in turn 
promotes IL-10 production. A study by Tuettenberg et al., (2009), found that T 
cell anergy and IL-10 secretion were impaired when ICOS-L and ICOS 
interactions were blocked in DC/T cell co-cultures. Moreover, in patients with 
ICOS-deficient CD4+ T cells, peripheral tolerance was not observed and these 
patients’ T cells were refactory to anergy induction (Tuettenberg et al., 2009). 
Similarly to PD-L1, ICOS-L expression was not modified following Siglec 
engagement. It remains to be determined whether Sia-Kd treated DCs have 
increased expression of molecules previously shown to contribute to a 
‘tolerogenic’ phenotype which could polarise CD4+ T cells to a suppressive 
phenotype, or a state of T cell anergy such as ILTs (Chang et al., 2002), or 
induce apoptosis of T cells such as Fas-L (Marin et al., 2018) given that T cell 
deletion was observed in our in vivo experiments. It would also be interesting to 
determine whether Sia-Kd targeted DCs impair T cell immune responses by 
altering their metabolic activity such as through tryptophan catabolism via  IDO 
(Xie et al., 2015), or perhaps Tregs are induced/ expanded  by DCs as a result 
of production of anti-inflammatory cytokines such as TGF-β (Zheng et al., 
2007).  
  
MHC I and II are expressed sub-optimally on tolerogenic DCs (Marin et al., 
2018). An interesting finding was the reduction of MHC I and II molecules on 
the surface of BM-DCs following α2,3 Sia-Kd targeting. The low expression of 
MHC I and MHC II molecules suggested that α2,3 Sia-Kd targeting may 
influence DCs to have a limited capacity to present antigen leading to reduced 
T cell activation. It has yet to be determined whether α2,3L Sia-Kd or α2,6 Sia-




Investigations into MHC expression following Siglec interaction has not been 
fully elucidated in vivo, however it is established that Siglec G expressed on 
SPLN- DCs may have a role in impairing MHC I-mediated antigen-presenting 
ability. One study demonstrated in CD8α+ DCs that upon pathogenic antigen 
engulfment, Siglec-G expressed within the phagosome inhibited NOX2 
activation and ROS production as a result of ITIM-SHP1 recruitment, and 
created a highly acidic environment within the phagosome (Ding et al., 2016). 
This led to excessive degradation of the antigen and inhibition of peptide-MHC I 
complex formation resulting in attenuated cross-presentation and CD8+ T cell 
activation (Ding et al., 2016). However, the aforementioned study did not report 
any significant differences in MHC I (H-2Kb) expression on murine splenic 
CD8α+ DCs between Siglec G+ and Siglec KO mice following the administered 
of L. monocytogenes that secrete OVA protein. Their study supports the idea 
that Siglec G is expressed within DC phagosomes on CD8α+ DCs and is 
involved in impairing MHC I:peptide interactions and CD8+ T cell immunity. Ding 
et al., (2016) did not see any difference in OT-II CD4+ T cell proliferation in vitro 
when Siglec G+/+ and Siglec G-/- CD8α SPLN-DCs were pulsed with OVA 
protein, suggesting that Siglec G may have a role inhibiting CTLs responses 
rather than CD4+ T cell responses. Given the relationship between Siglec G and 
MHC I, it may be worth investigating CD8+ T cell immune responses following 
sialylated alloantigen targeting.  
 
Siglec G is also established as a negative regulator of DAMP release (Toubai et 
al., 2014), which are released from the physical trauma caused by the skin 
transplant (Benichou et al., 2011). The inhibitory role of Siglec G may provide 
some suggestion as to why B6.Batf3-/- mice which lack Siglec G-expressing 
CD8α+ DCs do not prolong allograft survival following α2,3 Sia-Kd targeting.  
 
Considering B6.Batf3-/- mice did not consist of a significant increase of these 
CD4+ CD62L+ Foxp3+ Tregs, these finding may suggest that CD8α+ DCs are 
required for the development of peripherally induced Foxp3+ Tregs. One study 
identified that these DCs specifically express B- and T-lymphocyte attenuator 
(BTLA) which is a receptor that binds specifically to herpes virus entry mediator 
(HVEM) resulting in up-regulation of CD5 expression on T cells (Jones et al., 
2016). Following engagement of BTLA and HVEM, CD5 expression is 
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increased, resulting in induction of Tregs. In fact, their study found that by 
blocking BTLA on CD8α+ DCs using an anti-BTLA, Treg induction was 
significant impaired (Jones et al., 2016). Therefore, targeting CD8α+ DCs and 
possibly Siglecs on these DCs using sialylated alloantigens may be required for 
Treg induction/ expansion, which was not observed in the B6.Batf3-/- 
transplanted mice.  
 
Similarly to Siglec 9 on human macrophages, mouse Siglecs also regulate 
inflammatory cytokines release in response to proinflammatory stimulus, such 
as LPS (Ando et al., 2008). It has already been established that α2,3-linked 
sialic acids that coat bacterium Group B Streptococcus (GBS), are able to 
interact with murine Siglec E on macrophages (Chang et al., 2014).  Their study 
demonstrated that Siglec E KO mice injected with GBS had increased IL-12 
transcript levels in comparison to WT mice (Chang et al., 2014). They were not 
able to detect any proinflammatory cytokines in mice 48 hours post infection, 
however, using RT-PCR increased levels of IL-12 mRNA was detected in the 
lungs of Siglec E KO mice (Chang et al., 2014). It was interesting to observe 
that out of all the sialylated constructs in the current study, α2,3-Sia-Kd targeted 
BM-DMs were the only cells with no significant increase of IL-12 in response to 
LPS which was not observed with BM-DCs, thus highlighting that Siglec 
engagement on different cell types may result in different immunosuppressive 
responses. Overall, sialylated alloantigen targeted macrophages may have an 
ability to limit IL-12 cytokines secretion and in turn may prevent allograft 
damage (de Paiva et al., 2009). It remains to be determined whether targeting 
macrophages with sialylated alloantigens impairs T cell proliferation and 
promote Tregs induction, but as we have confirmed Siglec expression, peptide 
binding and dampened proinflammatory IL-12 cytokine production, they may 
prove to be promising targets.  
 
Recipient B cells have been shown to act as APCs by presenting alloantigens 
to indirect alloreactive T cells and contributing to transplant rejection (Shiu et al. 
2015). However, in one clinical trial renal graft rejection was exacerbated when 
patients received the B cell depleting monoclonal antibody Rituximab, 
suggesting that B cells also have a regulatory role and can limit alloreactivity 
(Jackson et al., 2015). CD22 and Siglec G are two B cell associated Siglecs 
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with ITIMs that recruit SHP-1 tyrosine phosphatases leading to inhibition of BCR 
signalling (Meyer et al., 2018). One study managed to assess the outcome of 
targeting CD22 using a sialylated antigen. In this study the authors targeted this 
receptor using a polymeric antigen that consists of a CD22 ligand (α2,6 Sia) 
and a BCR-binding antigen (Courtney et al., 2009). The antigen used was 2,4-
dinitrophenyl (DNP) that can interact with DNP-specific BCRs (Courtney et al., 
2009). They discovered that targeting B cells with a DNP construct stimulated 
rapid Ca2+ influx into the cytosol of B cells, thereby signifying B cell activation. 
On the contrary targeting B cells with DNP/CD22L resulted in little to no Ca2+ 
release (Courtney et al., 2009). These results suggested that targeting Siglec 
CD22 and the BCR with a sialylated antigen impairs B cell activation (Courtney 
et al., 2009). Therefore as future work, it would be worth measuring calcium 
influx levels of Kd and Sia-Kd targeted B cells, to determine whether B cell 
Siglec and Sia-Kd interaction impairs B cell activation. In addition, instead of 
targeting total population of B cells, our study may be modified to target 
antigen-specific B cells in vitro similarly to Courtney et al., (2009), to confirm 
whether B cells are truly altered by sialylated alloantigen targeting- this may be 
one of the flaws in our study.  
 
Unlike DCs, sialylated alloantigen targeting to Siglecs on B cells did not induce 
CD4+ Foxp3+ Tregs nor was there T cell proliferation with unsialylated Kd 
peptide. This does not come as a surprise as recently, a study demonstrated 
that B cells require activation using anti-CD40 antibodies prior to T cell co-
culture to increase CD80/86 expression and support T cell activation (Rossetti 
et al., 2018). As B cells in our study were not stimulated prior to co-culture, this 
may account for the lack of T cell activation observed. However, this still leaves 
the question why Kd-treated B cells produce cytokines that support the 
maintenance Tregs but Sia-Kd treated B cells did not unanswered. It is a 
possibility that targeting Siglecs on B cells does not induce Tregs, but rather 
modulates B cell activation only.  
 
The definitive answer for why targeting Siglecs on DCs is better at prolonging 
graft survival than targeting Siglecs on B cells requires more investigation. It 
has been consistent that targeting DCs with α2,3 sialylated alloantigens 
promoted tolerogenic immune responses in comparison to targeted B cells as 
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demonstrated by induced Tregs in vitro and prolonged transplant survival in B6 
transplanted mice and B6.Rag-/-  mice (devoid of B cells). Therefore, it is still up 
for debate whether sialylated alloantigen targeting to B cells helps to promote 
tolerance. However, human B cell Siglec CD22 has become a promising target 
to modify autoimmune diseases. Humanized anti-CD22 antibody, Epratuzumab, 
is currently in-use in clinical trials for the purpose of down-regulating BCR 
engagement thereby inhibiting B cells activation and possibly reducing 
incidences of autoimmune disease (Sieger et al., 2012). As mentioned earlier, 
transitional B cells were amongst the population of B cells thought to prolong 
MHC-l mismatched skin graft survival (Moreau et al., 2014) thereby 
demonstrating the importance of their presence for tolerance. However, 
Epratuzumab has been shown to deplete some populations of transitional and 
naïve B cells (Dorner et al., 2016; Chu et al., 2018). This brings the question as 
to whether engaging CD22 Siglecs with sialylated alloantigens may be 
depleting transitional B cells which are required for allograft survival, especially 
as we have confirmed sialylated alloantigen binding to transitional subsets and 
no allograft survival when B6 WT mice were targeted with α2,6 Sia-Kd.  
 
We have also seen graft prolongation in B6 mice in response to α2,3 Sia-Kd 
treatment in comparison to saline, Kd, α2,3L Sia-Kd and α2,6 Sia-Kd treatment, 
despite this, grafts were eventually rejected and did not induce indefinite skin 
graft survival. It may be a possibility that another pathway, known as the semi-
direct pathway of allorecognition may be contributing to the rejection of the 
grafts. Unlike, the indirect pathway where alloantigen peptides derived from the 
donor MHC are presented via recipient DCs, the semi-direct pathways entails 
the transfer of the entire MHC molecules to recipient DCs. Therefore, recipient 
DCs are able to stimulate indirect CD4+ T cell responses via self-MHC II 
presenting donor alloantigens as well as direct CD8+ T cells responses via 
donor MHC I. As we have used B6.Kd donor skin with an MHC I transgene that 
expresses H-2Kd, it would have been a possibility that direct allorecognition 
would have mediated eventual rejection, particularly in the WT models.  
 
To further assess the contribution of targeting Sia-alloantigen to DCs and/or  
macrophages, B6 mice expressing DTR under the CD11c promoter could be 
used. Injection of DT into these mice leads to the transient loss of all CD11c+ 
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DCs and/or macrophages (van Blijswijk et al., 2013). Mice would receive 100ng 
of DT prior to and after administration of Sia-Kd or PBS (untreated control). 
Following the targeting regimen, mice would receive a Kd expressing skin 
transplant and rejection measured as previously described. The results from 
these experiments will inform us about the level of contribution these Siglecs-
expressing CD11c+ APCs have on transplant tolerance. A disadvantage to 
CD11c.DTR mice, is that multiple infusions of Diptheria toxin for the long-term 
depletion of DCs, has proven to be fatal to mice due to cardiac complications 
(Männ et al., 2016) as unexpected DTR expression on non-immune cells have 
been reported (Zaft et al., 2005). To overcome this, mixed irradiation chimeras 
where WT mice would be reconstituted with bone marrow from CD11c.DTR 
mice, thus generating a chimera can be used (van Blijswijk et al., 2014).  
  
Given our in vitro data, where all sialylated constructs induced Tregs and 
impaired TCR75 T cells proliferation, it was surprising that unlike α2,3 Sia-Kd, 
graft prolongation was not observed following α2,6 Sia-Kd treatment. This 
finding is contradictory to Perdicchio et al., (2016), where they demonstrated 
targeting endogenous DCs with α2,6 Sia-OVA one week before sensitization 
with OVA/poly(I:C)/anti-CD40, showed marked increase of CD4+ Foxp3+ Tregs 
and a reduction of effector CD4 and CD8 T cells. Some of the major differences 
between their study and this thesis are the models used and the doses of 
antigen targeted in situ. We injected 10μg α2,6 Sia-Kd sialylated alloantigen, 
whereas Perdicchio et al., (2016) targeted DCs in situ with a higher dose 50μg 
Sia-OVA protein, therefore in relation to α2,6 Sia-Kd, a higher dose may be 
required to mediate an immunoregulatory immune response and possibly 
increase the proportions of CD4+ Foxp3+ Tregs, which was observed following 
α2,6 Sia-OVA targeting. The aforementioned study used OVA protein and two 
'adjuvants' poly(I:C) and anti-CD40 antibody to assess the regulatory role of 
α2,6 Sia-OVA, whereas we assessed the regulatory role of a Kd peptide in the 
absence of these reagents. It can be argued that the immune responses are 
significantly different between these two treatments, as the placement of donor 
skin onto a recipient mouse can trigger multiple inflammatory immune reactions, 
such as physical trauma impacted by the surgical process where DAMPS are 
released, and a sudden exchange of donor and recipient lymphocytes upon 
vascularisation of the graft, stimulates cytokine release and activation of CD4 
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and CD8 T cells (Benichou et al., 2011). Poly (I:C) on the other hand is an 
adjuvant that can mimic a PAMP so that it can interact with TLR 3 expressed on 
DCs (Apostolico et al., 2019). Poly (I:C) replicates the immune system reaction 
to a viral infection and stimulates T cell activation (Martins et al., 2014). In fact 
mice, treated with an antibody targeted to DEC-205 plus Poly (I:C) led to a 
stronger effector immune response as opposed to mice treated with the 
antibody alone, thus demonstrating the potential of Poly (I:C) as an adjuvant 
(Apostolico et al., 2019). Although both Poly (I:C) treatment and skin transplant 
stimulate a proinflammatory immune response, the discrepancies in the models 
used may contribute to the difference in findings following α2,6 Sia antigen/ 
alloantigen targeting in vivo.  
 
Antigen-specific deletion is a known mechanism to promote tolerance by 
immunizing mice at a steady state with soluble antigen. In relation, we have 
found that B6 and B6.Batf3-/- mice treated with native Kd peptide or sialylated Kd  
alloantigens promoted deletion of adoptively transferred TCR75 CD4+ T cells, in 
comparison to mice treated with no peptide, without deletion or expansion of 
endogenous Tregs. Our findings with Kd complement that of Tanriver et al., 
(2010). Therefore, antigen-specific deletion may be one of the mechanisms 
partially contributing to graft survival following alloantigen targeting by reducing 
the pool of alloreactive T cells, although we have yet to confirm how this 
deletion is caused. The marked decrease of alloantibodies, may be accounted 
for alloreactive T cell deletion, however, this has yet to be confirmed (Steele et 
al., 1996).  
 
In order to achieve transplant tolerance, a targeting regimen should have the 
ability to induce tolerance that is specific to the donor Ags/ allograft as opposed 
to being broad immunosuppressive towards non-transplant related antigens, 
such as pathogenic or viral antigens that require an effector immune response 
for their elimination. Although we noticed that Kd alloantigen specific TCR75 
CD4+ T cells were deleted following peptide treatments, we did not assess non-
alloantigen specific CD4+ T cell deletion. Perdicchio et al., (2016), assessed 
whether targeting DCs with sialylated OVA protein were suppressive towards 
non-antigen specific T cells. They identified that DCs loaded with Sia-OVA and 
unsialylated MOG peptide were unable to induce Foxp3+ Tregs from MOG-
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specific CD4+ T cells, additionally, Tregs were only induced when OVA-specific 
OT-II CD4+ T cells were introduced into the MLR (Perdicchio et al., 2016). Thus 
demonstrating that sialylated antigen targeted DCs mediate antigen-specific 
tolerance (Perdicchio et al., 2016).  Therefore as future work, we could assess 
whether Sia-Kd treated DCs induce antigen-specific tolerance or are broadly 
immunosuppressive, inhibiting non-Kd specific T cells. This can be tested by 
loading DCs with sialylated Kd and unsialylated MOG peptide, followed by co-
culture with MOG-specific 2D2 CD4+ T cells in an MLR.  
 
7.1.2 Not all sialylated alloantigens mediate allograft survival  
 
We have so far demonstrated that DCs targeted with the all the sialylated 
constructs (α2,3 Sia-Kd, α2,3L Sia-Kd, α2,6 Sia-Kd) induced Tregs and impaired 
T cell proliferation in vitro. In vivo, T cell deletion also occurred when mice were 
treated with these constructs without deleting the Treg pool. Despite this, only 
α2,3 Sia-Kd treatment prolonged allograft survival and α2,3L Sia-Kd (longer-
sialylated-glycan-glycopeptide) and α2,6 Sia-Kd targeting did not prolong 
allograft survival. Due to the α2,3 sialic acid linkage on both α2,3L Sia-Kd and 
α2,3 Sia-Kd, we expected the former to prolong allograft survival as well. 
However, as we did not have a fluorochrome-conjugated α2,3L Sia-Kd 
construct, we could not confirm binding of this peptide to APCs, we could also 
question whether the modification of the sialic acid linkage may have modified 
the α2,3L Sia-Kd property to hit Siglecs in vivo and thereby not being as 
effective at prolonging transplant survival. To this end, we can suggest that this 
longer α2,3L Sia-Kd is not as effective as the shorter α2,3 Sia-Kd, at improving 
allograft survival. 
 
7.1.3 Targeting with Kd monomer instead of Kd peptide 
 
Kd is an immunodominant peptide derived from the entire MHC I Kd molecule; 
therefore, the T cells that specifically respond to this Kd peptide have a TCR that 
recognises this single peptide only. Tanriver et al., (2010), identified that 
targeting with the Kd peptide did not induce indefinite skin transplant tolerance 
unlike targeting recipient’s with a Kd monomer (entire MHC I H-2Kd), where 
indefinite skin graft survival was observed. Therefore as future work, it would be 
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interesting to determine whether the Kd monomer could somehow be 
encapsulated within in a sialylated barrier (e.g. liposomes or nanoparticles) (Ali 
et al., 2018) and administered to recipients (Spence et al., 2015). This could 
target more alloreactive T cells as an entire MHC monomer would consists of 
multiple epitopes that can be recognized by multiple TCRs, thus a much larger 
pool of alloreactive T cells.  
 
The short course of graft survival may also raise the question as to whether the 
dose and number of infusions were sufficient enough to induce lasting 
tolerance. We have demonstrated that targeting peptide 10 days before 
transplant did not promote transplant survival in comparison to targeting mice 1 
day before. As future work, assessing different doses of peptide and targeting 
at different time-points could be used to determine the optimal targeting 
regimen. For example in Tanriver et al., (2010) study, they trialled various doses 
of 33D1-Kd monomer such as 2μg and 20μg, where the latter proved to be more 
efficient at T cell deletion and was therefore used in their in vivo skin transplant 
experiments. One significant difference between the current and 
aforementioned study is their monomer was administered 14 days prior to 
transplant whereas we administered peptide 10 days and 1 day prior to 
transplant, where the latter was more successful in prolonging allograft survival. 
So, it would appear that 14 days may not be efficient for promoting allograft 
survival using sialylated alloantigen. One thing to consider is the dose of 
sialylated alloantigen that is administered. We opted for 10ug of peptide, which 
was the same dose used in some of Tanriver et al., (2010) in vivo experiments 
which demonstrated alloreactive non-Treg T cell deletion with 33D1-Kd peptide.  
Conversely, Perdicchio et al., (2016) opted for a higher dose of 50ug of 
sialylated OVA protein, followed by priming mice 7 days post infusion, therefore 









7.1.4 Can sialylated alloantigen targeting to DCs be applicable to human 
transplant survival therapy?  
 
Majority of the clinical trials focused on TolDCs comprise of administration of 
DCs as opposed to in situ targeting. The safety of administering autologous 
antigen-loaded TolDCs was tested in 2001 by Dhodapkar et al. where they 
administered immature DCs to healthy volunteers subcutaneously, resulting in 
no signs of toxicity or autoimmunity. A single dose of 2 × 106 monocyte-derived 
immature DCs treated with influenza matrix peptide (MP) and keyhole limpet 
hemocyanin (KLH) generated significant reduction of MP-specific IFN-γ 
producing T cells, with little difference in the total population of effector T cells, 
suggesting that this tolerance regimen was antigen specific (Dhodapkar et al., 
2001). This was one of a few studies that paved the way for the use of antigen-
pulsed human TolDCs in generating transplant tolerance. A pilot study in 2012 
investigated the effects of targeting autologous immature monocyte-derived 
DCs pulsed with myelin peptide antigens as means of a prospective 
immunotherapy for relapsing-remitting multiple sclerosis patients (Raïch-Regué 
et al., 2012). Impaired proliferation and a reduction of proinflammatory cytokines 
of myelin-specific T cells which were enriched from multiple sclerosis patients, 
and co-cultured with myelin peptide pulsed autologous TolDCs was observed, 
suggesting this to be potential TolDC therapy to treat this autoimmune disease 
(Raïch-Regué et al., 2012). A significant difference between the current study 
and the trials by Raïch-Regué et al., (2012) and Dhodapkar et al., (2001), is 
their method of pulsing DCs, prior to administration, whereas we have targeted 
DCs in situ. Despite this, an important similarity between the studies was 
observed; reduced antigen-specific effector T cell responses after treatment, 
therefore suggesting that targeting antigen-loaded DCs or targeting DCs in situ 
are effective tolerance induction strategies. 
 
Overall, there is potential of using sialylated alloantigens for promoting 
tolerance in human trials. As a potential targeting regimen, DCs may be 
targeted with sialylated alloantigens and then administered to recipients or 
sialylated alloantigens can be administered in situ to target endogenous DCs. 
Perdicchio et al., (2016) demonstrated in murine models that targeting sialylated 
alloantigens in vitro to autologous DCs promoted tolerance when injected into 
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recipients. We did not attempt to pulse autologous DCs with the constructs and 
administer these to transplant mice as it has been demonstrated by Smyth et 
al., (2013), that Kd-pulsed autologous DCs did not prolong allograft survival. 
Although targeting Kd-pulsed autologous DCs did not improve transplant 
survival in mice, this regimen may prove to be more efficient in the human 
recipients, as highlighted in section 1.4.1.2  (pg. 27).  
 
Despite successes in human clinical trials, there are several disadvantages to 
creating TolDCs in vitro as opposed to targeting DCs in situ (as mentioned in 
Chapter 1). However, an important consideration to take into account when 
targeting endogenous DCs, is the immune status of the recipient and whether 
the DCs within the recipient are immature or have been activated by a pre-
existing condition. For example, targeting alloantigens to a transplant recipient 
who may be experiencing diseases which can cause the recipient to remain in 
an activated state may exacerbate rejection as targeting matured/activated DCs 
can promote an effector immune response. However, studies have discovered 
that Siglec E on DCs and macrophages dampened TLR signalling and 
proinflammatory cytokine production as a result of NF-κB attenuation in the 
presence of LPS stimuli (Wu et al., 2016; Boyd et al., 2009). Interestingly, in a 
human setting, Siglec 9 expressed on immature monocyte-derived DCs that 
were targeted with artificial glycopolymers linked with α2,3 or α2,6 sialic acid, 
were shown to reduce IL-12 cytokine levels even in the presence of LPS. 
Therefore, targeting Siglecs on murine as well as human -DCs may regulate 
immune responses, even under proinflammatory stimuli that has the potential to 
lead to activation of DCs (Ohta et al., 2010).  
 
Another issue is whether antigens need to be sialylated in order to promote 
tolerance, or whether administration of peptide antigen and sialic acid 
separately can mediate a better or similar effect. Perdicchio et al., 2016 
confirmed that DCs were only tolerogenic when targeted with Sia-OVA as 
opposed to being targeted with sialic acids and OVA separately. Hence, in 
order to mediate tolerance by Siglec targeting, sialic acids would be need to be 




As with human clinical trials (Moreau et al., 2012), more preclinical work will 
need to be carried out to establish the optimum targeting procedure, such as 
dose of Sia-antigen, number of infusions, time-point in which the antigen (whole 
antigen or peptide antigen) is administered, route of administration and whether 
targeting autologous DCs with sialylated alloantigens is more efficient that 
targeting endogenous DCs. It will also need to be established whether targeting 
a sialylated peptide derived from the donor MHC I would be better at promoting 
tolerance rather than a sialylated whole MHC I monomer especially since 
Tanriver et al., (2010), identified that targeting recipient mice the Kd peptide did 
not induce indefinite skin graft survival unlike targeting with an MHC I Kd 
monomer.  
 
We have shown that α2,3 Sia-Kd treatment prolonged allograft survival, but 
does not induce indefinite skin graft prolongation. This targeting regimen may 
be useful as a combination therapy with other regimens such as rapamycin to 
stabilize Foxp3 expression on Tregs (Battaglia et al., 2006; Singh et al., 2012) 
or administration of Kd alloantigen- specific Tregs and low-dose IL-2 (Kulachelvy 
et al., 2019) to support their growth and expansion rather than a stand-alone 
therapy.  
Although mouse models have shown promise in investigating Treg therapy in 
transplantation in vivo, one disadvantage is the immune disparity in species 
between rodents and humans, for example humans consist of memory T cells 
which have the potential to become alloreactive, whereas mice which are 
housed in specific pathogen and viral free isolators do not contain such cells 
(Kenney et al., 2016). In order to overcome this, humanised mouse models 
have been used as a preclinical tool; in short these immunodeficient mice are 
engrafted/ reconstituted with human cells so that they consist of a functional 
human immune system. As an example, human myeloid DCs generated from 
PBMCs, were made tolerogenic by transducing these cells with an adenovirus 
encoding IL-10 (Coates et al., 2001). Once the these DCs were introduced into 
a humanized NOD-scid chimeric mouse model that was adoptively transferred 
with allogeneic mononuclear cells, and engrafted with human skin, incidences 
of graft rejection was reduced with reduced damage to the skin graft (Coates et 
al., 2001). Overall, humanized mouse models can be used to establish if 
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targeting human APCs with sialylated alloantigen can promote tolerance. This is 
something which can potentially be addressed prior to human clinical trials.  
Similarly to mice, humans also have different DCs subsets (Collin & Bigley, 
2018). CD141+ DCs are a human DC subset which are also known to express 
Siglecs (mentioned in a review by Crespo et al., 2013), which can be derived 
from human blood as well as skin, these cells have similar cross-presentation 
capacity as murine CD8α+ DCs (Chu et al., 2012). These DCs have been 
described as tolerogenic due to their ability to secrete IL-10, induce T cell 
hyporesponsiveness and induce Tregs (Chu et al., 2012). In order to assess the 
immunoregulatory capacity of these DCs in an in vivo humanized GVHD mouse 
model, CD141+ monocyte-derived DCs treated with vitamin D3 were 
administered to NSG mice reconstituted with human PBMCs (Chu et al., 2012). 
The authors identified significant graft survival in mice treated with vitamin D3 
CD141hi DCs as opposed to mice treated with vitamin D3 CD141dim DCs, 
suggesting the potential role of these human DC subsets to promote tolerance 
(Chu et al., 2012). Therefore, it has been established that certain human 
subsets can be targeted to promote tolerance, however whether these subsets 
express Siglecs or whether human Siglecs on DCs [Table. 4] can be targeted 
with sialylated alloantigens  to modulate these DCs has yet to be elucidated.  
 
Although human Siglecs have demonstrated inhibitory functions [Table 4], 
targeting particular Siglecs on human DCs should be approached with caution. 
In 2014, it was established that human Siglec 7 is expressed on a particular 
subset of monocyte-derived DCs known as CD1 DCs (Kawasaki et al., 2014). 
Although Siglec 7 has shown to be inhibitory for sialylated pathogen interaction 
(Crocker et al., 2007), the authors of the 2014 study demonstrated otherwise. 
Delivery of mycobacterium antigens which was encapsulated within a liposome 
coated with lipid- ligand for Siglec 7 (Rillahan et al., 2013), to CD1 DCs induced 
rapid T cell activation and was proposed as an effective vaccination against 
bacterial infection (Kawasaki et al., 2014). In addition, Siglec 7 on human 
monocytes has also been shown to induce proinflammatory immune response 
following targeting with sialic acid-free pathogens (Varchetta et al., 2012). 
Therefore, as an immunotherapeutic approach, further investigation into which 
specific human Siglecs should be targeted to promote tolerance will need to be 
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done and whether particular Siglecs should be blocked to avoid cross-reactivity 
of sialylated alloantigens with potential activatory Siglecs (Kawasaki et al., 
2014).  
 
Another precaution to take note of when extending the current study to human 
subjects, is that inhibitory Siglecs are expressed on a variety of immune cells 
(Crocker et al., 2012), which can be advantageous considering transplant 
rejection is mediated by numerous immune cells. One human study highlighted 
Siglec 9 expression on CD8+ effector T cells (Haas et al., 2019). They identified 
that following engagement of sialic acid ligands present on tumours were able 
to engage with Siglec 9 expressing CTLs and in turn functionally inhibit them 
(Haas et al., 2019). Therefore, targeting on different immune cells including 
APCs may prove to be an effective graft survival strategy; however this 
approach requires much further investigation.  
 
7.2 Final conclusion 
 
Overall, this thesis has demonstrated for the first time that targeting sialylated 
alloantigen to Siglec-expressing recipient antigen presenting cells, particularly 
DCs (and possibly a particular DC subset CD103+ and/or CD8α+), may 
represent a novel mechanism to regulate allorecognition in an antigen-specific 
manner [Fig. 7.1]. As described in Table 3, the studies by Ettinger et al., (2012) 
and Tanriver et al., (2010) demonstrate the potential of targeting a particular 
subset of DCs by targeting either receptor DEC205 or DCIR2, respectively, to 
promote allograft survival. We have demonstrated that multiple receptors 
(Siglecs) that may have been targeted by sialylated alloantigen also promote 
allograft survival. Given that we have identified allograft survival in WT mice as 
opposed to B6.Batf3-/- mice following α2,3 Sia-Kd targeting, it may be that 
targeting Siglecs on subsets CD8α+ and/or CD103+ DCs are required and that 
targeting Siglecs on other DC subsets using sialylated alloantigen may not have 
a significant role. However, it has yet to be confirmed which Siglec and DC 
subset is definitely targeted.  
 
Given that allograft survival was established in a B6.Rag-/- mouse model in the 
absence of B cells following α2,3 Sia-Kd targeting, Siglec expressing B cells 
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may not play a significant role in mediating allograft survival. In addition to DCs, 
sialylated alloantigen targeted macrophages may have also contributed to 
allograft survival as we have observed Siglec expression and peptide binding in 
vitro.  
 
The current study provides an insight into the possibility of targeting Siglec-
expressing DCs using sialylated alloantigens to promote allograft survival. 
Given our findings in mouse, targeting Siglecs in humans to promote allograft 
survival may be advantageous given their abundance on human DCs [Table 4], 
and expression on DC subsets such Siglec 6 on AXL+ pre-DCs, a newly 
identified DC subset, thought to be efficient at stimulating T cell activation 
(Vallani et al., 2017; Collin & Bigley, 2018).  The findings in this thesis could 
contribute to immunotherapeutic strategies to combat chronic rejection by 
targeting Ag-specific indirect immune responses within the transplant recipient 
without the use of prolonged immunosuppressive therapy. This thesis has 
overall suggested that targeting Siglec expressing APCs using sialylated 
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Appendix figure 1.  Siglecs are expressed on B6 BM-DCs. For Siglec 
expression, day 6 or 7 B6 BM-DCs were stained using anti-mouse CD11c 
APC/PE and either anti-mouse Siglec E- PE, Siglec F- PE, Siglec G- PE, Siglec 
H-PE and CD169-PE. Live cells were gated on FSC, SSC. A. Percentage of 
BM-DCs expressing CD11c. B. Percentage of BM-DCs expressing Siglec 
CD169. C. Percentage of BM-DCs expressing Siglec F. D. Percentage of BM-
DCs expressing Siglec G. E. Percentage of BM-DCs expressing Siglec H. F. 























































































































































































































































































































































































1µg/ml Kd or α2,3 Sia-Kd 10µg/ml Kd or α2,3 Sia-Kd 
1µg/ml Kd or α2,3 Sia-Kd 10µg/ml Kd or α2,3 Sia-Kd 
1µg/ml Kd or α2,3 Sia-Kd 10µg/ml Kd or α2,3 Sia-Kd 
1µg/ml Kd or α2,3 Sia-Kd 10µg/ml Kd or α2,3 Sia-Kd 
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Appendix figure 2. Targeting BM-DC Siglecs with Sia-Kd leads to 
suppressed proliferation of TCR75 CD4+ T cells and IL-2 in vitro. B6 BM-
DCs were pulsed with 1 or 10µg/ ml concentrations of peptide and co-cultured 
with CD4+ T cells from TCR 75 Rag -/- mice at a 1:1, 1:5, 1:10 DC: T  ratio. A. T 
cell proliferation was assessed on day 3 following the addition of 3H thymidine 
for the last 18hrs of the culture. Proliferation is expressed as counts per minute 
(CPM) +/- SD.  Data represents 2 experiments out of 3 performed. Each bar 
represents a technical triplicate +/-SD and statistical comparisons were made 
using One-way ANOVA and Tukey’s multiple comparisons test. B. IL-2 cytokine 
present in culture supernatants was determined using an IL-2 sandwich ELISA. 
Data represents 2 experiments out of 3 performed. Each bar represents a 
technical triplicate +/-SD and statistical comparisons were made using One-way 
ANOVA and Tukey’s multiple comparisons test. Statistical significance was 































Appendix figure 3. Gating strategy for T cell proliferation assays. B6 DCs 
or B cells were pulsed with 10µg/ml peptide and cocultured with CFSE labelled 
TCR75 CD4+ T cells at 1:10 ratio. After 3 days, cells surface stained with CD4 
antibody, followed by analysis of CFSE proliferation. Cells were gated on live 
cells (FSC vs. SSC), doublets were excluded followed by gating on CD4+ T cells 
that were CFSE+. A. Gating strategy for DC/T co-cultures. B. Gating strategy for 





























Appendix Figure 4. Gating strategy and titration experiments for in vitro 
Treg induction.  B6 BM-DCs were pulsed with 10µg/ml peptide and cocultured 
with TCR75 CD4+ T cells at 1:5 or 1:10 ratio  with subsequent addition of 5U IL-
2 at day 0. After 3 days, expression of Foxp3 was measured by intracellular 
staining and subsequent flow cytometry. A. Cells were gated on live cells (FSC 
vs. SSC); doublets were excluded followed by gating on CD4+ Foxp3+ cells. B.T 
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cell only control. C. Treg induction for 1:5 DC: T ratio. D. Treg induction for 1:10 
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Appendix Figure 5. Gating strategy for ICOS-L and PD-L1 expression on 
BM-DCs. B6 derived BM-DCs targeted with no peptide, Kd or α2,6 Sia-Kd were 
pulsed for 4 hours with 10 µg/ml peptide  at 37°C incubation and analysed using 
flow cytometry. Cells were gated on live cells (FSC vs. SSC), doublets were 
excluded followed by gating on CD11c+  DCs. A. CD11c+ PD-L1+ BM-DCs. B. 




































Appendix figure 6. Trial transplant experiment on B6.Rag2-/- mice to 
compare graft survival following B6 CD4+ T cell or CD4+ TCR75 T cell 
reconstitution. A. (1 mouse/ group) B6.Rag2-/- mice received either 2x105, 1 
x105 or 0.5x105 B6 CD4+ T cells (i.v.) 1 day before BALB/c skin transplant. Mice 
were monitored daily and skin was deemed rejected when >90% of donor skin 
had undergone necrosis.  B. B6.Rag2-/- mice (1 mouse/ group) received either 
2x105, 1 x105 or 0.5x105 TCR75 CD4+ T cells (i.v.) 1 day before BALB/c skin 
transplant. Mice were monitored daily and skin was deemed rejected when 






























Appendix Figure 7. Indirect alloantigen-specific CD4+ T cells are deleted 
following peptide targeting, without deleting CD4+ Foxp3+ Tregs in vivo.  
B6 mice were administered with 2 x 106 TCR75 T cells (Thy1.1) 1 day before 
mice received Kd 10µg/200µl saline, α2,3 Sia-Kd 10 µg/200µl saline, α2,3L Sia-
Kd 10 µg/200µl saline, or α2,6 Sia-Kd 10 µg/200µl saline  i.v. No peptide 
controls received 200µl saline i.v. only. Ten days later spleens and lymph nodes 
were harvested and stained for CD4, Thy1.1 and Foxp3. Live cells were gated 
on forward scatter (FSC), side scatter (SSC), CD4 versus Thy1.1 cells. (A). 
Number of cellular events of Thy1.1+ T cells within CD4+ gate following saline 
(n=3 mice in group), Kd (n=3 mice in group), α2,3 Sia-Kd (n=3 mice in group), 
α2,3L Sia-Kd (n=2 mice in group), and α2,6 Sia-Kd (n=1 mice in group) targeting 
in B6 mice. (B). Percentage of CD4+ Foxp3+ Tregs following saline (n=2 mice in 
group), Kd (n=2 mice in group), α2,3 Sia-Kd (n=2 mice in group), α2,3L Sia-Kd 
(n=2 mice in group), and α2,6 Sia-Kd (n=1 mice in group) targeting in B6 mice. 
Horizontal line between data points represent the mean and error bars 
represent +/- SEM.  
B 
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